Surgery and radioimmunotherapy in peritoneal carcinomatosis of colorectal origin. by Koppe, M.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/49709
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Surgery and radioimmunotherapy in 
peritoneal carcinomatosis of colorectal origin
The studies described in this thesis were partially supported by a grant from the 
Netherlands Organization for Health Research and Development (ZonMw);
grant number: 920-03-220.
The publication of this thesis was financially supported by
Boehringer Ingelheim BV
MSD
Ortho Biotech
Lilly Nederland
Baxter
ERBE Benelux
Genzyme
KCI Medical BV
Bioprof
Surgery and radioimmunotherapy in peritoneal carcinomatosis of colorectal 
origin; thesis, Radboud University Nijmegen, The Netherlands
The work described in this thesis was performed at the Departments of Surgery
(Head prof. dr. R.P. Bleichrodt) and Nuclear Medicine (Head prof. dr. F.H. Corstens),
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Cover
‘Theodor Billroth im Hörsaal’ by Adelbert F. Seligmann (1890)
Layout and cover design
FYN Werk, Fleur Bominaar (www.fynwerk.nl)
Printed by
Gildeprint Drukkerijen, Enschede, The Netherlands
ISBN 90-9021014-8
Copyright © by Manuel J. Koppe, 2006, Nijmegen
All rights preserved. No part of this book may be reproduced, stored in a retrieval system, or 
transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, 
without prior permission of the holder of the copyright.
Surgery and radioimmunotherapy in  
peritoneal carcinomatosis of colorectal origin
een wetenschappelijke proeve 
op het gebied van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de Rector Magnificus prof. dr. C.W.P.M. Blom
volgens besluit van het College van Decanen
in het openbaar te verdedigen op woensdag 8 november 2006
des namiddags om 1.30 uur precies
door
Manuel Jacob Koppe
geboren op 24 december 1973
te Kitwe, Zambia
Promotores:   Prof. dr. R.P. Bleichrodt
    Prof. dr. W.J.G. Oyen
Copromotores:   Dr. O.C. Boerman
    Dr. T. Hendriks
Manuscriptcommissie :  Prof. dr. Th. Wobbes
    Prof. dr. A.J. van der Kogel
    Dr. F.A.N. Zoetmulder (NKI/AvL)
Table of contents
Preface  9
Outline of this thesis
Chapter 1 13
Antibody-guided radiation therapy of cancer
Adapted from Cancer and Metastasis Reviews 2005; 24: 535-63
and British Journal of Surgery 2005; 92: 264-76
Chapter 2 63
Peritoneal carcinomatosis of colorectal origin; incidence and current 
treatment strategies
Annals of Surgery 2006; 243: 212-22
Chapter 3 89
Radioimmunotherapy of experimental peritoneal carcinomatosis of 
colorectal origin
International Journal of Cancer 2003; 106: 965-72
Chapter 4 111
Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y- or 
177Lu-labeled anti-CEA monoclonal antibody MN-14 in mice with 
small peritoneal metastases of colorectal origin
Journal of Nuclear Medicine 2004; 45: 1224-32
Chapter 5 131
Combination therapy using the cyclooxygenase-2 inhibitor parecoxib 
and radioimmunotherapy in nude mice with small peritoneal 
metastases of colonic origin
Cancer Immunology, Immunotherapy 2006; 55: 47-55
Chapter 6 151
Combination therapy using gemcitabine and radioimmunotherapy in 
nude mice with small peritoneal metastases of colonic origin
Cancer Biotherapy & Radiopharmaceuticals 2006; in press
•
•
•
•
•
•
•
Chapter 7 167
Radioimmunotherapy is an effective adjuvant treatment modality after 
cytoreductive surgery of experimental peritoneal carcinomatosis of 
colonic origin
Journal of Nuclear Medicine 2006; in press
Chapter 8 189
Timing of adjuvant radioimmunotherapy after cytoreductive surgery 
in experimental peritoneal carcinomatosis of colonic origin
Submitted
Chapter 9 203
General discussion & future prospects
Summary 209
Samenvatting 217
List of publications 225
Dankwoord 231
About the author 235
•
•
•
•
•
•
•
•

Outline of this thesis

11
Peritoneal carcinomatosis, also known as peritoneal carcinosis or carcinosis peritonei, can be defined as the presence of multiple metastatic implants of carcinoma on the peritoneum. The description ‘peritoneal carcinomatosis’ was 
first used by Sampson in 1931, who described peritoneal carcinomatosis in relation to 
ovarian cancer, probably the malignancy with the highest propensity to disseminate 
intraperitoneally. In the last 25 years, the peritoneal cavity has been recognized as one 
of the frequent sites of recurrence in colorectal cancer as well. Until recently, patients 
with peritoneal carcinomatosis of colorectal origin were considered incurable and 
treated with palliative chemotherapy and surgery when needed. In the nineteeneight-
ies Paul Sugarbaker, an American surgeon, pioneered a different approach, based on 
the resection of as much macroscopic disease as possible (cytoreductive surgery) fol-
lowed by intraperitoneal chemotherapy, frequently under hyperthermic conditions. 
This aggressive approach was primarily aimed at improving locoregional control of 
disease. However, to date it has become clear that some patients may be even cured 
with this approach. The Sugarbaker approach has contributed to a better understand-
ing of peritoneal surface malignancy and probably represents an important step 
forward in the treatment of peritoneal carcinomatosis of colorectal origin. Still, the 
majority of patients undergoing cytoreductive surgery and adjuvant intraperitoneal 
chemotherapy eventually present with recurrent disease, even after complete removal 
of all macroscopic disease. Other adjuvant treatment modalities are therefore neces-
sary in order to improve the outcome of this particular patient category. 
The availability of monoclonal antibodies directed against tumor-associated antigens 
has offered the possibility to guide cytotoxic agents selectively to tumor cells, while 
normal tissue are relatively spared. After more than 50 years of research, radioimmuno-
therapy, using radiolabeled monoclonal antibodies, has been accepted as one of the 
standard treatments for patients with non-Hodgkin lymphoma. Clinical results of 
radioimmunotherapy in patients with solid cancers, however, have been disappoint-
ing. Still, small volume or minimal residual disease has been recognized as a possibly 
suitable target for radiolabeled antibodies. 
This thesis is based upon the the hypothesis that radioimmunotherapy might be an 
effective treatment modality for peritoneal carcinomatosis of colorectal origin. Since 
ideally radioimmunotherapy could be applied in combination with cytoreductive sur-
gery, it was decided to use mouse and rat models of small volume peritoneal carcino-
matosis, i.e. resectable intraperitoneal tumor xenografts. To test this hypothesis, the 
efficacy of radioimmunotherapy was first investigated and optimized in a nude mouse 
model of peritoneal carcinomatosis. Subsequently, in a rat model the efficacy of radio-
immunotherapy when applied as adjuvant treatment after cytoreductive surgery is 
investigated.
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The development and evolution of modern chemotherapy during the second half of the twentieth century has improved the clinical outcome of patients with various forms of cancer.1 Still, in the far majority of malignancies the ef-
ficacy of chemotherapy is very limited, with ninety percent of all drug cures occurring 
in only 10% of cancer types.2 For these reasons, the feasibility and efficacy of various 
forms of immunotherapy has been subject of investigation in both preclinical and 
clinical research. These include active immunotherapy by means of immunization us-
ing components extracted from human tumors, and passive immunotherapy using 
monoclonal antibodies (MAbs), directed against tumor-associated antigens (TAAs), 
i.e. antigens that are expressed at higher levels in tumors as compared to normal tis-
sues.3-5 Both passive and active immunotherapy have been reviewed elsewhere and are 
beyond the scope of this review. Since the initial results of therapy with naked MAbs 
were disappointing, MAbs were conjugated to drugs, biologic toxins or radionuclides, 
in order to achieve a preferential delivery of these toxic agents to tumor lesions, while 
sparing normal tissues. Results of therapy using MAbs conjugated to drugs or toxins 
have been reviewed elsewhere.6,7
Radioimmunotherapy (RIT) using of MAbs labeled with radionuclides has two ma-
jor advantages over the application of MAbs conjugated with either drugs or toxins. 
Firstly, tumor cells not expressing the target antigen can still be sterilized by the so-
called crossfire phenomenon, i.e., radiation energy emitted by radionuclides bound to 
antibodies targeting adjacent tumor cells.8 Secondly, radionuclides are not subject to 
multidrug resistance. Although promising results have been obtained in RIT for the 
treatment of non-Hodgkin lymphoma (NHL),9 clinical results in patients with solid 
cancers have been modest.10 
In this article, a brief overview of the history of RIT is given and relevant aspects of 
the application of radiolabeled MAbs for the treatment of cancers are discussed. Fi-
nally, the results of RIT of NHL and several solid cancers (colorectal cancer, ovarian 
cancer, breast cancer, and renal cell cancer) are reviewed. 
Historical overview of RIT
The first theory on the existence of proteins with specific binding capabilities to 
pathogenic organisms, thus acting as ‘magic bullets’, was postulated at the end of the 
19th century by the German pathologist Paul Ehrlich in his famous side-chain theory 
(“Seitenkettentheorie”).11 It took almost 50 years before this concept was translated to 
tumor biology and treatment by Gorer, who showed that an antitumor serum obtain-
ed from black mice was able to suppress the growth of leukemia cells in albino mice.12 
However, the first attempts to use unconjugated MAbs for the treatment of cancer 
proved to be disappointing. After it had been recognized in 1950 that proteins could 
be labeled with 131I without significantly altering their immunological specificity, 13 
Pressman and Korngold tested the tumor-targeting potential of a 131I-labeled rabbit 
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antiserum in rats bearing osteosarcoma and confirmed preferential antibody uptake 
in the tumor xenografts.14 The first clinical trial investigating the therapeutic efficacy 
of radiolabeled antibodies was performed in the 1950s by Beierwaltes, who treated 
fourteen patients with metastatic melanoma with 131I-labeled rabbit antibodies and 
reported a pathologically confirmed complete remission in one patient.15 In 1965 Gold 
and Freeman described the discovery of the carcino-embryonic antigen (CEA), that 
was expressed both in colon adenocarcinoma as well in fetal colon, but that was al-
most absent in normal healthy colon.16 In 1974 Mach et al. were the first to report the 
feasibility of targeting CEA-expressing human colon cancer xenografts in mice using a 
radiolabeled polyclonal anti-CEA serum.17 In the late 1970s Goldenberg et al. success-
fully targeted colon cancer in patients using a polyclonal goat anti-CEA antiserum.18 
Nowadays, CEA has not only become one of the most extensively used tumor markers 
in clinical oncology, but also, due to its pronounced expression in various carcino-
mas, one of the most targeted TAAs in RIT. Interest in the clinical use of antibodies 
boomed after the development of the hybridoma technique by Kőhler and Milstein in 
1975.19 This technique relies on the fusion of antibody-producing B-lymphocytes, ob-
tained from mice immunized with cancer cell extracts, with malignant myeloma cells 
(Figure 1). The resulting immortal hybridoma cell lines allowed the production and 
isolation of pure MAbs of predefined specificity against a single epitope. Moreover, 
with this method gram quantities of these antibodies could be produced eliminating 
the batch-to-batch variations, which hampered the development of polyclonal anti-
bodies for clinical use. For the development of the hybridoma technique Kőhler and 
Milstein were awarded the Nobel Prize in Medicine in 1984. Furthermore, using the 
same technique, several other TAAs could be idientified, such as Mucin-1 (MUC-1) 
expressed on the majority of adenocarcinomas, the tumor-associated glycoproteins 
(TAG-72) expressed on ovarian, breast and colorectal carcinomas and G250 on renal 
cell carcinomas. Since then, the efficacy of RIT using radiolabeled MAbs has been 
subject of investigation in virtually every cancer in animal models and/or in patients. 
Promising results have been obtained in patients with NHL, due to their high intrin-
sic radiosensitivity, the good access of the radiolabeled MAbs to the tumor cells and 
the intrinsic anti-tumor activity of the antibodies themselves via antibody dependent 
cytotoxicity (ADCC), complement dependent cytotoxicity (CDC) and other mecha-
nisms, as summarized by Postema et al.9 This has resulted in the first registered radi-
olabeled MAbs directed at the surface antigen CD-20 for the treatment of B-cell NHL 
(90Y-labeled anti-CD20 MAb Zevalin® (Idee Pharmaceuticals, San Diego, CA, USA) and 
131I-labeled anti-CD20 MAb Bexxar® (Corixa, Seattle, WA, USA)).
Antibodies structure and size
Antibodies or immunoglobulin molecules are produced by B-lymphocytes in response 
to a pathogenic challenge. Immunoglobulins consist of two Fab domains and a Fc 
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Figure 1
The hybridoma technique by which large quantities of monoclonal antibodies (MAbs) against a par-
ticular antigen can be produced. 
1. A mouse is immunized by injection of a particular antigen, in order to stimulate the production of 
antibodies against this antigen. The antibody forming B-lymphocytes are isolated from the spleen.
2. The single antibody-producing B-lymphocytes are fused with malignant myeloma cells, thus creat-
ing an immortal cell line. The resulting cell is called a hybridoma.
3. Hybridomas producing identical antibodies are allowed to multiply in culture, thus creating an 
immortal hybridoma cell line that produces MAbs. Adapted from M.J. Koppe et al. Radioimmu-
notherapy and colorectal cancer. British Journal of Surgery 2005; 93: 264-76. Copyright British 
Journal of Surgery Society Limited. Reproduced with permission.
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domain, the first containing the variable regions responsible for specific binding to 
the target antigen of the MAb. The Fc fragment is necessary for activation of the com-
plement cascade or effector cell interaction. There are several subclasses of immuno-
globulins, the IgG subclass being the most commonly used in RIT. IgG antibodies are 
large proteins, with a molecular weight of 150 kDa, which limits the diffusion of the 
antibodies from the blood into the tumor, resulting in a heterogeneous intratumoral 
distribution.20 Furthermore, IgG antibodies are characterized by a long circulatory 
half-lives in plasma of three to four days. Due to this slow clearance from the blood, 
tumor-to-background ratios are usually low.21,22 In order to increase the tumor-to-non-
tumor ratios of the radiolabel, smaller antibody fragments have been investigated for 
their tumor-targeting capabilities. These fragments are produced by enzymatic diges-
tion of intact IgG antibodies, and are called F(ab’)2 (MW 100 kDa) or F(ab) (MW 40 
kDa), as shown in Figure 2. Although the maximum uptake in tumor is reached at 
earlier time points after intravenous administration and tumor-to-nontumor ratios 
Figure 2
Most important forms of monoclonal antibodies used in clinical radioimmunotherapy.
A Whole (murine) IgG (MW 150 kDa). Va, variable region; Co, constant region; B F(ab’)2 fragment 
(MW 100 kDa); C Fab’ fragment (MW 50 kDa); D Chimeric IgG (67% human). The constant regions 
of the murine antibody have been replaced by their human analogues; E Humanized IgG (90-95% hu-
man); F Fully human IgG; G Bispecific antibody. The antibody, with both arms originating from two 
separate antibodies, is reactive with two distinct antigens.
Drawing: M.G. Steffens. Adapted from M.J. Koppe et al. Radioimmunotherapy and colorectal cancer. 
British Journal of Surgery 2005; 93: 264-76. Copyright British Journal of Surgery Society Limited. 
Reproduced with permission.
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of radiolabeled MAb fragments are, indeed, significantly higher than those obtained 
with intact IgG MAbs, the absolute uptake in tumor of radiolabeled MAb fragments is 
usually lower and the tumor retention times are shorter than those of intact MAbs.23 
Furthermore, an important feature of MAb fragments as opposed to intact MAbs is 
their route of excretion. While intact MAbs are primarily catabolized by the liver and 
spleen, MAb fragments are mainly excreted via the kidneys, thereby increasing uptake 
in the kidneys and consequently the kidney absorbed radiation dose.24 
Immunogenicity
A complicating factor in the application of antibodies is the immune response of the 
patient against the radiolabeled MAbs. The first MAbs being investigated for radioim-
munoscintigraphy and RIT were murine antibodies, which can provoke an immune 
response in humans. As a result, human-anti-mouse-antibodies (HAMAs) are almost 
invariably formed, which, upon repeated administration of MAbs to patients, com-
plex the circulating MAbs thereby leading to an accelerated clearance from the blood. 
As a consequence, the formation of HAMAs generally prevents effective targeting of 
the tumor after a second administration of the radiolabeled MAb. In order to reduce 
the immunogenicity of the antibodies, chimeric antibodies were designed combining 
constant domains of human antibodies with murine variable regions of murine anti-
bodies. Although chimeric antibodies proved to be less immunogenic as compared to 
murine antibodies, human-anti-chimeric antibodies (HACAs) still develop frequently. 
In the 1990s humanized antibodies were introduced. Humanized antibodies are al-
most completely of human origin, with only the complementarity determining re-
gions (CDRs) being murine. With the introduction of phage display libraries or by use 
of transgenic mice, fully human antibodies can be produced.25 However, the affinity of 
antibodies produced by phage display for its antigen is generally lower.
Radionuclides
The most commonly used radionuclides in RIT are beta-emitters, although Auger-
electron emitting radionuclides and alpha-emitters can also be used. Beta-particles 
are electrons that are emitted from the nucleus of an unstable atom. Iodine-131 (131I) 
and Yttrium (90Y) are the most commonly used beta-emitters in RIT. Rhenium-186 
(186Re), Rhenium-188 (188Re), Copper-67 (67Cu) and Lutetium-177 (177Lu) are beta-emit-
ters that have been considered for RIT more recently. These radionuclides differ with 
respect to physical half-life, the presence or absence of gamma-rays, the energy of 
the beta-particles and consequently the range of the beta-particles in tissue, as sum-
marized in Table 1. These factors are important with respect to the eventual radiation 
energy dose that is delivered to the tumor, which can be estimated by dosimetric 
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analysis.26 For example, minimal disease consisting of tumor nodules with a diameter 
of only a few millimeters, theoretically, are not suitable for targeting with 90Y-labeled 
MAbs, since the energy of the beta-particles is so high that 70% of the radiation en-
ergy is deposited outside these small tumors. Indeed, several preclinical studies have 
shown that medium-energy beta-emitters, such as 131I and 177Lu are more effective for 
the treatment of small tumor nodules,27-29 whereas, conversely, high-energy beta-emit-
ters such as 90Y are more suitable for RIT of larger tumors.29,30
Another significant factor influencing the tumor-absorbed radiation dose is the fate of 
the radiolabel after internalization of the radiolabeled MAb into the tumor cell. Inter-
nalization of the antibody depends on various factors, including the antibody, the tar-
geted antigen and the tumor cell. However, most antibodies, including those that tar-
get antigens located on the surface of the tumor cell, such as anti-CEA antibodies, are 
eventually catabolized.31 After internalization of the radiolabeled MAb, the antibody 
is degraded in the lysosomes. After intralysosomal metabolization of radioiodinated 
MAbs that are radioiodinated by conventional methods, the radioiodinated tyrosine 
residues are excreted, thereby reducing the residence time of the radioiodine in the 
tumor.32 Radiolabeling of antibodies with 90Y or 177Lu is performed by linking these 
radionuclides to chelators (DTPA or DOTA), which are chemical moieties that compex 
free metal ions. These chelators are conjugated to the antibodies and subsequently ra-
diolabeled. After catabolization of MAbs labeled with 90Y- or 177Lu-DTPA/-DOTA, the 
catabolic products are the radiolabeled chelators conjugated to, in most cases, lysine 
(e.g. 90Y- or 177Lu-DOTA-lysine). Whereas radioiodinated tyrosine is excreted by the 
cell, the 90Y- or 177Lu-DTPA/DOTA-lysine metabolites are trapped within the lyso-
somes, thereby increasing the tumor retention time of these radiolabels.27
Dosimetry
Radiation dose calculations, dosing schedules and doses delivered to tumors and nor-
mal organs are subject to intensive discussion. There are various ways to determine 
the radioactivity dose to be administered:
fixed doses,
body weight based doses,
body surface area based doses,
doses based on the estimated whole body dose, or
doses based on the estimated red marrow dose.
For almost all radiolabeled MAbs, phase I studies have been conducted to determine 
the maximum-tolerated dose (MTD). Without exception dose-limiting toxicity con-
sists of leuco- and thrombocytopenia. In general, dosimetric calculations cannot 
forecast the outcome of therapy, nor can it accurately predict the grade of toxicity 
following RIT. The need for patient-specific dosimetry is a matter of debate. Some 
research groups advocate the role of individual dosing based on a diagnostic study for 
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dosimetric purposes. Others showed that RIT can safely be based on body weight of 
the patient only, without the need for upfront dosimetric calculations before treat-
ment, provided that platelet counts are normal and bone marrow involvement is less 
than 25%.33
Dose-limiting toxicity and strategies to enhance the administered 
activity dose
Radiation toxicity to radiosensitive normal tissues, especially the bone marrow, limits 
the activity dose that can be administered safely and consequently, forms a major 
obstacle that limits the therapeutic efficacy of radiolabeled MAbs. Several strategies 
have been explored to improve the tumor targeting of radiolabeled MAbs and simul-
taneously prevent or overcome the dose-limiting bone marrow toxicity. The most im-
portant include, 1. the use of antibody fragments, 2. pretargeting strategies, 3. bone 
marrow support or transplantation.
In order to prevent bone marrow toxicity, the use of antibody fragments has been in-
vestigated in various animal models34-36 and clinical studies.34,37,38 Antibody fragments 
generally clear faster from the blood and normal tissues than intact IgG antibodies. 
However, as mentioned above, the accumulation of radiolabeled antibody fragments 
in tumor is usually lower. Yet, the use of antibody fragments allows the administra-
tion of higher activity doses as compared to intact MAbs.39
Another interesting method to improve the tumor targeting of radiolabeled antibod-
ies while simultaneously reducing bone marrow toxicity is the so-called pretargeting 
approach. In “pretargeted” RIT the radionuclide is administered separately from the 
tumor targeting antibody. In the first step the unlabeled anti-tumor antibody is ad-
ministered and allowed to accumulate in the tumor. In a later phase, preferably when 
the antibody has cleared from the circulation, the radionuclide is administered as a 
rapidly clearing agent with high affinity for the unlabeled molecule that was injected 
in the first phase.40 Preclinical as well as clinical studies have indicated that pretar-
geted RIT can result in higher tumor-absorbed radiation doses as compared to “clas-
sical” RIT, using directly radiolabeled MAbs.41 However, whereas the radiation dose to 
the bone marrow is significantly reduced, renal excretion of the radiolabeled hapten 
results in relatively high radiation dose to the kidneys. Preclinical as well as clinical 
studies have shown that in pretargeted RIT the kidney-absorbed radiation dose can 
result in severe glomerulosclerosis and renal failure, which typically occurs several 
months after therapy.42 
In pretargeted RIT two main approaches can be distinguished, based on the inter-
action between the first and second injectate: 1. (strept)avidin and biotin interac-
tion or 2. antibody-hapten interaction. The first approach is based on the extremely 
avid interaction between (strept)avidin and biotin. The affinity constant (1015 M-1) of 
the (strept)avidin-biotin is 1,000,000-fold higher than that of the average antigen-
Antibody-guided radiation therapy of cancer
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antibody interaction. In the first pretargeting studies mice and rabbits with tumor 
xenografts the target was pretargeted with biotinylated antibodies, after which ra-
diolabeled avidin was administered. These studies provided proof of principle that 
radiolabeled avidin could accumulate in the biotinylated target.43-45 It was, however, 
observed that the radiolabeled avidin also bound to the biotinylated antibody in the 
circulation. To lower the concentration of the biotinylated antibody in the blood, an 
‘avidin chase’ was given, prior to injection of the radiolabeled avidin, which accelerated 
the tumor uptake as well as the blood clearance of the radiolabeled (strept)avidin.46,47 
Furthermore, investigators realized soon thereafter that the rapid pharmacokinetics 
of biotin would be fully exploited, if one would pretarget the tumor with avidin and 
administer radiolabeled biotin in the last step.48,49
The second pretargeting approach is based on the use of so-called bispecific antibod-
ies, i.e. antibodies with affinity to both the tumor-associated antigen as well as a hap-
ten, e.g. a radiolabeled peptide. Due to the relatively low affinity of the hapten for the 
bispecific MAb (109 M-1) as compared to the biotin-avidin interaction (1015 M-1), the 
bispecific MAb-hapten complexes formed in the circulation are relatively labile. As a 
consequence, the administration of a clearing agent to accelerate the blood clearance 
of the bispecific MAbs prior to the administration of the radiolabeled hapten is not 
necessary, which is a major advantage of this pretargeting strategy over avidin-bi-
otin pretargeted RIT. In addition, with the development of humanized bispecific an-
tibody constructs, this method makes us of reagents that will not evoke an antibody 
response in patients. 
Finally, because in RIT using directly radiolabeled the red marrow is the dose-limiting 
organ, autologous marrow or peripheral blood stem cell (PBSC) or even whole blood 
reinfusion has been investigated as a means to overcome bone marrow toxicity. Press 
et al. were the first to investigate the feasibility and efficacy of this approach in pa-
tients with NHL, a disease frequently located in the bone marrow. It was shown that 
autologous PBSC reinfusion allowed the administration of myeloablative doses of RIT 
in patients with NHL.50-52 Evidence that reinfusion of autologous PBPCs, or bone mar-
row can ameliorate the bone marrow suppression and, indeed, modify the myelotoxic-
ity in high-dose RIT was furthermore reported in patients with breast cancer, medul-
lary thyroid cancer, and CRC.53-56 Colnot et al. demonstrated the feasibility of further 
dose-escalation of 186Re-based RIT in patients with advanced squamous cell carcinoma 
of the head and neck by stimulating the bone marrow with granulocyte colony-stimu-
lating factor (G-CSF) and reinfusing one litre of unprocessed whole blood three days 
after administration of the radiolabeled MAbs.57 The results indicated that the MTD 
could be doubled from 1 to 2 GBq/m2. The latter method, however, is only suitable 
when radionuclides with relatively short half-lives, such as 186Re or 90Y, are used, since 
whole blood specimens can be stored for maximally three days. 
Chapter 1
24
Clinical results of RIT in NHL
The first report on the treatment of NHL with monoclonal antibodies (MAbs) dates 
from 1980, when the use of idiotypic MAbs against malignant lymphoma cells in a 
patient was described.58 In 1997, rituximab – a chimeric anti-CD20 MAb – became 
commercially available. Nowadays, it is widely used, and indications are still expand-
ing. Radiolabeled MAbs have been applied successfully in lymphoma treatment. In 
2002 and 2003, respectively, two radiolabeled murine anti-CD20 MAbs were approved 
for clinical use by the FDA. Still, RIT of lymphoma patients is mainly given in trials, in 
order to define the role of RIT in routine NHL management. An overview of clinical 
studies with various MAbs and various radionuclides is presented in Table 2.51,59-77 In 
the following the representative trials will be discussed.
90Y-ibritumomab (Zevalin®)
90Y-ibritumomab was the first radiopharmaceutical to be approved for the treatment 
of follicular lymphoma patients who relapse or are refractory following rituximab 
treatment. Ibritumomab and rituximab are very much alike: Ibritumomab is the 
murine ancestor of the chimeric MAb rituximab. In the phase I study using 90Y-la-
beled ibritumomab in 14 patients, RIT was preceded by various amounts of unlabeled 
ibritimomab. Predosing with unlabeled MAbs resulted in improved biodistribution of 
the radiolabeled MAb and decreased doses to the spleen and spine.78 In a subsequent 
multicenter trial, 50 patients were pretreated with unlabeled rituximab, followed by 
90Y-labeled ibritumomab.76 In that trial the currently used dose of rituximab and 90Y-
ibritumomab was determined: 14.8 MBq/kg was chosen if platelet counts were above 
150 × 109/l, and a dose of 11.1 MBq/kg if platelet counts ranged between 100 and 150 
× 109/l. The infusion of 90Y-ibritumomab was preceded by two infusions of 250 mg/m2 
rituximab with a one-week interval. The overall response rate in this study was 68% 
(13 CRs and 21 PRs).
In a subsequent phase III trial, RIT with 90Y-ibritumomab was compared with rituxi-
mab alone in 143 patients with relapsed or refractory low-grade follicular or trans-
formed CD20-positive NHL.77 Patients received either a single intravenous dose of 
14.8 MBq/kg of 90Y-ibritumomab preceded by two infusions of 250 mg/m2 rituximab 
(n = 73), or four weekly doses of 375 mg/m2 of rituximab (n = 70). The overall response 
rate was 80% for the 90Y-ibritumomab group versus 56% for the rituximab group. CR 
rates were 30% and 16% in the RIT and rituximab groups, respectively.
Zevalin® has been approved for clinical use in both the USA and the European Union. 
Registration in the USA includes imaging using 111In-ibritumomab following the first 
rituximab infusion. Zevalin’s product information mentions that 90Y-ibritumomab 
should not be administered to patients with altered biodistribution as determined by 
imaging with 111In-ibritumomab. In the European Union, imaging using 111In-ibritu-
momab is thought to be unnecessary, although opinions differ.79
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131I-tositumomab (Bexxar®)
In June 2003, the FDA approved Bexxar® for the treatment of patients with CD20-
positive follicular NHL, with and without transformation, whose disease is refracto-
ry to rituximab and has relapsed following chemotherapy. Registration was preceded 
by a randomized open-label multicenter study, comparing the efficacy and safety of 
131I-labeled tositumomab to unlabeled tositumomab.62 Seventy-eight patients were 
enrolled. Patients receiving 131I-tositumomab therapy were dosed according to pro-
tocol, i.e. 450 mg of unlabeled tositumomab and a tacer dose of 185 MBq 131I labeled 
to 35 mg of tositumomab, followed one to two weeks later by the therapeutic dose 
of 131I-tositumomab, again preceded by 450 mg of unlabeled tositumomab. The dos-
ing scheme is discussed in more detail later. The patients randomized to unlabeled 
tositumomab treatment received two doses of 485 mg, i.e. the same total antibody 
dose that is administered to patients treated with 131I-tositumomab. Confirmed re-
sponses were documented in 23 of 42 (55%) patients who received tositumomab RIT 
(33% CR, 21% PR), and 6 of 36 (17%) patients who received tositumomab (8% CR, 8% 
PR), respectively. The median duration of confirmed responses for Bexxar®-treated 
patients has not been reached yet, and for unlabeled tositumomab treated patients 
it was 18 months. This study documents that the radioiodine component of RIT 
using 131I-tositumomab provides significant therapeutic effect over and above that 
provided by unlabeled tositumomab with an acceptable toxicity profile.62
As mentioned earlier, the dosing scheme of Bexxar® differs from the dosing scheme 
of Zevalin®. Whereas the latter uses the patient’s body weight to dose the radiop-
harmaceutical, the former depends on pretherapy dosimetry. In a phase I study, 
nine patients were treated with one or two doses of 131I-tositumomab, preceded by 
a tracer dose and by variable amounts of unlabeled antibody to determine whether 
presaturation of non-specific binding sites or reservoirs of non-malignant B cells 
would allow better access to tumor sites.80 Optimal tumor targeting was obtained 
when administering 685 mg unlabeled tositumomab prior to administration of the 
radioiodinated MAb. Myelotoxicity occurred when whole-body radiation doses ex-
ceeded 0.75 Gy, which was thus defined as the MTD.81 In the following multicenter 
phase II trial, all patients received two infusions of 450 mg unlabeled antibody, one 
preceding the tracer dose, one preceding the therapeutic dose of 131I-tositumomab.74 
Aim of the dosimetric study is to determine the therapeutic amount of activity to 
be infused, leading to an estimated whole-body dose of 0.75 Gy, if platelet counts are 
above 150 × 109/l. If platelet counts were between 100 and 150 × 109/l, the patient 
should receive less activity, leading to a whole-body dose of 0.65 Gy.
90Y-epratuzumab (LymphoCide Y-90)
Epratuzumab is the only humanized MAb used for RIT of NHL patients. This hu-
manized MAb was produced in order to reduce the immunogenicity of the murine 
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anti-CD22 MAb LL2. This antibody has been used in clinical trials labeled with 131I, 
90Y, and 186Re. A preclinical study suggested a better biodistribution for 90Y-epratu-
zumab than for 131I- or 186Re-epratuzumab.82 In a first clinical study, comparing 131I- 
and 90Y-labeled epratuzumab, treatment with both radiolabels was equally safe, 
and pharmacokinetics and dosimetry were similar, but the tumor dosimetry of 90Y-
epratuzumab appeared to be more favorable than that of 131I-epratuzumab.67 90Y was 
chosen for further trials. A dose-escalation study showed that treatment with 90Y-
epratuzumab was tolerated well at a dose of 0.74 GBq/m2 by patients who had not 
been treated with high-dose chemotherapy prior to RIT.83 In a group of lymphoma 
patients with high-dose chemotherapy prior to RIT, a dose of 0.37 GBq/m2 did not 
lead to dose-limiting toxicity.83
Protein doses in all infusions are low: only 0.75 mg epratuzumab per kg body weight 
is given without any preceding unlabeled antibody infusion. Even low doses of ac-
tivity are associated with responses. A group at the University Hospital in Lund, 
Sweden, gave patients two or three injections of only 185 MBq 90Y-epratuzumab/m2. 
Patients with prior high-dose chemotherapy and stem cell rescue received only 92.5 
MBq/m2. In five of eight patients, partial or complete responses were observed.84
At the Radboud University Nijmegen Medical Center, The Netherlands, we have 
been studying the use of 186Re-labeled epratuzumab in a dose-escalation study.71 
Eighteen patients with CD22-positive NHL were included in this trial, 15 of whom 
were treated with 186Re-epratuzumab. After inclusion, a tracer dose of 750 MBq 
99mTc-epratuzumab was infused. Whole-body gamma-camera images were made on 
the day of and one day after infusion. In case of unfavorable biodistribution – pre-
dominant uptake in bone marrow and spleen – no RIT was given, as was the case 
in 2 patients. If a normal biodistribution was seen, patients were treated one week 
later with 186Re-epratuzumab. The maximum-tolerated dose appeared to be 2.0 GBq/
m2. A CR was observed in 1 of 15 patients treated, 4 patients had a PR lasting several 
months to more than a year. Four patients had stable disease following one single 
injection with 186Re-epratuzumab.
Myeloablative RIT
At the University of Washington in Seattle, WA, the group of Press et al. used Bexx-
ar® for the treatment of refractory NHL. They re-infused stem cells after RIT to en-
able administration of high, myeloablative doses of radiolabeled tositumomab. In 
aiming at myeloablation, toxicity to organs other than the bone marrow will limit 
the radiation dose that can be tolerated. Therefore a dose escalation study was de-
signed in which the dose to tumor and critical normal organs was calculated us-
ing dosimetry and biopsy specimens after a diagnostic procedure with 131I-labeled 
MAbs. This study showed that doses less than 27.25 Gy to normal organs did not 
cause serious, irreversible non-hematological toxicity.51 In subsequent trials, doses 
of 131I-tositumomab estimated to deliver 27 Gy to the dose-limiting organ, gener-
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ally the lungs, were administered.85 This myeloablative approach led to complete 
responses in 30 of 36 patients.86 A long-term follow-up study of the 29 patients 
treated with myeloablative doses of Bexxar® has documented estimated overall and 
progression-free survival rates of 68% and 42%, respectively, with a median follow-
up time of 42 months.
Another approach is the combination of myeloablative RIT and high-dose chemo-
therapy, followed by autologous hematopoietic stem cell rescue. The role of RIT as 
reported here differs from other forms of RIT. In these cases RIT replaces total body 
irradiation. The duration of response achieved by this highly effective approach 
should especially be compared with the duration of response after chemotherapy 
followed by total body irradiation and stem cell support. In a trial using Bexxar® 
and etoposide and cyclophosphamide, the overall survival and the progression-free 
survival of the group treated with myeloablative RIT appear retrospectively to be 
better than in the historic, conventionally treated control group.87 Nademanee et al. 
presented data on the use of Zevalin® in combination with the same chemothera-
peutics (etoposide and cyclophosphamide), followed by autologous stem cell trans-
plant.88 They concluded that the addition of RIT to high-dose chemotherapy did not 
increase transplant-related toxicity, nor did it delay engraftment. They suggested 
that myeloablative RIT could replace TBI in this regimen, although further studies 
and longer follow-up are required.
First-line treatment
In most trials using RIT to treat NHL patients, patients with relapsed of refrac-
tory lymphoma were recruited, some of them heavily pretreated. Recently, very en-
couraging results of first-line treatment of lymphoma patients with radiolabeled 
antibodies were published.68 In that study, 76 previously untreated patients with 
stage III or IV follicular lymphoma were enrolled. They were treated with Bexxar® 
according to the aforementioned dosing scheme. The overall response rate was as 
high as 95%, 57 of 76 patients achieving a CR (75%) and 15 a PR (20%). The 5-year pro-
gression-free survival (PFS) was 59%, with a median PFS of 6.1 years. Toxicity was 
very mild, especially when compared to normal first-line treatment: only 4 patients 
experienced grade IV neutropenia. On the other hand, hypothyroidism was induced 
in 13-19% of patients. The use of a murine MAb in this untreated group of patients is 
disadvantageous: HAMA were induced in 48 of 76 patients (63%), possibly prohibit-
ing the use of murine MAbs in case of recurrence.
Although the results are excellent, Connors warns for a possible selection bias.89 
The group treated appears to consist of apparently younger patients with less bulky 
disease. Therefore, more, preferably randomized trials are needed.
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Clinical results of RIT in solid cancers
So far the application of radiolabeled antibodies for the treatment of patients with 
solid cancers has been less successful than in patients with NHL. This can only par-
tially be attributed to the generally lower sensitivity to radiation of solid cancers. In 
addition, solid cancers are targeted less efficiently with radiolabeled antibodies than 
hematological malignancies owing to a combination of tumor-related factors. These 
include a limited vascular supply, heterogeneous uptake of the antibody in the tumor, 
and elevated interstitial pressure in combination with a relatively long transport dis-
tance in the interstitium.90 As a consequence, the uptake of radiolabeled antibodies 
in solid tumors is impaired (generally about 0.001 – 0.01% of the injected dose per 
gram of tumor) and tumor-absorbed radiation doses usually do not exceed 1,500 cGy 
in most instances. Still, it has been appreciated that, since the uptake in tumor is in-
versely correlated with tumor size, minimal residual disease may constitute a suitable 
target for radiolabeled antibodies. Indeed, RIT has shown to be very effective in ani-
mal models of small volume carcinoma and may even be more effective than equally 
toxic chemotherapy in, for example, experimental colon cancer.91
The cancer types that have been targeted in clinical RIT were chosen based on their 
antigen-expression profile and the availability of antibodies directed against these an-
tigens. The malignancies most commonly targeted in clinical RIT are epithelial can-
cers, e.g. colorectal cancer, ovarian cancer, medullary thyroid cancer, and, to a lesser 
extent, breast, prostate and renal cell cancer. The most commonly targeted antigens 
are the carcinoembryonic antigen (CEA, mainly in colorectal, medullary thyroid and 
breast cancer), tumor-associated antigen-72 (TAG-72, mainly in colorectal, ovarian 
and breast cancer), Mucin-1 (MUC-1, mainly in ovarian and breast cancer), and G250 
(renal cell cancer). Almost all patient series published to date on the application of 
RIT for the treatment of solid cancers are derived from phase I/II trials, in which the 
radiolabeled antibodies were administered in dose-escalating steps with the aim to 
determine the maximal tolerated dose. As a result, in most studies suboptimal doses 
were administered in most cases. Furthermore, the patients eligible for these phase 
I/II RIT trials almost invariably had metastatic, mostly bulky disease, and had been 
heavily pretreated with chemotherapy and/or radiotherapy. Complete responses have 
rarely been reported, although in many studies a few patients still experienced minor, 
partial or mixed responses or stabilization of previously progressive disease. In most 
trials, 131I or 90Y were the radionuclides applied, although in some trials 186Re, 188Re, or 
177Lu were used.
In the following the most important and representative results will be reviewed for 
RIT of colorectal cancer, ovarian cancer, breast cancer and renal cell cancer. Finally, 
the trials published to date on the therapeutic efficacy of pretargeted RIT will be sum-
marized.
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Colorectal cancer
TAAs targeted in clinical RIT of colorectal cancer include CEA, TAG-72, A33, the colon 
specific antigen p (CSA-p), and the epithelial cellular adhesion molecule (Ep-CAM, also 
known as 17-1A).92 The best representative trials have been summarized in Table 3.
CEA
Since 95% of colorectal carcinomas express CEA, this antigen has been the most tar-
geted antigen in patients with colorectal cancer. To date, fourteen trials have been 
published reporting the results of 131I-, 90Y- or 188Re-based RIT using seven different 
anti-CEA antibodies in patients with CRC. 
Juweid et al. investigated the pharmacokinetics, immunogenicity and therapeutic 
efficacy of 131I-labeled F(ab’)2 fragments of the murine anti-CEA MAb NP-4 (also 
known as IMMU-4).39 Thirteen patients with CEA-expressing disseminated cancers, 
among whom eight with colorectal cancer, were treated with repeated administra-
tions of 131I-labeled NP-4 (up to 9.4 GBq per administration). Although the majority 
of patients developed HAMAs after their second administration leading to acceler-
ated clearance of the radiolabeled MAbs, seven patients (among whom four patients 
with metastatic CRC) showed stabilization of previously progressive disease for up 
to seven months.39 
Mittal et al.93 investigated the toxicity and efficacy of the 131I-labeled NP-4 IgG MAb 
at 1110 MBq or 2220 MBq/m2 combined with hyperthermia in six patients with ad-
vanced CRC. One patient showed a minor response, two reported symptom improve-
ment whereas in five patients there was a drop in serum CEA levels.
The largest series of patients that were treated with 131I-labeled NP-4 was published 
by Behr et al.,94 who tested the antitumor activity of escalating activity doses of 131I-
labeled NP-4 IgG in 57 patients with CEA-expressing malignancies (among whom 29 
patients with CRC). The activity doses administered were varied between 1628 MBq 
and 9953 MBq, which were based on dosimetric estimates of the radiation dose to the 
red marrow. Antitumor effects were seen in twelve of 35 assessable patients, includ-
ing one partial remission, four mixed/minor responses and seven stabilizations of 
previously progressive disease. It was not specified which patients responded.
Juweid et al. were the first to test the efficacy of 188Re-based RIT using the murine 
IgG1 MAb MN-14 in eleven patients with disseminated CEA-positive cancers, among 
which ten patients with colorectal carcinoma.95 The murine MN-14 MAb is a second-
generation anti-CEA antibody with a ten-fold higher affinity than the NP-4 MAb (1 x 
109 M-1).96 Patients were treated with repeated administrations of 188Re-labeled MN-
14 at escalating dose levels, varying from 740 MBq till 2886 MBq. The MTD of frac-
tioned doses of 188Re-MN-14 was reached at 2220 MBq/m2, with red marrow suppres-
sion being the only dose-limiting toxicity observed. No therapeutic responses were 
recorded. The authors concluded that, since high doses of 188Re-labeled MAbs can be 
administered on an outpatient basis, 188Re might be a suitable radionuclide for RIT. 
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An important disadvantage of 188Re, however, is its short half-life of only 17 hours, 
which is inefficient when used in combination with long circulating IgG antibodies. 
As a result, a substantial proportion of the activity administered will have decayed at 
the time the radiolabeled MAbs have localized in the tumor. 
Because of the immunogenicity of the murine form of the MN-14 MAb (seven out of 
nine patients developed a HAMA-response), the antibody was humanized. To date, 
three reports have been published on RIT using the humanized MN-14 in patients 
with advanced CRC. Behr et al.97,98 and Hajjar et al.99 tested the toxicity and thera-
peutic efficacy of 131I-labeled hMN-14 in patients with CRC. Behr et al. focused on 
patients with small-volume liver metastases (<2 cm) of CRC, whereas Hajjar et al. 
included patients with gross metastatic disease of colorectal, pancreatic or gastric 
cancer. Behr et al. found the maximal tolerated activity dose of 131I-hMN-14 at 2220 
MBq/m2, with higher doses leading to grade IV haematological toxicity. Possibly due 
to a different patient population, Hajjar et al. reported the MTD to be 1480 MBq/m2. 
Hajjar et al. did not observe responses, whereas Behr et al. reported three partial 
remissions and eight minor responses in their larger series of 30 patients. 
Interestingly, Behr et al. were the first to report on the administration of adjuvant 
RIT using 131I-hMN-14 at MTD (2220 MBq/m2) in nine patients within six weeks after 
complete resection of liver metastases of colorectal origin.98 At a median follow-up of 
27 months, only two patients had developed a recurrence. Although seemingly prom-
ising, these results should be interpreted cautiously, as the group of patients is small 
and the study noncontrolled. Nevertheless, as mentioned previously, in solid cancers 
adjuvant RIT should be most effective, since tumor uptake of the radiolabeled MAb 
and thus the tumor-absorbed radiation dose increases with decreasing tumor size.
Wong et al. published three articles reporting the results of 90Y-based RIT, using the 
MAb cT84.66 in patients with CRC.100-102 cT84.66 is a high affinity (Ka=1.16 x 1010 M-
1) chimeric anti-CEA MAb. After showing effective localization of the radiolabeled 
MAb in three patients with metastatic CRC,100 an activity dose escalation study was 
carried out in a total of twenty-two patients with CEA-positive malignancies, of 
which 18 were CRCs.102 The MTD of 90Y-cT84.66 was reached at 814 MBq/m2, with 
reversible thrombocytopenia and leukopenia being dose-limiting. Antitumor effects 
were observed in five patients, including stable disease in three and mixed responses 
in two.
In an attempt to improve the efficacy of 90Y-cT84.66, it was combined with 5-fluor-
ouracil (5-FU), delivered as a five-day continuous infusion.101 The MTD of this combi-
nation was reached at 618 MBq/m2 and 1000 mg/m2/day. Although no objective re-
sponses were recorded, eleven patients with previously progressive disease displayed 
stable disease for three to eight months and one patient showed a mixed response. 
Other anti-CEA antibodies that have been tested for radioimmunotherapeutic ap-
plication include F656 and F023C5.103 Ychou et al. investigated the toxicity and MTD 
of single doses of 131I-labeled F(ab’)2 fragments, derived from MAb F6, in ten patients 
with nonresectable liver metastases of colorectal origin, who failed conventional 
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chemotherapy. The F6 MAb is a murine IgG1 antibody, which recognizes the Gold-1 
CEA-specific epitope.104 Activity doses administered varied between 3219 MBq and 
11100 MBq. Haematological toxicity was limited to grade II up to 9250 MBq, whereas 
after administration of 11100 MBq 131I-F(ab’)2 grade IV haematological toxicity devel-
oped, which was resolved by means of autologous bone marrow support. Out of nine 
evaluable patients, one patient showed a partial response of one small liver metasta-
sis, two patients had stable disease, whereas the remaining six showed progression 
of disease two to three months after therapy. 
Behr et al. investigated the therapeutic efficacy of a single administration of 131I-la-
beled MAb F023C5 in ten patients with small volume metastatic disease of CRC (all 
lesions ≤ 3 cm).103 F023C5 is a murine IgG1 MAb with a relatively low affinity constant 
(0.5 x 107 M-1) for CEA. The administered activity doses varied from 1850 MBq/m2 to 
2960 MBq/m2, although the MTD had not yet been reached at the highest dose level. 
Radioimmunoscintigraphy showed that all known tumor localizations were targeted. 
Dosimetric analysis indicated that the tumor absorbed radiation dose increased ex-
ponentially with decreasing tumor size, with the highest dose of 0.50 cGy/MBq ob-
served in a 0.5 cm tumor lesion. One patient had a complete remission, two patients 
had partial remissions whereas four patients showed stabilization of progressive dis-
ease, lasting for longer than 12 months.
TAG-72
TAG-72 was first identified in 1985 as the target antigen of the B72.3 antibody, which 
had been generated against membrane-enriched fractions of human metastatic 
breast carcinomas.105 TAG-72 is a high molecular weight glycoprotein complex (240-
400 kDa), which is expressed on 80% of colorectal carcinomas, whereas expression 
on normal tissues is limited.106 Besides CRC, various other adenocarcinomas, includ-
ing gastric, pancreatic, breast, lung, prostate and ovarian cancers express the TAG-
72 antigen. Anti-TAG-72 RIT has been studied in five trials involving patients with 
CRC.107-111 The first report was published in 1992 by Meredith et al.,108 who treated 
twelve patients with metastatic colon cancer with fractionated doses of 131I-labeled 
chimeric MAb B72.3 (IgG4, affinity constant 2.54 x 109 M-1) at total doses of 1036 
MBq/m2 or 1332 MBq/m2. Bone marrow suppression was the only significant side 
effect, which was significantly reduced when the total dose was fractionated. Nine 
of twelve patients developed an antibody response to the chimeric antibody, altering 
its kinetics in some patients in subsequent therapy courses. A minor response was 
observed in one patient. 
In the subsequent four trials in which TAG-72 was targeted, the murine MAb CC-49 
was used. CC-49 is a second generation anti-TAG-72 MAb and has a six-fold higher 
affinity (1.62 x 1010 M-1) for the TAG-72 antigen as compared to B72.3. Murray et al.111 
and Divgi and coworkers107 treated patients with metastatic CRC with 131I-labeled CC-
49 with the aim to determine its toxicity and efficacy. Murray et al. treated fifteen pa-
tients at 2775 MBq/m2 and did not observe a response. Divgi and coworkers treated 
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24 patients with escalating doses of 1665-8436 MBq/m2 and reported stabilization of 
disease in six patients four weeks post-therapy and a minor response in one patient, 
who received a second administration. 
Mulligan and co-authors have been the first to investigate the toxicity and MTD of 
177Lu-based RIT using the DOTA-conjugated CC-49 MAb in a small series of patients 
with advanced adenocarcinoma.110 Of the three patients described, three had colon 
cancer, five had breast cancer whereas one patient suffered from lung cancer. Unex-
pected and unexplained uptake in the bone marrow resulted in grade IV haemato-
logical toxicity and limited the maximal tolerated activity dose at only 555 MBq/m2. 
Tumor imaging was observed in all patients, although not all known tumor sites 
were visualized. Despite the relatively low activity doses administered, two patients 
experienced stabilization of previously progressive disease. Unfortunately, it was not 
specified which patients showed stable disease.
Meredith et al.109 performed the only study investigating the efficacy of dual-antibody 
RIT using two antibodies, directed at TAG-72 and CEA. This was done in an attempt 
to overcome heterogeneity of tumor antigen expression. In addition, interferon-α 
(IFN) was added to enhance the expression of both antigens in the tumor. Fourteen 
patients with metastatic CRC were treated with anti-CEA murine MAb COL-1 and 
anti-TAG-72 murine MAb CC-49, both labeled with 131I at a total dose of 2775 MBq/
m2. Although dual-antibody RIT combined with IFN treatment appeared to result in 
enhanced tumor targeting and consequently higher radiation doses at tumor sites 
as compared to historical controls, the estimated tumor absorbed radiation doses 
varied from four to thirteen Gy, which is too low to result in objective responses. The 
murine CC-49 MAb was highly immunogenic, since human anti-mouse antibody im-
mune responses were recorded in almost all patients in the above mentioned trials.
A33
The A33 antigen is an extensively studied antigen, which is expressed by the epithelia 
of the gastrointestinal tract as well as by carcinomas of the colon and rectum.112,113 
A33 is a relatively small antigen (MW 43 kDa), which, because of its high and homog-
enous expression in 95% of metastatic colorectal carcinomas, has been targeted in 
two phase I/II RIT trials in patients with CRC.114,115 In these trials, the A33 antigen 
was targeted using the radioiodinated homonymous murine IgG2a MAb A33. After 
having shown scintigraphically and by radioactivity measurements of tissue biopsies 
that MAb A33 preferentially accumulated in metastases of patients with advanced 
CRC,116 Welt et al. conducted two phase I/II trials investigating the MTD and thera-
peutic efficacy of 125I- and 131I-labeled MAb A33. In their first trial, 23 patients with 
advanced CRC were treated with escalating activity doses of 131I-labeled A33 (1110-
3330 MBq/m2).114 Three mixed responses were observed, whereas in two patients CEA 
serum levels decreased after RIT. In their second trial, 21 patients with metastatic 
CRC were treated with A33 labeled with the Auger-electron emitter 125I (1850-12950 
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MBq/m2).115 Besides one mixed response, twelve patients experienced stabilization of 
previously progressive disease.
Ep-CAM
The Ep-CAM antigen, also known as the 17-1A antigen, is a 40 kDa transmembrane 
glycoprotein, which is expressed by normal gastrointestinal epithelium and at a 
higher level by several epithelial cancers, such as lung, breast, prostate, ovarian and 
colorectal carcinoma. It was described by Göttlinger et al. in 1986, who then called it 
the epithelial cell surface antigen 17-1A.117 An important feature of the Ep-CAM anti-
gen is that is not shed into the circulation, so that no complexation with circulating 
MAbs is to be expected. To date, one phase I/II trial has been reported, investigating 
the efficacy of anti-Ep-CAM RIT, using escalating activity doses (740-9250 MBq) of 
125I-labeled murine IgG2a MAb 17-1A in 28 patients with advanced CRC.118 Ten pa-
tients showed stabilization of disease. 
CSA-p
CSA-p can be demonstrated in approximately 60% of colorectal carcinomas and 
was first identified in 1974 by Pant et al.119 To date, one phase I trial investigating 
anti-CSA-p RIT has been published. Sharkey et al. administered escalating activity 
doses of 131I-labeled IgG (403 – 3633 MBq) or F(ab’)2 fragments (311 – 2960 MBq) of 
the murine Mu-9 MAb to 25 patients with advanced gastrointestinal cancer, among 
which 21 patients with CRC, with the aim to explore the targeting capabilities of Mu-
9 and to assess its pharmacokinetics and immunogenicity.38 Dosimetric analysis of 
scintigraphic images revealed a two times higher tumor-absorbed radiation dose per 
administered MBq for the 131I-Mu-9 IgG as compared to that of 131I-Mu-9 F(ab’)2, al-
though the dose absorbed by the normal organs, except for the kidneys, was two- to 
threefold less for the F(ab’)2. The majority of patients developed a HAMA response, 
although levels in patients treated with F(ab’)2 fragments were lower. Although the 
patients described took part in an ongoing RIT study, tumor responses of anti-CSA-p 
RIT were not reported.
Ovarian cancer
Ovarian cancer has been targeted in RIT trials using mainly antibodies directed 
against the MUC-1 antigen and a few other tumor-associated glycoproteins, such as 
TAG-72 and gp-38.120 Because of its high propensity to stay confined to the perito-
neal cavity until very late in the course of the disease, radiolabeled antibodies have 
been administered intraperitoneally in most trials. Indeed, in several preclinical and 
clinical studies it was demonstrated that the intraperitoneal route of administration 
results in higher uptake of radiolabeled antibodies in tumor as compared to the intra-
venous route of administration.121-126 Other authors, however, could not confirm an 
advantage of intraperitoneal over intravenous administration.127 It has furthermore 
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been suggested that intravenous administration may result in a more homogeneous 
uptake in intraperitoneal tumors, as compared to intraperitoneal administration.128 
Several clinical trials on RIT in patients with ovarian cancer have been published. The 
best representative trials have been summarized in Table 4.
MUC-1 
One of the very first clinical trials of RIT in patients with ovarian cancer was carried 
out by Epenetos et al., who treated 24 patients with stage III ovarian cancer, after 
cytoreductive surgery and first-line platinum-based chemotherapy, with escalating 
activity doses of 131I-labeled MAb HMFG-1, HMFG-2, AUA 1 or H17E2.129 Clinical re-
sponses were limited to those sixteen patients with minimal residual or small-vol-
ume disease (<2 cm). Four patiens experienced complete responses for up to 3 years, 
whereas five patients showed stable disease for up to 20 months. Interestingly, three 
patients that had microscopic disease only at the time of RIT showed a pathologically 
confirmed complete response, as demonstrated during a second-look laparoscopy.
In a second trial, Nicholson et al. tested the efficacy of 666 MBq/m2 90Y-labeled HMFG-
1 MAb in 21 patients with stage IC-IV ovarian cancer who had no macroscopic disease 
after cytoreductive surgery and completion of platinum-based chemotherapy.130 Six-
teen patients were still alive ten years after treatment, which was significantly bet-
ter than the median survival of less than four years of a matched historical control 
group. Epenetos et al. reported later that within the subgroup of 21 patients who 
experienced a complete remission following cytoreductive surgery, chemotherapy, 
and intraperitoneal RIT, the median survival had not yet been reched at a follow-up 
of >12 years.131 Based on these promising results a multicenter phase III RCT was 
initiated, comparing the efficacy of 90Y-DOTA-HMFG1 to no treatment in a total of 
447 patients with ovarian cancer with no evidence of disease following cytoreduc-
tive surgery and platinum- or taxol-based chemotherapy, as confirmed by diagnostic 
laparoscopy. Unfortunately, preliminary results have indicated that adjuvant RIT did 
not result in a significant survival benefit in these patients.132 
TAG-72
The majority of ovarian carcinomas express TAG-72.133 The first antibody used for 
radioimmunotherapeutic application was the murine MAb B72.3. After studying the 
clinical pharmacology, metabolism and tissue distribution and confirming prefer-
ential uptake of 90Y-labeled B72.3 in tumor in nine patients with ovarian cancer,134 
Rosenblum et al. performed a dose-escalation phase I study of RIT using 90Y-DTPA-
B72.3 in a total of 58 patients with ovarian cancer.135 Continous intravenous infusion 
of EDTA was applied in order to suppress the uptake of 90Y in bone, which allowed 
the administration of higher activity doses. Two minor, and two complete esponses 
were noted in four patients who received 555-1110 MBq. 
Alvarez et al. conducted two phase I/II trials, in which they investigated the toxicity 
and efficacy of the second-generation anti-TAG-72 MAb CC49, labeled with either 90Y 
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or 177Lu.136,137 In their first trial, 27 patients with ovarian cancer, who failed conven-
tional chemotherapy, were treated with 177Lu-CC49. The maximal tolerated activity 
dose was established at 1665 GBq/m2, at which dose-limiting myelosuppression was 
encountered.136 Serial radioimmunoscintigraphic imaging revealed intraperitoneal 
tumors in 19 out of 27 patients up to 19 days after administration of the radiolabeled 
antibodies. There seemed to be a correlation between tumor mass and response. Of 
the 13 patients with measurable disease, one showed a partial response. Of the nine 
patients with <1 cm tumor nodules, two patient showed stable disease for 4 and 5 
months, respectively, whereas the remaining 7 patients progressed within 21 months. 
Five patients had microscopic disease only on study entry. Of these, one showed evi-
dence of progression at 10 months, whereas the remaining four patients remained 
disease-free at 6-35 months post-treatment.
Meredith et al. subsequently tested the feasibility and efficacy of the combination 
of intraperitoneal RIT using 177Lu-CC49 and intraperitoneal Paclitaxel (100 mg/m2) 
in 34 patients with ovarian cancer.138 Chemotherapy was given 48 hours prior to the 
administration of the radiolabeled antibodies. In addition patients received subcuta-
neous injections of IFN α2b in order to enhance the expression of TAG-72. The MTD 
of 177Lu-CC49 within this combination treatment regimen was reached at 1480 MBq/
m2, above which dose-limiting bone marrow toxicity occurred. Four out of seventeen 
patients with measurable disease on CT had partial responses, whereas four out of 
27 patients with nonmeasurable disease experienced progression-free time intervals 
of >18 months. 
After showing the feasibilty of the combination of RIT using 177Lu-CC49 and Paclitax-
el in a phase I trial, Alvarez et al. treated twenty patients with persistent or recurrent 
ovarian cancer after conventional cytoreductive surgery and chemotherapy, with a 
combination of RIT using 90Y-labeled CC49 and chemotherapy using paclitaxel, with 
the aim to feasibility and MTD of 90Y-CC49 when applied within an intraperitoneal 
combined modality treatment protocol.137 Patients received subcutaneous injections 
of interferon (IFN) alpha2b as well. The MTD of 90Y-CC49 was reached at 895 MBq/m2 
with hematological toxicity being dose-limiting. Of nine patients with measurable 
disease, two had partial responses for up to 4 months. Eleven patients had nonmeas-
urable disease. Of these four patients remained disease-free, three of whom longer 
than 18 months post-treatment. 
gp-38
Another tumor-associated glycoprotein targeted with radiolabeled antibodies in 
ovarian cancer is gp-38, a 38 kDa protein that was identified as the alpha isoform of 
the folate receptor. Being a marker for malignant transformation in the ovary, it is 
constitutively expressed at high levels in up to 90% of nonmucinous ovarian carci-
noma, while expression levels at other epithelial tissues are low.139 
Anti-gp-38 RIT has been applied in patients with ovarian cancer, using the murine or 
chimeric MOv18 MAb. After demonstrating preferential uptake of intraperitoneally 
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or intravenously administered 131I-labeled murine MOv18 MAb in tumor in 30 pa-
tients with ovarian cancer,126 Crippa et al. tested the efficacy of high-dose intraperi-
toneal RIT using 131I-MOv18 (3700 MBq) in sixteen patients with minimal or small 
volume ovarian cancer (macroscopic disease < 5 mm or positive blind biopsies and/or 
positive peritoneal washing).140 Clinical follow-up and/or third-look evaluation per-
formed 90 days after RIT showed complete response in five patients, stable disease 
in six patients and progressive disease in the remaining five patients. Of the five 
patients that experienced a complete response, one patient remained clinically dis-
ease-free for 34 months, whereas the remaining four patients relapsed after a mean 
disease-free period of 10.5 months. The murine MOv18 MAb, however, was highly 
immunogenic, with HAMA formation in fifteen out of sixteen patients. 
At the Vrije Universiteit medical center (Amsterdam, The Netherlands) Van Zanten-
Przybysz et al. studied the pharmacokinetics and efficacy of RIT using 131I-labeled 
chimeric MAb MOv18 (3 GBq) in three patients with ovarian cancer.141 In addition, 
the tumor-absorbed radiation dose was estimated by means of dosimetric analysis of 
repeated radioimmunoscintigraphic images. All patients experienced stabilization of 
disease for two to six months, as assessed by CT scans and serum CA 125 measure-
ments. Tumor-absorbed radiation doses varied from 600 to 3800 cGy. None of the 
patients developed a HACA response. 
Breast cancer
Because of its common prevalence, its relative radiosensitivity, and the availability 
of MAbs against TAAs, breast cancer has been one of the first malignancies targeted 
with radiolabeled antibodies. TAAs targeted in RIT in patients with breast cancer 
include CEA, MUC-1, and L6, as recently reviewed by Sally DeNardo.142 The best rep-
resentative trials have been summarized in Table 5.
CEA
Although CEA expression has been reported in only 19% of breast cancers,143 anti-
CEA radioimmunodetection and RIT has been evaluated in patients with breast can-
cer with several MAbs, including the murine IgG1 NP-4, and the second-generation, 
high-affinity chimeric MAb T84.66. 131I and 90Y were the radionuclides used. RIT us-
ing 131I-labeled NP-4 has been investigated in a mixed adenocarcinoma patient group 
with some responses in patients with breast cancer.142 Wong et al. evaluated the tox-
icity of single-dose RIT using 90Y-labeled DTPA-conjugated chimeric MAb T84.66 in 
patients with metastatic breast cancer and established the MTD at 814 MBq/m2, with 
grade 3 reversible myelosuppression being dose-limiting.144,145 After imaging studies 
confirmed tumor-targeting, six patient received higher activity doses of 90Y-DTPA-
cT84.66 in combination with autologous PBSC support. Clinical responses were 
achieved, including stabilization of disease progression for up to four months, im-
provement in bone scans, a 50% reduction of a metastasis, and the reduction of pleu-
•
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ral effusion or bone pain for up to 14 and 3 months, respectively, which suggests that 
stem-cell supported 90Y-DTPA-cT84.66-based RIT might have therapeutic potential 
in patients with breast cancer.
MUC-1
RIT using antibodies directed against the MUC-1 antigen has been tested in patients 
with breast cancer using various antibodies, including BrE-3 and the m170.146 De-
nardo et al. conducted a phase I dose-escalation trial, with the aim to determine the 
pharmacokinetics and maximal tolerated dose of 90Y-MX-DTPA-labeled BrE-3 in six 
patients with metastatic breast cancer.147 Whereas the highest dose applied was only 
342 MBq/m2, three patients showed objective evidence of a response, e.g. a partial re-
sponse in one, and reduction of arm swelling and skin lesions in another. In a subse-
quent phase I trial the feasibility and efficacy of a single high-dose administration of 
90Y-DTPA-BrE-3 combined with PBSC support was investigated in nine patients with 
metastatic breast cancer, who had been heavily pretreated with chemotherapy.148 De-
spite PBSC support, grade 4 thrombocytopenia and leucocytopenia was observed 
in four and two patients, respectively. Four out of eight patients with measurable 
disease showed objective partial responses. 
Because the majority of the patients rapidly HAMA against the murine BrE-3 MAb, 
a humanized version of BrE-3 was developed. Kramer et al. investigated the phar-
macokinetics and biodistribution of 111In-MX-DTPA-labeled hBrE-3 in seven patients 
with metastatic breast cancer. hBrE-3 proved to have a lower immunogenicity as 
compared to the murine BrE-3 (only one patient developed a HAHA response) while 
tumor-targeting properties were preserved. Dosimetric analysis indicated that a ra-
diation dose of 1.9 ± 0.8 cGy/MBq could be delivered to tumor assuming that the 
biodistribution of 90Y-MX-DTPA-hBrE-2 would have been similar to that of 111In-MX-
DTPA-hBrE-2. A phase I dose-escalation study was then initiated, in which patients 
with metastatic breast cancer received a single administration of high-dose RIT using 
90Y-MX-DTPA-hBrE-2, two weeks later followed by reinfusion of G-CSF mobilized 
PBSCs. Preliminary reports to date indicate that the maximal tolerated activity dose 
is substantially increased, with two patients having received 1850 MBq/m2 without 
encountering dose-limiting toxicity. Two patients showed partial responses, three 
patients showed stabilization of previously progressive disease, four patients expe-
rienced improvement of symptoms, whereas one patient showed progressive dis-
ease.146 
L6
The L6 cell surface antigen is highly expressed on the various carcinomas, including 
breast, lung, colorectal and ovarian cancer,149 and as such, has generated interest as 
a target for RIT. DeNardo et al. tested the efficacy of anti-L6 RIT using repeated ad-
ministrations (four monthly cycles) of 131I-labeled chimeric MAb L6 in ten patients 
with metastatic breast cancer, who had failed conventional chemotherapy.150 Activity 
•
•
Antibody-guided radiation therapy of cancer
43
doses varied from 740-2590 MBq/m2 and were administered after a diagnostic imag-
ing dose of 131I-cL6. Myelotoxicity was dose-limiting. Six patients experienced clini-
cally measurable tumor responses, consisting of partial responses in three patients 
and short-term stabilization of rapidly progressive disease in one patient. 
As mentioned previously, Richman et al. reported on three additional patients who 
were treated with 131I-L6 at 5550 MBq/m2 with PBSC support, which controlled bone 
marrow toxicity.54 One of these patients, treated with cyclosporin A to prevent HACA 
formation, received even three therapy cycles, rendering her clinical condition mark-
edly improved for up to nine months. 
Renal cell cancer
Several tumor-associated antigens have been targeted in experimental models of RIT 
of renal cell cancer (RCC). The only antigen used in clinical RIT is G250, which has 
been targeted using the homonymous MAb G250. Table 6 summarizes the character-
istics of the reported trials on RIT using G250 in patients with RCC.
At the Radboud University Nijmegen Medical Center as well as the Memorial Sloan 
Kettering Cancer Institute several clinical studies have been conducted on the fea-
sibility, toxicity and efficacy of RIT using radiolabeled G250. Oosterwijk et al.151 de-
termined the optimal protein dose of the murine G250 MAb in fifteen patients with 
their renal cell cancers still in situ. Seven or eight days prior to tumor nephrectomy, 
fifteen patients received a diagnostic dose of 131I-labeled G250. Clear tumor localiza-
tion was observed in all twelve patients with G250 positive tumors and in one of 
three patients with G250 negative tumors. The smallest lesion visualized was 8 mm, 
whereas uptake of the radiolabel in the tumor reached as high as 0.12% ID/g.
In a subsequent therapy study, Divgi et al. administered escalating activity doses 
(1110-3330 MBq/m2) of 131I-labeled G250 to patients with metastatic renal cell can-
cer.152 The MTD was reached at 3330 MBq/m2, with bone marrow toxicity being dose-
limiting. Altough there were no objective responses, seventeen out of thirty-three 
evaluable patients showed stabilization of disease-progression. The murine G250 
MAb, however, proved highly immunogenic since all patients developed a HAMA 
response.
After the development of the chimeric form of G250, Steffens et al.153 performed a tu-
mor-targeting study with tracer-doses of 131I-labeled chimeric G250 in patients with 
renal cell cancer. It was shown that focal uptake of 131I-cG250 in RCC lesions could be 
very high (up to 0.52% of the injected dose per gram). Dosimetric analysis confirmed 
that potentially tumoricidal radiation doses, up to 1.95 cGy/MBq, could be guided to 
RCC lesions.In a subsequent phase I study involving twelve patients with metastatic 
RCC, Steffens et al. subsequently established the maximal tolerated activity dose of 
131I-cG250 at 2220 MBq/m2.154 In this study, one patient showed a partial response, 
whereas another patient experienced stabilization of previously progressive disease 
for >6 months. 
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After Steffens et al. demonstrated the feasibility of RIT using 131I-labeled cG250 in 
patients with metastatic renal cell cancer, Brouwers et al. performed a phase I/II trial 
with the aim to define the feasibility and efficacy of repeated high-dose 131I-cG250.155 
Twenty-seven patients with progressive metastatic renal cell cancer received a thera-
peutic infusion of 2220 MBq/m2 131I-cG250 (=MTD). Three patients experienced grade 
4 hematological toxicity after the first therapy course and were considered not eligible 
to receive a second course of RIT. After completion of the first RIT course, nineteen 
patients received a second therapeutic infusion of 131I-cG250. Grade 4 hematological 
toxicity limited the maximal tolerated dose of a second RIT course of 131I-cG250 to 
1665 MBq/m2, or approximately 75% of the MTD of the first RIT course. Dosimetric 
analysis revealed an inverse correlation between tumor size and radiation absorbed 
dose, although there was a wide variation in the tumor radiation doses. No objective 
responses were recorded. Still, four out of fifteen evaluable patients who received 
two therapy courses experienced stabilization of previously progressive disease for 
up to six months.
Divgi et al. tested the tolerability and efficacy of fractionated RIT which consisted 
of up to three therapy courses of 131I-cG250 in fifteen patients with metastatic and 
progressive renal cell cancer.156 Thus, it was reckoned, bone marrow toxicity might 
be reduced, enabling the delivery of higher tumor-absorbed doses. The administered 
activity dose of the first administration amounted 1110 MBq (30 mCi). In the follow-
ing administrations, each separated by 2-3 days, the activity dose was determined by 
“topping up” the whole body activity to 1110 MBq (30 mCi). Five patients received 
two cycles of therapy, while only two patients were able to complete three cycles. 
Out of fourteen evaluable patients, seven patients showed stable disease, for 2-11 
months. Hematological toxicity was dose-limiting. Furthermore, dosimetric analysis 
could not substantiate evidence of bone marrow sparing by fractionation.
Brouwers et al. performed an intra-patient analysis comparing the targeting prop-
erties of 111In-labeled ITC-DTPA-cG250 with 131I-labeled cG250 in five patients with 
metastatic RCC.157 Four days post-injection of the radiolabeled antibodies, 111In-ITC-
DTPA-cG250 revealed significantly more RCC lesion than 131I-cG250 (47 versus 30). 
Quantitative analysis of the images furthermore revealed higher activities of 111In-
ITC-DTPA-cG250 than 131I-cG250 in 20 of 25 lesions. Most likely, the higher activities 
of 111In-ITC-DTPA-cG250 in the metastatic lesions are caused by internalization and 
subsequent intracellular retention of the radiolabel, which implies that residualizing 
radionuclides, such as 90Y or 177Lu, might be better suitable for RIT using cG250 in 
patients with RCC than 131I. Currently, at the Radboud University Nijmegen Medical 
Center a phase I/II therapy trial has been initiated, investigating the efficacy of 177Lu-
labeled ITC-DTPA-cG250 in patients with RCC.
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Pretargeted RIT trials
Preclinical and clinical research on the application of pretargeted RIT using the 
(strept)avidin-biotin or bispecific antibody methodology has been extensively re-
viewed by Boerman et al.41 To date, four reports have been published on pretargeted 
RIT using therapeutic activity doses in patients with metastatic carcinoma. Table 7 
summarizes the characteristics of the reported trials on pretargeted RIT in patients 
with epithelial cancers.
Bardies and colleaugues investigated the feasibility of pretargeted RIT in five pa-
tients with metastatic medullary thyroid cancer and five patients with metastatic 
small-cell lung cancer, whose tumors were pretargeted with the anti-CEA x anti-
DTPA-In bsMAb F6-734.158 Four days later, patients received a diagnostic dose (222-
370 MBq) 131I-labeled di-DTPA. Dosimetric analysis of radioimmunoscintigraphic 
images revealed that the radiation dose to the medullary thyroid carcinoma lesions 
was much higher (range: 113 - 470 Gy/MBq) than the radiation dose to the SCLC le-
sions (range: 4.6 - 22 Gy/MBq), suggesting that MTC might be a more suitable target 
for this pretargeted RIT. Subsequently, Kraeber-Brodéré et al. tested the feasibility 
and therapeutic efficacy of pretargeted RIT in 26 patients with recurrent medullary 
thyroid carcinoma.159 Tumors were pretargeted with 20-50 mg anti-CEA x anti-DTPA-
In bsMAb, after which 1.48 - 3.7 GBq 131I-di-DTPA was administered four days later. 
Dose limiting toxicity was hematological; an activity dose of 1.78 GBq/m2 could be 
administered safely. The radiation dose to the tumor ranged from 7.9 - 500 Gy/MBq. 
Of the seventeen evaluable patients, five showed minor responses, four experienced 
symptom improvement (pain relief), whereas in four patients serum calcitonin levels 
decreased.
As expected, in a similar pretargeted RIT study reported by Vuilez et al. in fourteen 
patients with small cell lung cancer, the radiation doses to the tumor were lower 7.0-
87 Gy/MBq.160 In that study, patients received a total of 1.48-6.66 GBq 131I-diDTPA 
four days after pretargeting with 20-80 mg anti-CEA x anti-DTPA-In bsMAb. Inter-
estingly, the MTD of the 131I-labeled di-DTPA peptide in these patients was much 
higher (5550 MBq) than the MTD in patients with medullary thyroid cancer, possibly 
because most patients with disseminated medullary thyroid cancer have micrometa-
static disease in the bone marrow. In the latter study in patients with small cell lung 
cancer, the activity dose was further escalated, until second organ toxicity. Patients 
receiving 5550 MBq or more, PBSCs were harvested prior to treatment and reinfused 
10-15 days after injection of the radioactivity. Out of 12 evaluable patients, two pa-
tients showed a partial response.
In a phase I trial Kraeber-Brodéré et al.161 attempted to optimize pretargeted RIT with 
respect to the bispecific hMN-14xm734 MAb dose and the time interval between the 
administration of the bispecific MAb and a 131I-labeled peptide. Thirty-five patients 
with CEA-expressing cancers were included, among whom 15 patients with CRC. Op-
timization of the BsMAb dose and the time interval between both injections allowed 
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the administration of high activity doses, that, based on dosimetric analyses, could 
be tumoricidal. Antitumor effects, however, were not reported.
Knox et al.162 performed a phase II trial investigating the therapeutic efficacy of pre-
targeted RIT in 25 patients with metastatic colon cancer, using the anti-Ep-Cam MAb 
NR-LU-10, conjugated to Streptavidin (NR-LU-10/SA) and 90Y-DOTA conjugated bi-
otin. One day after the administration a clearing agent (biotin-galactose-albumin) 
was administered to remove unbound circulating NR-LU-10/SA. Finally, one day af-
ter administration of the clearing agent, 90Y-DOTA-conjugated biotin was adminis-
tered. Due to reactivity of NR-LU-10/SA with bowel epithelium as well as the rapid 
renal clearance of 90Y-DOTA-biotin from the blood, haematological toxicity was less 
severe than nonhaematologic toxicity, which consisted of grade 3, 4, or even 5 di-
arrhoea in 32% of patients. Two patients, however, experienced partial responses, 
whereas four patients had stabilization of progressive disease for up to 20 weeks. 
Importantly, two patients showed significant elevations of serum creatinine levels 
seven and eight months after therapy, that could not be explained by disease pro-
gression. This important observation once again points at the potential danger of the 
application of radiolabeled haptens in pretargeted RIT, with respect to irreversible 
radiation damage to the kidneys.
Conclusion
The appealing concept of systemically delivering targeted radiotherapy by means of 
radiolabeled antibodies for the treatment of cancer has had a history of more than 
50 years. With the introduction of MAbs thirty years ago, a great number of tumor-
associated antigens have been identified. Since then, huge progress has been made 
in understanding the complexity and difficulties of this treatment modality. To date, 
RIT has emerged as an accepted treatment for patients with NHL, for which two radi-
olabeled MAbs have been approved in the US by the FDA for therapeutic application. 
The therapeutic application of radiolabeled MAbs in solid cancers, however, has met 
considerable difficulties, mainly because uptake of the radiolabeled MAbs in tumor 
tissue in many cases is too low to result in tumoricidal radiation doses to the tumors. 
The limited number of clinical phase I/II RIT trials, using different antibodies and 
radionuclides at various activity doses yet precludes the drawing of any firm conclu-
sion on the potential promise of RIT in the treatment of patients with solid cancers. 
Most patients included in these trials suffered from advanced, mostly bulky, meta-
static disease, which is a highly unfavorable setting for the application of radiolabeled 
antibodies. As a result, radiation doses delivered to the tumors by the radiolabeled 
antibodies were probably below tumoricidal doses in most cases. Whereas in the ma-
jority of patients in most studies disease progression was observed, a few patients, 
however, still experienced objective partial remissions or short-term stabilization of 
previously progressive disease. The observation of some tumor responses in these 
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heavily pretreated patients with bulky disease once again suggests that RIT in pa-
tients with small volume disease may be much more effective. The modest therapeutic 
results of RIT in patients with solid cancers may therefore leave room for qualified 
optimism. Although several strategies aimed at increasing the therapeutic window 
are currently under investigation, patient selection may be the most important factor 
determining the eventual success of Paul Ehrlich’s concept of magic bullets in RIT for 
patients with solid cancers. Based on the results thus far achieved, the time may have 
come to design clinical trials in which RIT is added to standard regimens, in order to 
establish the place of this treatment modality. Since small volume disease has been 
recognized as the most suitable setting for the application of radiolabeled MAbs in 
solid cancers, RIT given as adjuvant treatment may prove its true value in patients 
with solid cancers, such as after resection of primary tumors with a high risk of dis-
tant metastases.
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Besides the lymphatic and hematogenous routes of dissemination, colorectal cancer (CRC) frequently gives rise to transcoelomic spread in the peritoneal cavity, which, ultimately, may cause peritoneal carcinomatosis (PC). During 
the course of disease of a patient with a gastrointestinal cancer, it is believed that 
there are two time points at which intraperitoneal spread or seeding of cancerous 
tumor emboli may occur.1 Firstly, intraperitoneal spread may occur pre-operatively as 
a result of full-thickness invasion of the bowel wall by an invasive cancer. Pre-opera-
tive seeding may also occur as a result of the rupture of a structure by a non-invasive 
tumor, such as the mucus producing cystadenocarcinoma of the appendix. This leads 
to the clinical syndrome of pseudomyxoma peritonei, characterized by massive in-
traperitoneal accumulation of mucus in the absence of organ metastases. This rare 
clinical entity has been reviewed elsewhere and is beyond the scope of this paper.2,3 
Secondly, intraperitoneal spread may be induced iatrogenically during surgery, when 
in-transit tumor cells or emboli escape from dissected lymph vessels, the bowel lumen 
or reach the peritoneal cavity through blood spill from the surgical field. 
Until recently, most oncologists considered PC a terminal condition, only to be palliat-
ed with systemic chemotherapy. However, it has been estimated that in approximately 
25% of patients with recurrent CRC, the peritoneal cavity seems to be the only site of 
metastatic disease, even after a detailed diagnostic work-up of the liver and lungs.4,5 
Because of this observation some surgical oncologists hypothesized that, similar to 
liver metastases, PC may be a first step of dissemination and should, therefore, not 
necessarily be interpreted as generalized disease.6,7 In recent years, a new therapeutic 
approach has been investigated in a dozen medical centers worldwide, aimed at loco-
regional control and long-term survival.8 This approach is based on aggressive cytore-
ductive surgery after which the peritoneal cavity is perfused with chemotherapeutics, 
sometimes under hyperthermic conditions, in order to sterilize (minimal) residual 
disease.
Here, the available literature on the incidence and prognostic significance of micro-
scopic peritoneal dissemination of tumor cells as well as on the incidence of true intra-
peritoneal recurrence in CRC is reviewed. Finally, the results of clinical trials investi-
gating the feasibility and efficacy of cytoreductive surgery followed by intraperitoneal 
chemotherapy (IPEC) for the treatment of PC of colorectal origin are discussed. 
Incidence and prognostic significance of intraperitoneally seeded 
tumor cells in colorectal cancer
Between 1980 and 2004, twelve papers have been published reporting the results of 
clinical studies on the incidence and/or prognostic relevance of microscopic perito-
neal dissemination of tumor cells in patients undergoing curative surgery for primary 
CRC.9-20 These trials focussed on patients with primary colorectal cancer who under-
went surgery with curative intent and excluded patients with evidence of hematoge-
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nous metastases, PC or ascites or patients who had undergone emergency surgery for 
obstructive of perforated cancers. The relevant trial characteristics are summarized in 
Table 1. 
Although the inclusion and exclusion criteria were similar, the studies differed with 
respect to design, methods of collecting the specimens and pathological staining tech-
niques. Four trials explicitly mentioned the inclusion of consecutive patients.12,15,17,19 
In eight trials material for cytological analysis was harvested by pouring normal sa-
line onto the serosal surface of the tumor bed immediately after entering the ab-
dominal cavity and, in some studies, again after the resection prior to closure of the 
abdomen.9-13,17-19 In two trials, material was obtained by gently touching, scraping or 
brushing the serosa overlying the tumor mass using a slide glass or brush,15,20 whereas 
in two trials both aforementioned techniques were used.14,16 In all but one trial an 
attempt was made to identify cancer cells using conventional cytology and/or im-
munocytochemistry. One trial used the sensitive polymerase-chain reaction (PCR) 
technology to detect the presence of free cancer cells in the peritoneal cavity.10 
In three trials an attempt was made to determine the sensitivity and/or specificity of 
the used method by searching for tumor cells in peritoneal lavage fluid obtained from 
patients with well-known peritoneal metastases and/or benign diseases undergoing 
surgery.9,10,17 In two of the three trials specificity was 100%,10,17 whereas in the third 
trial nonspecific immunocytochemical staining in one of six control patients with di-
verticular disease resulted in a specificity of 83%.9 One trial included a well-defined 
positive control group of 22 patients with well-established PC, nineteen of whom had 
tumor-positive cytology, corresponding to a “sensitivity” of 86%.17 
Incidence of peritoneal seeding
Peritoneal lavage fluid obtained prior to resection proved tumor positive in 3% to 
28%,9-14,16-20 whereas scraping the serosa overlying the primary tumor site or pressing 
slide glasses on the serosa overlying the tumor generally resulted in somewhat higher 
incidence rates of 15% to 42%.14,16,20 Interestingly, Uras et al.16 and Ojima et al.14 tested 
the accuracy of serosal stamp cytology by including serosal stamps of bowel surfaces 
far away from the primary tumor. These control stamps were tumor-positive in 3%. 
In four trials, peritoneal lavage was performed prior to as well as after resection of 
the tumor. Where reported, the conversion rate from tumor-negative pre-resection to 
tumor-positive post-resection lavage fluid, apparently as a result of the surgery, varied 
considerably from 0 till 10%.10,11
Prognostic significance of peritoneal seeding
Several authors have made an attempt to (univariately) correlate the finding of tumor-
positive cytology with various clinicopathological parameters, including pathological 
TNM stage, malignancy grade, locoregional recurrence rate and/or survival. Although 
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in ten trials the incidence of tumor-positive cytology correlated significantly with 
more advanced stages of disease, especially T-stage,11,12,16,17,19,20 Solomon et al.15 could 
not confirm this correlation in a large prospective series of 105 patients with CRC. In-
stead, Solomon et al. found tumor cells on the serosal surface of resection specimens 
more frequently after resections of distal tumors, that required anterior or abdomi-
noperineal resections. 
Interestingly, Yamamoto et al.18 and Kanellos et al.12 found tumor-positive cytology 
to be significantly correlated with the risk of intraperitoneal recurrence. Both groups 
used similar techniques of instilling normal saline in the peritoneal cavity immediately 
after entering the abdomen in 113 and 189 patients undergoing curative resection for 
CRC, respectively. Conventional Papanicolaou and Giemsa staining of the peritoneal 
lavage revealed tumor cells in 5.8% and 20% of patients, respectively. The relative risk 
of intraperitoneal recurrence in those patients with tumor-positive cytology as op-
posed to patients with tumor-negative cytology was 16.5 (95% CI 4.8-57.5, P=0.0004) 
and 2.9 (95% CI 1.0-8.2, P=0.047), respectively. 
Two trials, finally, reported that tumor-positive cytology correlated with impaired 
overall or disease-free survival.10,17 However, in none of the studies multivariate analy-
ses were carried out to determine whether tumor-positive cytology has an independ-
ent prognostic impact or is merely a confounding prognostic indicator. 
Incidence of intraperitoneal recurrence in colorectal cancer
Since hematogenous metastases have always been the main cause of disease-related 
death in CRC, the intraperitoneal route of dissemination has long been regarded as 
less important. In the nineteen-seventies and -eighties, however, several authors pub-
lished retrospective studies concerning the patterns of failure in patients with CRC, 
recognizing the peritoneal cavity as a common site of recurrence after potentially 
curative surgery. These patient series were either retrospective clinical follow-up stud-
ies,21-28 reoperation series,29,30 or autopsy studies of patients who had succumbed to 
CRC.23,31 Table 2 summarizes the incidence rates of intraperitoneal failure reported in 
these studies. It should be noted that since in the late nineteen-eighties the surgical 
technique of resection in rectal cancer has changed towards total mesorectal excision 
(TME) and preoperative radiotherapy, the local recurrence rates after surgery for rec-
tal cancer has dramatically decreased to less than 3%.32 Whether or not the introduc-
tion of the TME technique has affected the incidence of PC is unknown.
Clinically evident locoregional failure, in most studies defined as recurrence in the 
bowel anastomosis or in the resection bed was reported in 5%-18% after curative re-
section of colon cancer. PC was reported in 4%-12% after curative resection of colon 
cancer, and in 2%-19% after curative resection of rectal cancer. Recently, Jayne et al.33 
retrospectively analyzed a large series of 3019 patients with CRC: 214 patients (7%) 
had synchronous PC at the time of resection of the primary tumor, whereas another 
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135 patients (4.5%) developed metachronous carcinomatosis. Of the patients with 
synchronous PC, 58% did not seem to have systemic metastatic disease.
Gunderson et al.29 studied the areas of failure in 91 patients with extrapelvic Dukes 
B or C colon cancer who underwent a planned second-look laparotomy six to twelve 
months after a potentially curative resection. Locoregional recurrence either alone or 
as a component of failure was confirmed in 48% of patients. PC as the sole pattern of 
recurrence or as a component of failure was found in 4% and 21%, respectively. Tong et  
al.30 mapped the sites of failure in patients who required relaparotomy for suspected 
recurrent proximal colon cancer and found local recurrence in 47% and diffuse PC in 
44% of patients.
Gilbert et al.23 showed that in a autopsy series of 45 patients who had succumbed to 
CRC, 18 patients had PC. In a similar autopsy series of 53 patients who died of colon 
cancer, Russell et al.31 reported a local recurrence rate of 38%, whereas 36% of patients 
had PC. 
These data indicate that in patients with CRC, intraperitoneal recurrence is a rather 
common phenomenon with important clinical consequences for both medical and 
surgical oncologists.
Systemic chemotherapy for peritoneal carcinomatosis of colorectal 
origin
To date, four clinical studies have been published dedicated to the efficacy of chemo-
therapeutic treatment of patients with PC of colorectal origin. In 1989, Chu et al.34 
prospectively analyzed a series of 100 patients with PC of nongynecologic cancers, 
among whom 45 patients with CRC, with the aim to identify prognostic factors. In 
those patients with CRC, of whom the majority was treated with 5-FU and Leucovorin 
(LV), median survival was six months. Shorter disease-free interval, the presence of 
lung metastases, and the presence of ascites correlated significantly with decreased 
survival. In 2000, Sadeghi et al.    35 reported the results of a French prospective multi-
center study of 370 patients with PC of nongynecologic malignancy. The 118 patients 
with PC of colorectal origin in this study had a median survival of only 5.2 months. 
Jayne et al.33 recently published an extensive series of 3019 patients with CRC. The 
392 patients who presented with PC had a median survival of 7 months. Finally, Ver- 
waal et al.36 conducted a phase III randomized controlled trial, comparing ultraradi-
cal cytoreductive surgery and adjuvant hyperthermic intraperitoneal chemotherapy 
(HIPEC) and systemic 5-FU-based chemotherapy with systemic chemotherapy and 
palliative surgery in patients with PC of colorectal or appendiceal origin, but without 
evidence of extraperitoneal, metastatic disease. Overall median survival of the 50 pa-
tients who were treated with systemic chemotherapy and palliative surgery was 12.6 
months, with a two-year survival rate of approximately 18%. Median time to disease 
progression was 7.6 months. The better survival of the patients that received chemo-
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therapy and conventional surgery within this RCT as compared to the above men-
tioned results reported by other authors, is probably due to patient selection, since 
patients had to be medically fit to undergo cytoreductive surgery and HIPEC and were 
not allowed to have hematogenous metastases. 
Thus, the reported median survival of patients with PC of colorectal origin, with of 
without hematogenous metastases, after chemotherapy-based treatment, varies be-
tween 5.2 and 12.6 months. 
Historical perspective of cytoreductive surgery
As mentioned above, the presence of peritoneal metastases has for long been regarded 
as a lethal disease, characterized by ‘contamination’ of the entire abdomen, for which 
complete R0 resection was considered not feasible and, consequently, any attempt 
thereto futile. In the nineteen-thirties Meigs, an American gynecologist, was the first 
to advocate cytoreductive surgery followed by adjuvant radiotherapy in patients with 
ovarian cancer, a disease with a very high propensity to disseminate to the peritone-
um.37 The survival rate after cytoreductive surgery for the treatment of ovarian cancer, 
however, remained poor. As a result, treatment of ovarian cancer mainly depended 
on chemotherapy and surgical strategies were not optimized until the late sixties and 
seventies, when Munnell and Griffiths independently demonstrated that better sur-
vival rates could be achieved by more extensive surgery with the size of residual dis-
ease being the most important prognostic factor.38-40 Thus, the concept of ultraradical 
cytoreduction of PC was introduced.
In view of the improved results of ultraradical cytoreductive surgery in ovarian can-
cer, surgical oncologists regained a renewed interest in the subgroup of patients with 
colorectal carcinomatosis without evidence of hematogenous metastases. In 1979, 
after testing the technique of hyperthermic peritoneal perfusion in fifteen dogs, 
Spratt et al. were the first to report the results of cytoreductive surgery followed by 
hyperthermic IPEC using thiothepa in a 35-year-old patient with pseudomyxoma 
peritonei.41,42 Except for minor pulmonary atelectasis with bacteremia the patient’s 
postoperative course was uneventful. In the early eighties, this approach was adopted 
and optimized by Sugarbaker, who investigated its therapeutic efficacy in patients 
with peritoneal metastases of various gastrointestinal cancers.43,44 Since then, cytore-
ductive surgery and adjuvant (hyperthermic) IPEC has been further developed and 
applied by 30 medical centers worldwide in patients with various kinds of peritoneal 
surface malignancy, including PC, sarcomatosis and peritoneal mesothelioma.8 Sev-
eral reviews have been published describing the techniques of cytoreductive surgery,45 
the rationale of hyperthermia46 and the various methods of the intraperitoneal ad-
ministration of chemotherapy.47
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Cytoreductive surgery and (hyperthermic) intraperitoneal chemo-
therapy in peritoneal carcinomatosis of colorectal origin
To date, 20 papers have been published reporting the toxicity, complications and 
survival results of trials investigating the morbidity, mortality and therapeutic ef-
ficacy of surgical cytoreduction followed by IPEC, either with or without hyperther-
mia, in patients with PC of colorectal origin.36,48-66 Relevant trial characteristics, as 
summarized in Table 3, differed with respect to design, patient selection and the 
treatment protocol. Thirteen studies were nonrandomized, single-arm, retrospec-
tive patient series, whereas three studies were comparative trials, two of which were 
randomized.36,50 
In nine trials only patients with PC of colorectal origin were included,48,51,52,54-57,59,65 
whereas in the remaining six trials patients with PC of appendiceal origin were also 
included.49,50,58,64,67,68 Since in the latter trials, the results were analyzed for patients 
with colorectal carcinomatosis separately, these reports were included in this re-
view. Furthermore, in seven trials patients with hematogenous metastases were 
eligible for inclusion.48,50,51,57,58,65,66 IPEC was administered intraoperatively in six tri-
als,36,51,55-57,64 early postoperatively in four trials,49,50,54,59 both intraoperatively and ear-
ly postoperatively in two trials,53,65 whereas in four patient series various protocols 
of administering chemotherapy intraperitoneally were utilized.48,58,66,67 In ten trials, 
IPEC was given under hyperthermic conditions,36,48,51,53,55-57,64-67 whereas in five trials 
it was not.49,50,54,58,59 Mitomycine-C was the most frequently used cytostatic agent, 
either alone,36,56,57,64 or in combination with 5-fluorouracil (5-FU)48,50,53,58,59,65,67 or Cis-
platin.55 Two trials, finally, used 5-FU alone,49,54 whereas in one trial oxaliplatin was 
administered.51
The clinical outcomes with respect to long-term survival varied considerably. In 
short, median survival varied from 12 till 32 months. One-year, 2-year, 3-year and, 
when reported, 5-year survival rates varied from 65-90%, 25-60%, 18-47% and 17-
30%, respectively. 
Toxicity and complications of cytoreductive surgery and (hyperthermic) in-
traperitoneal chemotherapy
Cytoreductive surgery followed by (hyperthermic) IPEC carries a high morbidity 
and a substantial mortality rate. Postoperative grade III and IV toxicity and com-
plications after cytoreductive surgery and adjuvant IPEC varied from 14% to 55%, 
whereas treatment-related mortality varied from 0 to 19%. 
Morbidity of cytoreductive surgery and (hyperthermic) IPEC can be categorized as 
surgery- or chemotherapy-related. Five studies have specifically addressed the tox-
icity and complications related to cytoreductive surgery and (hyperthermic) IPEC, 
two of which in patients with colorectal or appendiceal cancer only.53,63,69-71 
Peritoneal carcinomatosis of colorectal origin
73
Esquivel et al.69 reported on the complication rate associated with cytoreductive 
surgery and early postoperative IPEC using mitomycin-C (MMC) and 5-FU in 44 pa-
tients with PC of appendiceal, colonic, small bowel or fallopian tube origin. Twenty-
two patients had been treated with induction IPEC prior to cytoreductive surgery 
and postoperative IPEC. The median duration of postoperative ileus was 21 days, 
which was related to age and the extensiveness of the surgical cytoreduction. In 
four patients, postoperative hemorrhage required surgical reintervention, whereas 
two patients developed pneumonia and respiratory failure requiring orotracheal 
intubation. Enteric complications, including small bowel fistulas, anastomotic dis-
ruption, bile leak and pancreatitis occurred in seven patients (16%), of whom six 
had been treated with induction IPEC. The authors concluded that, since induction 
IPEC carries an increased risk for postoperative enteric complications, this treat-
ment modality should only be reserved for patients with small volume disease.
Jacquet et al.53 reported the morbidity and mortality rate of cytoreductive surgery 
and (hyperthermic) IPEC (MMC) in 60 patients with PC of colorectal or appendiceal 
origin. Serious complications were encountered in 35% of patients, with anasto-
motic leakage or bowel perforations being the most frequent and significantly cor-
related to the number of peritonectomy procedures and the duration of the opera-
tion. Three patients (5%) died from treatment-related causes. 
Verwaal et al.63 reported the toxicity of cytoreductive surgery and (hyperthermic) 
IPEC (MMC) in a series of 102 patients with PC of colorectal or appendiceal origin 
that had been treated according to the same protocol in prospective phase I, II or 
III trials. Grade 3, 4, or 5 toxicity, as recorded in accordance to the Common Toxic-
ity Criteria published by the National Cancer Institute (NIH CTC), was observed in 
65%. Surgical failures were encountered in 35 patients (35%), resulting in abdominal 
sepsis in sixteen patients (16%). Twenty-one patients (21%) developed intra-abdom-
inal abscesses that could be drained percutaneously. A total of eight patients (8%) 
died due to treatment-related causes, six of whom due to abdominal sepsis. Patients 
with higher tumor loads, incomplete cytoreductions, blood loss exceeding 6 liters 
and patients with three or more anastomoses had an increased risk of having a com-
plicated postoperative course. 
Stephens et al.71 described a series of 183 patients with PC of gastrointestinal ori-
gin who underwent 200 cytoreductive surgeries followed by (hyperthermic) IPEC 
(MMC). Combined grade 3 or 4 toxicity was noted in 27% of patients, peripancrea-
titis being the most frequent complication in 6%, followed by fistulization (4.5%), 
hemorrhage (4.5%) and hematologic toxicity (4%). Three patients (1.5%) died of 
treatment-related toxicity, two of whom due to severe hematologic toxicity. Treat-
ment-related mortality was 1.5%. The duration of the surgery, the number of peri-
tonectomy procedures, resections of anastomoses were significantly associated 
with the occurrence of grade 3, 4 or 5 toxicity, whereas (hyperthermic) IPEC-related 
variables were not. 
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Table 3. Characteristics of trials investigating the efficacy of cytoreductive surgery 
and intraperitoneal chemotherapy in patients with peritoneal carcinomatosis 
of colorectal origin
Reference Total 
No. of
patients
Origin tumor I.p. cytostatic 
agent used
Timing i.p. 
chemo-
therapyColon Rectum Appendix
Sugarbaker et al.58 181 Not spec. Not spec. 130 MMC + 5-FU Various
Sugarbaker et al.59
64
64 0 0 MMC + 5-FU Early postop.
Schneebaum et al.56 15 Not spec. Not spec. Not spec. MMC Intraop.
Elias et al.67 64 46 9 9 5-FU or MMC
Intraop./
Early postop.
Culliford et al.49 64 47 0 17 FUDV/LV Early postop.
Witkamp et al.64 29 22 4 3 MMC Intraop.
Pilati et al.55 34 34 0 0 MMC + cisplatin Intraop.
Verwaal et al.36 105 75 12 18 MMC Intraop.
Elias et al.50 35 27 3 5 MMC + 5-FU Early postop.
Carmignani et al.48 27 Not spec. Not spec. Not spec. MMC + 5-FU
Intraop./
Early postop.
Mahteme et al.54 18 16 2 0 5-FU Early postop.
Elias et al.51 24 Not spec. Not spec. 0 Oxaliplatin Intraop.
Shen et al.57 77 74 3 0 MMC Intraop.
Glehen et al.52 53 48 5 0 MMC Intraop.
Glehen et al.66 506 466 40 0 Various Various
Kecmanovic et al.65 18 14 4 0 MMC + 5-FU
Intraop./
Early postop.
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Table 3. Continued
Reference Hyper-
thermia 
applied?
mortality Median
survival
1-year
survival
2-year
survival
3-year
survival
5-year
survival
Sugarbaker et al.58 No 1.7% 18 m 55% 40% 35% _
Sugarbaker et al.59 No
not 
reported
12 m _ _ _ _
Schneebaum et al.56 Yes 0% _ _ _ _ _
Elias et al.67 Yes 9.3% 26 m 85% 60.1% 47.1% 27.4%
Culliford et al.49 No 0% 34 m 85% 60% 35% 28%
Witkamp et al.64 Yes 3% 20 m 82% 45% 23% _
Pilati et al.55 Yes 0% 18 m _ 31% _ _
Verwaal et al.36 Yes 8% 22.4 m 65% 40% _ _
Elias et al.50 No 19% _ 80% 60% 30% 20%
Carmignani et al.48 Yes 0% _ 58% 25% 18% _
Mahteme et al.54 No 0% 32 m 70% 60% 30% 30%
Elias et al.51 Yes 8% _ 83% 75% 65% _
Shen et al.57 Yes 12% 16 m _ _ 25% 17%
Glehen et al.52 Yes 4% 13 m 55% 32% _ 11%
Glehen et al.66 Yes 4% 19.2 m 72% _ 39% 19%
Kecmanovic et al.65 Yes 0% 15 m _ _ _ _
Not spec. not specified; MMC mitomycin-C; 5-FU 5-fluorouracil; Early postop. early postoperative; 
Intraop. intraoperative
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Glehen et al.70 analyzed the morbidity and mortality rates following 216 consecutive 
cytoreductive surgeries and (hyperthermic) IPEC in 207 patients with PC. Most pa-
tients suffered from ovarian, colorectal or gastric cancer. Grade III/IV toxicity was 
encountered in 51 patients (23.6%), digestive fistulization (6.5%) and hematological 
toxicity (4.5%) being the most frequent complications. Seven patients (3.4%) died 
from treatment-related complications.
Prognostic indicators of survival
Univariate and multivariate analyses of most series of patients with PC of colorectal 
origin revealed several clinical (preoperative), surgical (intra- and postoperative), 
and pathological factors predictive of survival. Clinical characteristics that have 
been univariately correlated to an improved survival are female gender,66 younger 
age,66 and clinical performance status.57 
The most important surgical factors that have been identified as predictors of sur-
vival are: the extent of carcinomatosis encountered at laparotomy36,48,49,51,52,58-60,65-67 
and the completeness of resection.36,48,49,51,52,54,57-60,64-66 Various scoring system were 
used to assess the extent of carcinomatosis. Most authors used the semi-quantita-
tive peritoneal cancer index (PCI), described by Jacquet and Sugarbaker.72 The PCI 
relies on the distribution and size of the cancer lesions throughout the abdomen. 
More extensive carcinomatosis or higher PCI was invariably associated with de-
creased survival. After the surgical cytoreduction, the size of residual disease was 
usually expressed as R1, meaning no macroscopic residual disease, R2a, meaning 
macroscopic residual disease less than 2.5 or 5 mm, or R2b, meaning macroscopic re-
sidual disease more than 2.5 or 5 mm in diameter. When reported, median survival 
following complete R1 resection of all macroscopic disease varied from 17.8 months 
to 39.0 months,52,54,57,60,65,66 whereas the reported five-year survival rates varied from 
20% till 54%.49,52,57,66 Median survival after incomplete R2a resection resulted in me-
dian survival times of 12.5 months till 24 months,36,52,54,57,60,66 with 5-year survival 
rates of between 10% and 29%.52,59,66 When macroscopic disease of more than 5 mm 
in diameter had to be left behind, the reported median survival varied between 5 
months and 12 months.36,52,57,59,60 None of these patients survived for five years.59,66 
Finally, bowel obstruction57, the presence of ascites,57 and the presence and resection 
of metastatic disease to the liver were reported to be significantly correlated with 
imparied survival.57,66 
Several authors have made an attempt to correlate the site of the primary tumor 
(colon vs. appendix vs. rectum) with prognosis.36,48,49,58,60,66 Verwaal et al. analyzed a 
series of 102 consecutive patients with PC of colorectal or appendiceal origin who 
had been treated with cytoreductive surgery followed by hyperthermic IPEC. The 
5 patients with PC of rectal origin had a median survival of 16.0 months, whereas 
those 82 patients with PC of colonic origin had a median survival of 21.6 months 
(relative risk 3.14, 95% CI 1.11-8.91, P=0.069). Similar results were reported by Cul-
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liford et al., although in their patient series six out of seventeen patients with ap-
pendiceal carcinomatosis had pseudomyxoma peritonei.49 Other authors, however, 
did not confirm worse survival of patients with PC of rectal origin as compared to 
patients with PC of colonic origin.36,66 Sugarbaker et al. reported on the efficacy of 
cytoreductive surgery and IPEC in a relatively large patient series of 51 patients with 
colorectal carcinomatosis and 130 patients with PC of appendiceal origin. Three-year 
survival of the patients with PC of appendiceal origin was significantly better than 
that of the patients with PC of colorectal origin (73% vs. 36%, P=0.0001). Other au-
thors, however, did not find a significant survival benefit for patients with appendi-
ceal carcinomatosis as compared to patients with PC of colonic or rectal origin.36,60,66 
Finally, other pathological factors that have been correlated with impaired survival 
include poor tumor differentiation,52,55,58-60,66 signet cell histology,60 and lymph node 
involvement.58,66 
The results of multivariate analyses on the above-mentioned clinicopathological 
factors were reported in five publications.49,52,57,60,66 In four of these, the extent of 
disease and/or the completeness of resection were the factors most prominently 
related to treatment success and survival.49,52,60,66 Shen et al. found the presence of 
ascites or bowel obstruction to have an even greater impact on survival.57 In the 
large multi-institutional patient series of 506 patients with PC of colorectal origin, 
Glehen et al. furthermore identified treatment by a second procedure, age less than        
65 years, and use of adjuvant chemotherapy as positive independent prognostic in- 
dicators, whereas the use of neoadjuvant chemotherapy, lymph node involvement,       
presence of liver metastasis, and poor histologic differentiation were negative inde-
pendent prognostic indicators.66 
Quality of life after cytoreductive surgery and (hyperthermic) intraperito-
neal chemotherapy
In recent years there is an increased interest in the impact of a disease as well as its 
treatment on the quality of life in patients with cancer.73 In ovarian cancer, cytore-
ductive surgery and adjuvant (intravenous) chemotherapy has clearly been shown 
to result in better survival and improved quality of life.74,75 Only two, interrelated 
studies have been published focusing on quality of life after cytoreductive surgery 
followed by (hyperthermic) IPEC for the treatment of PC in nongynecologic ma-
lignancy. McQuellon et al.  76 investigated the quality of life of 64 patients with vari-
ous peritoneal surface malignancies, 16 of whom of colonic origin, in the first year 
after cytoreductive surgery and (hyperthermic) IPEC. Quality of life was assessed 
by means of the Functional Assessment of Cancer Therapy-Colon (FACT-C) scale, 
analysis of various activities of daily living, the Brief Pain Inventory, the Center 
for Epidemiologic Studies-Depression (CES-D) scale, and the Eastern Cooperative 
Oncology Group (ECOG) performance status rating scale. Before surgery, patients 
with ascites had a significantly lower quality of life as compared to patients with-
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out ascites. However, patients with ascites reported an improved overall quality of 
life immediately after surgery whereas those patients without ascites reported a 
decreased quality of life during the first three months after the surgery. From three 
months postoperatively onwards, quality of life improved relative to baseline. At 
one year after surgery, 58% of patients reported a normal performance status rating 
whereas 14% had to spend extra time in bed during the day due to disease- or treat-
ment-related symptoms. The mean scores at activities of daily living, however, were 
still lower than the general population norm, even after successful treatment and 
symptom reduction.
In a second publication, McQuellon et al.77 reported the quality of life of seven-
teen patients who had survived more than 3 years after cytoreductive surgery and 
(hyperthermic) IPEC for PC. Sixteen patients reported no limitations on moderate 
activities whereas ten patients described their health as very good or excellent. 
Controlled studies
To date, three controlled studies have been published verifying the efficacy of cy-
toreductive surgery and (hyperthermic) IPEC. Of these studies, two were rand-
omized. Mahteme et al.  54 compared eighteen patients with PC of colorectal origin, 
who had been treated with cytoreductive surgery and early postoperative IPEC (5-
FU, Cisplatinum, or Irinotecan) as well as intravenous 5-FU-based chemotherapy, 
with eighteen matched control patients with PC, who received intravenous chemo-
therapy only. The median survival as well as the two-year and five-year survival rates 
of the patients who were treated with cytoreductive surgery and IPEC were signifi-
cantly better than those of the control group (32 months vs 14 months, and 60% vs 
10% and 28% vs 5%, respectively (P=0.01)). The authors concluded, that, although 
selection bias may have influenced the results, the results indicate that cytoreduc-
tive surgery followed by IPEC can be beneficial and result in complete remission of 
the disease for a prolonged period of time. 
The seemingly better results of the aggressive surgical approach with respect to 
survival led Verwaal et al.36 to conduct a randomized controlled trial (RCT), inves-
tigating the efficacy of this treatment as compared to merely palliative treatment, 
consisting of systemic chemotherapy and surgery when indicated. One hundred-
and-five patients with established PC of colorectal or appendiceal origin, without 
hematogenous metastases, were randomized to be treated with either cytoreductive 
surgery and hyperthermic IPEC using MMC followed by systemic 5-FU/LV based 
chemotherapy or systemic chemotherapy alone and palliative surgery when neces-
sary. Despite the rather high postoperative mortality of 8%, median survival af-
ter surgical cytoreduction and (hyperthermic) IPEC was 22.3 months, which was 
significantly better (P=0.032) than the median survival of 12.6 months, obtained 
in the control arm. Several comments on this RCT seem justified. Firstly, in both 
treatment arms patients had surgical interventions, the effect of which remains un-
Peritoneal carcinomatosis of colorectal origin
79
known. Secondly, patients in the standard treatment arm were treated with 5-FU-
based chemotherapy. Several new cytostatic agents, such as irinotecan and oxali-
platin have been introduced. When combined with 5-FU/LV, both irinotecan and 
oxaliplatin have been shown to be superior to 5-FU/LV alone in advanced CRC.78-81 
Therefore, it cannot be excluded that the observed survival difference between the 
patients treated with cytoreductive surgery, (hyperthermic) IPEC and systemic 5-
FU/LV versus the patients treated with systemic 5-FU/LV and palliative surgery, 
may become less pronounced, when chemotherapy is changed to a combination of 
5-FU/LV and irinotecan and/or oxaliplatin.
The second RCT was conducted by Elias et al.,50 who randomized patients with es-
tablished PC to be treated with cytoreductive surgery with or without early postop-
erative IPEC. Unfortunately, due to difficulties in patient recruitment, the trial was 
prematurely terminated after 35 patients. Two-year survival rate after cytoreductive 
surgery was 60%. Early postoperative IPEC had no measurable effect on treatment 
outcome.
Conclusions
Improved insights into the mechanisms and incidence of intraperitoneal spread of 
CRC have contributed to a better understanding and a different perception of the 
pathologic basis of PC. Even though the reported incidence rates of intraperito-
neally exfoliated cancer cells during resection of primary tumors varied widely, the 
presence of free tumor cells in the peritoneal cavity of some patients was repeatedly 
demonstrated in all studies. Although the presence of exfoliated tumor cells in the 
peritoneal cavity, similar to micrometastases in blood or bone marrow,82-84 may not 
be an independent prognostic factor, it seems plausible that these tumor cells may 
indeed contribute to intraperitoneal treatment failure. In fact, in two studies a cor-
relation was found between the presence of free tumor cells in the peritoneal cavity 
and intraperitoneal tumor recurrence.12,18
Despite the favorable results of cytoreductive surgery and adjuvant (hyperthermic) 
IPEC in patients with PC of colorectal origin, the results should be interpreted with 
caution for several reasons. Firstly, the reported trials differed significantly with 
regard to patient selection. In some trials patients with hematogenous metastases 
were eligible for inclusion, whereas other patient series also included patients with 
appendiceal carcinomatosis or pseudomyxoma peritonei. The latter two disease en-
tities are may have a relatively favorable prognosis as compared to PC of colorectal 
origin. Secondly, the design of the combination treatment inflicted on the patients 
differed widely with regard to the timing of the IPEC (preoperative, intraoperative, 
postoperative or combinations), the method of administration of the chemother-
apy (open or closed abdomen), the cytostatic agent(s) utilized and whether or not 
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chemotherapy was given under hyperthermic conditions. Thirdly, the patient series 
published to date all come from specialized tertiary referral centers. 
Nonetheless, the results in terms of survival after cytoreductive surgery and (hyper-
thermic) IPEC appear much better than those obtained in historical controls and 
have, indeed, been shown to be superior to conventional chemotherapy-based treat-
ment in one RCT.36 Given the high morbidity and mortality rates of cytoreductive 
surgery and (hyperthermic) IPEC as well as the high failure rate of 80%, it is of 
the utmost importance to select only those patients for this treatment modality 
that could benefit the most. Univariate and multivariate analysis of several clinico-
pathological parameters repeatedly showed the extent of the carcinomatosis and, 
consequently, the extent of surgery to be the most important factors related to 
postoperative morbidity and mortality. In all patient series, postoperative morbid-
ity and mortality was predominantly determined by surgery-related factors, such as 
the number of anastomoses, peritonectomy procedures, and the amount of blood 
loss. Toxicity clearly attributable to the hyperthermic IPEC was relatively rare. 
Furthermore, despite the differences in timing and methods of intraperitoneally 
administering chemotherapy, the completeness of resection has proven to be the 
most important prognostic factor predictive of survival in almost all patient series 
reported to date. Patients, in whom complete resection of all macroscopic disease 
was not feasible, invariably showed a dismal prognosis similar to that of histori-
cal controls.61 Interestingly, complete resection frequently resulted in survival rates 
comparable to those obtained after resection of liver metastases.85 Cytoreductive 
surgery and (hyperthermic) IPEC should therefore only be offered to patients with 
limited and resectable disease.
According to Sugarbaker as well as Verwaal et al. the time has come to accept cy-
toreductive surgery and (hyperthermic) IPEC as one of the standard treatments 
for patients with limited carcinomatosis.86,87 Sugarbaker argues that the acquisition 
of level I evidence by meta-analysis of data from several well-designed RCTs may 
not be necessary for experimental therapies to mature into standard of care. For 
example, while there has never been an RCT confirming the superiority of resec-
tion of liver metastases of colorectal origin over systemic chemotherapy, surgery 
is generally accepted as standard of care in selected patients with liver metastases 
of colorectal origin. Others recognize the efficacy of the cytoreductive surgery but 
argue that, based on only one RCT, it is too early to accept it as part of a procedure 
in which (hyperthermic) IPEC is applied.88 With the completeness of resection be-
ing the most important prognostic factor, it could, indeed, be questioned whether 
(hyperthermic) IPEC is mandatory after complete resection. For that reason Mans-
field88 recognizes the need to move forward and pleads for a new multicenter RCT, 
comparing cytoreductive surgery followed by (hyperthermic) IPEC and systemic 
chemotherapy with cytoreductive surgery and systemic chemotherapy alone, re-
sembling the design of the RCT conducted by Elias et al.50 In fact, such a trial is 
currently considered at the Netherlands Cancer Institute. 
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Given the small number of medical centers worldwide currently practicing cytore-
ductive surgery and (hyperthermic) IPEC for the treatment of PC, larger-scale ap-
plication of this treatment modality may be challenging. Both the surgery and the 
administration of (hyperthermic) IPEC are technically demanding procedures, for 
which a learning curve exists.86 The further implementation of cytoreductive sur-
gery and (hyperthermic) IPEC for the management of PC of colorectal origin should 
therefore be pursued with caution and should still be applied as part of controlled 
trials. 
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Besides the lymphatic and hematogenous routes of dissemination, colorectal cancer frequently gives rise to intraperitoneal (i.p.) spread of tumor cells. Microscopic i.p. dissemination of cancer cells can be demonstrated in 10% to 
47% of patients undergoing surgery for colorectal cancer, depending on the detection 
method used.1,2 This so-called seeding of tumor cells may lead to peritoneal carcinoma-
tosis (PC), a condition characterized by the deposition of multiple metastatic nodules 
on the peritoneal surfaces. Although the clinical picture of patients with metastatic 
colorectal cancer is frequently dominated by liver metastases, peritoneal metastases 
can be a major source of morbidity3 and prognosis of patients with this condition 
is dismal, with a reported median survival of 6 months.4 Although PC is generally 
considered a terminal condition only to be palliated, there is a renewed interest in 
the subgroup of patients with metastatic disease limited to the peritoneal cavity. In 
the past two decades, a new treatment modality was developed, combining surgical 
cytoreduction and i.p. chemotherapy with the aim of achieving locoregional, i.e., i.p. 
tumor control. Although encouraging results in terms of survival have been reported, 
the morbidity and mortality rates of this aggressive approach are considerable and in 
many cases treatment is neither radical nor curative. This warrants the development 
of new, more specific treatment modalities for PC, which could ideally also be used in 
an adjuvant setting. 
Radioimmunotherapy using radiolabeled monoclonal antibodies (MAbs) directed 
against tumor-associated antigens offers the opportunity to selectively irradiate 
tumor cells while normal tissues are relatively spared. Promising results have been 
reported in patients with hematological malignancies, presumably due to their high 
intrinsic radiosensitivity and the relatively good access of the radiolabeled antibodies 
to the cancer cells.5,6 Solid cancers, however, proved to be much less sensitive to this 
form of treatment due to various reasons, including a limited vascular supply, het-
erogeneous uptake of the antibody in the tumor, and elevated interstitial pressure in 
combination with a relatively long transport distance in the interstitium.7 These bar-
riers especially apply to larger tumors. Therefore, minimal residual disease (and occult 
metastases) is generally considered the optimal setting for therapy using radiolabeled 
MAbs.8 In this regard, promising results have been reported by Epenetos et al.,9 who 
observed a ten-year survival rate of over 78% after treatment with 90Y-labeled HMFG1 
MAb in 21 patients with ovarian cancer, who had achieved complete remission after 
cytoreductive surgery and platinum-based chemotherapy.
Although colorectal carcinoma is not very radiosensitive,10 the potential of radioim-
munotherapy has been subject of investigation in several preclinical11-14 and clinical 
studies15-19. The majority of preclinical studies investigated its efficacy in nude mice 
bearing subcutaneous xenografts. These studies showed that radioimmunotherapy 
may be superior to equitoxic chemotherapy.11 Therefore, it seemed worthwhile to as-
certain the efficacy of radioimmunotherapy in early-stage peritoneal carcinomatosis 
of colorectal origin.20-22 
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Here we report the results of studies investigating the application of 131I-based radio-
immunotherapy using the anti-CEA MAb MN-14 in an experimental model of small 
peritoneal metastases of colonic origin.
Materials and methods
Animals
Male nude BALB/c mice, 6-8 weeks old, weighing 20-25 grams were used in the experi-
ments. Mice were accustomed to laboratory conditions for at least one week before 
experimental use and were housed under clean, nonsterile standard conditions in fil-
ter-topped cages (5 mice per cage), with free access to animal chow (Snif Voer, Soest, 
The Netherlands) and water. All experiments were approved by and carried out in 
accordance with the guidelines of the local Animal Welfare Committee.
Cell line
The human colon carcinoma cell line LS174T was obtained from the American Type 
Culture Collection (Rockville, MD). LS174T is a rapidly growing, moderately to well 
differentiated human colon carcinoma cell line, characterized by a moderate level 
of CEA-expression (114 ng/107 cells; 5,000 – 10,000 epitopes/cell).11,23 LS174T was 
cultured and maintained as monolayers on plastic in RPMI-1640 medium (GIBCO, 
BRL Life Sciences Technologies, The Netherlands) supplemented with 10% fetal calf 
serum (GIBCO), 2 mM L-glutamine, penicillin (100 units/mL) and streptomycin 
(100 µg/mL) at 37ºC in a humidified atmosphere with 5% CO2. Prior to inocula-
tion, tumor cells were washed with 0.9% sodium chloride, disaggregated with 0.25% 
trypsin and resuspended in complete medium to the appropriate concentration. 
Monoclonal antibody
The murine MN-14 MAb is a high-affinity (Ka = 10
9 liters/mol) class-III anti-CEA IgG1 
antibody, produced by a hybridoma cell line culture, kindly provided by Immuno-
medics, Inc. (Morris Plains, New Jersey, USA).24 The antibodies were purified by 
protein A chromatography, as described previously.25 Purity was checked by fast pro-
tein liquid chromatography (FPLC) on a Phenomenex Biosep 3000 column, using 
phosphate buffered saline (PBS, pH 7.2) as eluens (1 mL/min).
Characterization of the experimental model
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Radioiodination
Antibodies were radioiodinated using the iodogen-method.26 Briefly, antibod-
ies (1.0 – 1.5 mg) and 125I or 131I were incubated at room temperature in 85 µl of PBS 
(0.10 M, pH 7.4) in a glass vial, coated with 50-100 µg iodogen. After ten to twelve 
minutes, the reaction was stopped by adding 100 µl of a saturated tyrosine solution. 
The reaction mixture was subsequently eluted on a PD-10 column, eluted with PBS, 
0.5% BSA. Labeling efficiency of all radioiodination reactions varied between 74% and 
92%. Radiochemical purity (RCP) was determined using instant thin-layer chromatog-
raphy (ITLC) on silicagel strips (Gelman Sciences, Ann Arbor, MI) using 0.10 M citrate 
buffer (pH 6.0) as the mobile phase. RCP’s of all preparations used in the experiments 
always exceeded 98%. Immunoreactivity of the radioiodinated MN-14 preparations 
was essentially determined as described by Lindmo et al.27 Briefly, a fixed amount of 
labeled antibody (10,000 cpm) was incubated (6 hours, 37 °C) with increasing concen-
trations of LS174T tumor cells (1.2 x 106 – 20 x 106 cells/mL) in 0.5 mL binding buffer 
(RPMI medium containing 0.5% BSA and 0.05% NaN3). A duplicate of the lowest cell 
concentration was incubated in the presence of an excess unlabeled antibody to cor-
rect for non-specific binding. After six hours of incubation at 37˚C, the cells were spun 
down (500 g, 5 min) and activity in the pellet was determined in a well-type gamma-
counter. The inverse of the tumor cell bound fraction was plotted against the inverse 
of the cell concentration and the immunoreactive fraction (IRF) was calculated from 
the y-axis absciss. Immunoreactivity of the radioiodinated MN-14 preparations used 
in the experiments varied between 70% and 90%. Labeled antibody preparations were 
administered within two hours after the labeling procedure.
Experimental model of peritoneal carcinomatosis
The metastatic pattern of LS174T tumor cells after i.p. inoculation was studied, as de-
scribed by Lopes Cardozo et al.28 Mice were inoculated intraperitoneally with 1.0 x 106 
LS174T cells, suspended in 500 µl of RPMI-1640 medium in a 2.5 mL syringe using a 23 
gauge needle. Mice were anaesthetized, bled and cervically dislocated at weekly inter-
vals. The abdominal cavity was conscientiously inspected. Spleen, liver and lungs were 
removed for routine histopathological H&E-staining and immunohistochemical stain-
ing using a rabbit-anti-human anti-CEA polyclonal antibody (A 0115, DakoCytomation, 
Glostrup, Denmark).29
Effect of the antibody protein dose on biodistribution
To determine the effect of antibody-protein dose on the biodistribution of radioiodi-
nated MN-14, mice received 10 µCi 131I-labeled MN-14 intraperitoneally at eight dif-
ferent MN-14 protein doses ten days after i.p. inoculation of 1.0 x 106 LS174T tumor 
cells (five mice per group). Specific activity of the radioiodinated MN-14 preparation 
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was 4.3 µCi/µg. Protein doses were adjusted by adding unlabeled MN-14 to a fraction 
of the same 131I-labeled MN-14 preparation and amounted 1, 10, 15, 20, 25, 30, 50 or 
100 µg (five mice per group). Mice were dissected 72 hours after administration of the 
radiolabeled antibody. Tumor, blood, liver, spleen, kidney, intestine, lung and muscle 
tissues were sampled, gently blotted dry, and weighed. Activity was measured in a 
shielded well-type gamma-counter (Wizard, Pharmacia-LKB, Sweden). To correct for 
physical decay and to calculate uptake of the radioiodinated antibody in each sample 
as a fraction of the injected dose, aliquots of the injected dose were counted simul-
taneously. The results were expressed as percentage of the injected dose per gram 
tissue (% ID/g).
Effect of the route of administration on biodistribution
To assess the effect of the route of administration on the biodistribution of radioiodi-
nated MN-14, mice were inoculated intraperitoneally with 1.0 x 106 LS174T tumor cells 
suspended in RPMI-1640 (500 µl). Ten days later, the mice received 10 µCi 131I-labeled 
murine MN-14 intraperitoneally and 5 µCi 125I-labeled MN-14 intravenously. Specific 
activities of the radioiodinated MN-14 preparations were 2.1 µCi/µg and 1.1 µCi/µg, 
respectively. Total protein dose of each preparation was adjusted to 10 µg per mouse 
(total: 20 µg per mouse). Mice were euthanized by O2/CO2-asphyxia and dissected at 
one, two, four, eight, 24, 48, 72, 96 and 192 hours after the administration of the radi-
olabeled antibody preparations (five mice per group). The same tissues as described 
above were sampled, weighed and counted in a well-type gamma-counter. Activity was 
expressed as % ID/g. Biodistribution data were processed using the Medical Internal 
Radiation Dose (MIRD) scheme30, in order to estimate the radiation dose that a thera-
peutic activity dose of 131I-labeled MN-14 would guide to the i.p. tumor deposits.
Radioimmunotherapy studies
Ten days after i.p. tumor inoculation, mice received i.p. injections of 131I-labeled MN-
14 at escalating activity doses: 62.5, 125, 250 or 500 µCi (ten mice per group). Activity 
dose escalation was terminated at 500 µCi, since this was previously determined as 
the maximal tolerated activity dose of 131I-labeled IgG antibody after i.p. administra-
tion (i.e. the dose level below the lowest activity dose level that caused death or loss of 
more than 20% of initial total body weight.)31 Control mice received unlabeled MN-14 
or 500 µCi 131I-labeled nonspecific IgG-control antibody.32 Preparations were adminis-
tered in 500 µl PBS, 0.5% BSA. Specific activity of the radioiodinated MN-14 and con-
trol antibody preparations was 38 µCi/µg and 27 µCi/µg respectively. Protein dose was 
adjusted to 20 µg by adding unlabeled MN-14 or unlabeled control antibody to a frac-
tion of the primary radioconjugate preparations. Mice were monitored daily and body 
weight and abdominal circumference was measured twice per week (MJK). Mice were 
euthanized by cervical dislocation when the abdominal circumference had increased 
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Figure 1a 
Blood levels and uptake in 
tumor after administra-
tion of escalating protein 
doses of MN-14. Tissues 
were sampled 72 hours 
post-injection of the radio-
iodinated MN-14 antibody. 
Values are given as means 
± standard deviation (five 
mice per group).
Figure 1b 
Tumor-to-blood ratios 
after administration of 
escalating protein doses 
of MN-14. Tissues were 
sampled 72 hours post-
injection of the radioio-
dinated MN-14 antibody. 
Values are given as means 
± standard deviation (five 
mice per group).
by 10% as compared to the abdominal circumference measured on the day of tumor 
inoculation. All i.p. tumor deposits were meticulously dissected and weighed.
Results
Experimental model of peritoneal carcinomatosis
The first macroscopic LS174T tumor deposits in the peritoneal cavity were observed 
seven days after i.p. inoculation, as was described by Esteban et al.13 Tumor deposits 
were small (1-3 mm in diameter) and predominantly located in the upper abdomen 
in the liver hilum, the greater omentum and adjacent to the spleen. Bulky disease, 
including macroscopic metastases on the diaphragm and hemorrhagic ascites was ob-
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served three to five weeks after tumor cell inoculation. Routine histopathological as 
well as immunohistochemical examination of the liver, spleen and lungs revealed no 
microscopic metastases at any time. Histopathological examination of the diaphragm 
showed deep invasion by tumor, without reaching the pleural surface.
Protein-dose escalation
To determine the maximum antibody protein dose that can be used for radioimmu-
notherapy, the biodistribution of escalating protein doses of intraperitoneally admin-
istered 131I-MN-14 was assessed 72 hours p.i. The uptake in the tumor deposits, blood 
levels as well as tumor-to-blood ratios as function of the MN-14 protein dose are pre-
sented in Figure 1a-b. The biodistribution of the radioiodinated MN-14 antibody was 
not affected by antibody protein doses up to 25 µg per mouse, whereas tumor-to-
blood ratios were similar up to doses of 20 µg. At higher doses, a lower tumor-to-blood 
level and a reduced uptake in the i.p. tumor deposits was observed, presumably due 
to saturation of the accessible CEA-epitopes in the tumor deposits. Uptake in other 
tissues was similar at all protein doses (data not shown).
Biodistribution of radioiodinated MN-14
The biodistribution of radioiodinated MN-14 in this model was studied following i.v. 
or i.p. administration and the results are summarized in Table 1a-b. The blood levels 
of radioiodinated MN-14 are presented in Figure 2a. At 8 hours p.i the blood level was 
still higher after i.v. administration. From 24 hours onwards the blood level of the 
intraperitoneally injected 131I-MN-14 and the intravenously injected 125I-MN-14 were 
similar. In all other normal tissues higher uptake was observed after i.v. administra-
tion until 24 hours p.i. (Table 1a and 1b). After both i.v. and i.p. administration the up-
take of the radiolabeled antibody in tumor deposits was relatively high. In the first 24 
hours following administration, the i.p. route led to higher uptake in the tumor than 
the i.v. route (Figure 2b; Table 1a and 1b). From 48 hours p.i. onwards tumor uptake 
was in the same range for both routes of administration. From two hours onwards af-
ter i.p. administration, uptake in tumor was approximately 50% ID/g. Highest uptake 
in the tumor after i.p. administration (58.5 ± 6.8 % ID/g, 24 hours p.i.) was similar to 
the maximum uptake after i.v. administration (47.9 ± 11.5 % ID/g, 48 hours p.i., two-
tailed P = 0.19, Mann-Whitney test). 
In Figure 2c the tumor-to-blood ratios following both routes of administration are 
depicted, indicating that in the first 24 hours the tumor-to-blood ratio after i.p. ad-
ministration was higher than that after i.v. administration (two-tailed P = 0.03, Mann-
Whitney test comparing tumor-to-blood ratios at 24 hours p.i.). 
When corrected for physical decay of 131I, the areas under the curve (AUCs) for 
blood were similar for both routes of administration (15.8 versus 15.0 h x µCi/g), 
whereas the AUC for tumor after i.p. administration was somewhat higher (66.6 
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Figure 2a 
Blood levels of radioio-
dinated MN-14 after i.v. 
versus i.p. administration 
in nude mice bearing peri-
toneal LS174T tumor xe-
nografts. Values are given 
as means ± standard devi-
ation (five mice per group).
Figure 2c
Tumor-to-blood ratios af-
ter i.v. versus i.p. adminis-
tration of radioiodinated 
MN-14 in mice bearing 
peritoneal LS174T tumor 
xenografts. Values are 
given as means ± stand-
ard deviation (five mice 
per group).
Figure 2b 
Uptake of radioiodinated 
MN-14 in peritoneal 
LS174T tumor xenografts 
after i.v. versus i.p. admin-
istration. Values are given 
as means ± standard devi-
ation (five mice per group).
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versus 53.1 h x µCi/g). Dosimetric analysis using the MIRD scheme30 indicated that 
i.p. radioimmunotherapy using 500 µCi of 131I-MN-14 would guide 317 Gy to tumors 
of 10 mg or 2.6 mm in diameter. 
Radioimmunotherapy
Eight mice (13%) developed subcutaneous tumors and were excluded from the analy-
sis. There was no mortality due to treatment. Three mice with excessive tumor growth 
had to be euthanized before the abdominal circumference had increased by 10%. The 
change in body weight at the time the abdominal circumference had increased by 10% 
is depicted in a scatter plot in Figure 3a. These data show that about 50% of mice had 
gained weight, while others had lost weight, indicating that weight change cannot be 
used as a predictor of therapeutic efficacy in this model. Abdominal circumference, 
however, proved to be a useful and reproducible indicator of i.p. tumor growth. When 
the abdominal circumference had increased by 10%, all mice showed marked signs of 
i.p. tumor growth. Figure 3b shows the mean tumor weight at the time abdominal 
circumference had increased 10% according to group. It varied between 2.2 ± 0.6 g) in 
mice that received 500 µCi of 131I-MN-14 and 3.9 ± 1.1 g) in mice that received 62.5 µCi 
of 131I-MN-14 (P=0.13, one-way ANOVA-test).
Median survival of the mice that received unlabeled MN-14 was 38 days (range 28-42). 
Survival was significantly improved with increasing activity doses of 131I-labeled MN-
14, as shown in a Kaplan-Meier plot in Figure 3c. Median survival of the mice treated 
62.5 µCi, 125 µCi, 250 µCi or 500 µCi of 131I-MN-14 was 42 days (range 42-52; P= 0.03), 
49 days (32-52; P=0.03), 63 days (59-104; P<0.0001) and 109 days (46-…, P<0.0001) 
respectively (Log rank test compared with unlabeled MN-14 control group). Median 
survival of the mice treated with 500 µCi 131I-labeled control antibody was 52 days (46-
73, P=0.002), which is comparable to that after treatment with 125 µCi 131I-MN-14.
In the group treated with 500 µCi 131I-MN-14, there were five long-term survivors 
(>100 days). Of these, one mouse was still alive without evidence of tumor growth 
five months after tumor cell inoculation. This mouse was euthanized and dissected. 
At dissection there was no macroscopic tumor. The macroscopic appearance of the 
abdominal cavity of this mouse is shown in Figure 3d in conjunction with a mouse eu-
thanized at the time its abdominal circumference had increased by 10% due to bulky 
i.p. tumor growth. However, routine histopathological and immunohistochemical 
examination of the greater omentum, diaphragm, of random biopsies of the perito-
neum and of the pancreas, liver, lungs en spleen revealed one micrometastasis in the 
pancreas (Figure 3e). 
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Figure 3a 
Scatter plot of body weight 
change at the time of 10% 
increase of abdominal cir-
cumference in mice bear-
ing peritoneal LS174T tu-
mor xenografts after 500 
µCi 131I-MN-14 (A), 250 
µCi 131I-MN-14 (B), 125 
µCi 131I-MN-14 (C), 62.5 
µCi 131I-MN-14 (D), unla-
beled MN-14 (E) or 500 
µCi 131I-labeled irrelevant 
antibody (F). 
Figure 3b 
Tumor weight at the time 
of 10% increase of ab-
dominal circumference in 
mice bearing peritoneal 
LS174T tumor xenografts. 
Values are given as means 
± standard deviation. Var-
iation between the groups 
is not statistically signifi-
cant (one-way ANOVA 
test; P=0.13).
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Figure 3d 
The effect of radioimmunotherapy on colon cancer xenografts in the peritoneal 
cavity. (1) Bulky i.p. tumor growth at the time the abdominal circumference 
had increased by 10%. (2) Macroscopic appearance of the abdominal cavity at 
dissection of a mouse five months after i.p. treatment with 500 µCi 131I-MN-14. 
No macroscopic tumor deposits were present.
1 2
Figure 3c 
Kaplan-Meyer survival plot 
of mice bearing peritoneal 
LS174T tumor xenografts 
after i.p. administration of 
escalating activity doses of 
131I-labeled MN-14, unla-
beled MN-14 or 131I-labeled 
irrelevant antibody (six to 
nine mice per group).
(Log-rank test for trend χ2 
= 20.75, P < 0.0001).
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Discussion
The primary aim of this study was to assess the therapeutic efficacy of radioimmuno-
therapy of small peritoneal metastases of colorectal origin in an experimental model. 
The radioiodinated anti-CEA MAb MN-14 preferentially accumulated in i.p. LS174T 
tumor xenografts. Quantitative analysis of the biodistribution data indicated that the 
i.p. route of administration resulted in a 25% higher radiation dose to the tumor as 
compared to the i.v. route of administration. I.p. radioimmunotherapy using 131I-la-
beled MN-14 proved to be very effective in delaying the growth of the tumor deposits, 
even at the lowest activity dose (62.5 µCi). 
The i.p. inoculation of tumor cells is a commonly used method to induce i.p. tumor 
growth mimicking some of the pathological features as seen in patients with perito-
neal carcinomatosis, including preferential seeding to the greater omentum and the 
diaphragm and the development of hemorrhagic ascites in the later stages.33 The hu-
man colon carcinoma cell line LS174T used in the described studies is an extensively 
used and well-characterized cell line.11,13,23,34-36 It is characterized by a moderately high 
CEA-expression and an aggressive growth pattern, which was reflected in a substan-
tial number of subcutaneous tumors in the present studies (13%). The high-affinity 
class-III anti-CEA murine monoclonal IgG1 antibody, MN-14, like other anti-CEA IgG 
antibodies is internalized only slowly and to a limited extent in CEA-expressing cancer 
cells.37,38 It was used since it has already been successfully exploited in experimental ra-
dioimmunotherapy models.11,39 In addition, a humanized version of this MAb has been 
developed and successfully used in patients with CEA-expressing cancers.15, 12, 40-32 Its 
high affinity, however, is reflected in a higher propensity to form immune complexes 
with circulating CEA in patients with elevated CEA-levels.41 
Figure 3e
H&E-staining (1) and anti-CEA-immunohistochemical (2) staining of the pancreas of the mouse 
shown in Figure 3d-2, revealing a micrometastasis of moderately differentiated adenocarcinoma (mag-
nification 100x).
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Before entering radioimmunotherapy studies, the present model was optimized with 
regard to two parameters, namely the maximum antibody protein dose still associated 
with optimal biodistribution, as previously described by Boerman et al.,42 and the op-
timal route of administration of the radiolabeled antibody.
As demonstrated by Steffens et al.43 in a nude mouse model of renal cell carcinoma, tu-
mor-associated antigens can be saturated at higher antibody protein doses. The small 
volume of the i.p. tumor nodules in the present model limited the maximum MN-14 
protein dose to 20-25 µg. At higher protein doses the uptake in the tumor nodules 
decreased (38 ± 5.6% ID/g at 25 µg versus 22 ± 2.4% ID/g at 30 µg) and tumor-to-blood 
ratio decreased as well (4.7 ± 1.1 at 20 µg versus 3.4 ± 0.4% ID/g at 25 µg), indicating 
that at higher antibody protein doses tumor-associated CEA was saturated. At higher 
protein doses the therapeutic efficacy will thus decrease, due to the reduced radiation 
dose to the tumor.42 
The rationale of i.p. administration of radiolabeled antibodies in models of peritoneal 
carcinomatosis is twofold: firstly, due to a gradual delivery from the abdominal cavity 
to the circulation, the radiation dose to the blood and consequently the red marrow 
(i.e., the dose-limiting organ) may be reduced. Secondly, i.p. administration may lead 
to a higher uptake in i.p. tumor xenografts and may thus be more effective.44 A few 
studies have been published, comparing the i.v. with i.p. administration of radiola-
beled MAbs for the detection or treatment of experimental and clinical peritoneal car-
cinomatosis.14,45-48 In the majority of these studies ovarian cancer models were used. 
Most studies reported the i.p. route of administration to be advantageous with regard 
to uptake in tumor and tumor-to-normal-tissue ratios. On the other hand, i.v. admin-
istration may result in a more homogeneous uptake in i.p. xenografts, as compared to 
i.p. administration.47 This may especially apply to larger tumors, as was elegantly dem-
onstrated by Ito et al.,47 who studied the intratumoral distribution of the anti-CEA 
MAb C110 after i.p. and i.v. administration by autoradiography in nude mice bearing 
relatively large (2-10 mm) i.p. LS174T tumor nodules. I.p. administration resulted in 
a high uptake in the tumor periphery and a considerably lower uptake in the tumor 
center, whereas an almost homogenous distribution throughout the tumor nodules 
was seen after i.v. administration. In the present study, tumor nodules were much 
smaller (1-3 mm) and i.p. administration led to a significantly higher uptake in the 
tumor nodules during the first 24 hours p.i. In our view, when tumor nodules are rela-
tively small, i.p. administration is therefore preferable for radioimmunotherapy. The 
blood levels were similar from 24 hours p.i. onwards and nearly identical AUC’s for the 
blood for both routes of administration were obtained. Assuming that the radiation 
dose to the blood reflects the radiation dose to the red marrow, this suggests that the 
administered activity given intraperitoneally equals the dose that can be administered 
intravenously. On the other hand, however, due to the high blood levels at early time 
points after i.v. administration, the dose rate to the bone marrow in the first hours 
after i.v. injection is higher than that after i.p. injection. Therefore, the MTD might be 
somewhat higher after i.p. administration. 
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In the therapy studies, abdominal circumference was used as a measure of i.p. tumor 
growth in order to predict therapeutic efficacy. Mice were monitored by one observer, 
to exclude inter-observer variability. I.p. tumor weight at dissection was similar in the 
groups, indicating that the increase in abdominal circumference correlated well with 
i.p. tumor load and can be used to estimate therapeutic efficacy. Results indicated that 
even the lowest dose of 131I-labeled MN-14 (62.5 µCi) resulted in a small yet significant       
delay in tumor outgrowth, as compared to the control group that received unlabeled 
MN-14. All mice, however, eventually developed macroscopic or microscopic tumor. 
The mean beta-emission of 192 keV of 131I appears to be suited for the treatment of 
tumor nodules with a diameter of a few millimeters. Therapeutic efficacy in the cur-
rent model might be improved using other radionuclides, such as 186Re or 177Lu. Theo-
retically, 90Y, because of its high mean beta-emission of 935 keV, seems to be a less 
suitable radionuclide for this setting. Esteban et al.34 studied the effects of 90Y-based 
radioimmunotherapy using an anti-CEA MAb in a similar model of small volume 
peritoneal LS174T carcinomatosis. Although inhibition of tumor growth proved to be 
significantly related to the activity dose administered, residual viable tumor growth 
was still found on histological examination of mice five weeks after receiving 120 µCi. 
In future experiments, the therapeutic efficacy of the above-mentioned radionuclides 
will be compared in the current model.
Finally, the observed dose-response relationship in the present study may have some 
useful implications. Firstly, at equitoxic activity dose levels lower than the MTD, the 
therapeutic efficacy of different radionuclides can be compared in a shorter period of 
time. Secondly, since there have been various reports on the use of radiosensitizers 
to enhance radioimmunotherapeutic efficacy, possible synergistic effects of chemo-
therapy combined with radioimmunotherapy in the current model can be studied at 
doses below MTD.
In summary, the radioiodinated MN-14 antibody accumulated preferentially in i.p. 
LS174T tumor nodules both after i.p. and i.v. administration. I.p. radioimmunother-
apy using 131I-labeled MN-14 significantly delayed the growth of peritoneal LS174T 
metastases, even at relatively low activity doses, which makes this model attractive 
for further investigation of the application of radioimmunotherapy for the treatment 
of early-stage PC.
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Radioimmunotherapy, using radiolabeled monoclonal antibodies (MAbs) against tumor-associated antigens, has not fulfilled its promise in solid cancers as it has done in hematological malignancies. Besides limited radiosensitivity 
of carcinomas as compared to hematological malignancies, solid tumors are gener-
ally characterized by a limited vascular supply, heterogeneous uptake of the antibody 
in the tumor, and elevated interstitial pressure in combination with a relatively long 
transport distance in the interstitium.1 Radioimmunotherapy is therefore considered 
to be more suitable for the treatment of microscopic or minimal residual disease, al-
lowing the radiolabeled MAbs to achieve uptake in tumors high enough to result in 
tumoricidal radiation doses.
An important issue in radioimmunotherapy is the selection of the radionuclide. Beta-
emitting isotopes, such as 131I and 90Y, are the most commonly used radionuclides in 
radioimmunotherapy. 186Re and 177Lu are beta-emitting radionuclides that have been 
considered for radioimmunotherapy more recently. The physical characteristics of the 
four mentioned radionuclides, however, differ significantly with respect to half-life, 
the presence of gamma-radiation, the energy of the beta-emission and consequently 
the maximum penetration depth of the beta-particles in tissue, as summarized in 
Table 1. 
We have previously characterized an experimental model of small peritoneal metas-
tases using the human colon carcinoma cell line LS174T.2 In this model radioimmu-
notherapy using 131I-labeled MN-14 was very effective in delaying the development of 
peritoneal carcinomatosis, even at relatively low activity doses. Therapeutic efficacy in 
this model might be improved using other radionuclides with more favorable charac-
teristics for radioimmunotherapy.
In the present study experiments were performed that aimed to select the most suit-
able radionuclide for radioimmunotherapy of small peritoneal metastases of colorec-
tal origin. For this purpose, first a series of experiments was carried out investigating 
the biodistribution of 131/125I-, 186Re- and 88Y-labeled MN-14 in nude mice with small 
intraperitoneal (i.p.) xenografts of colon cancer. Then the therapeutic efficacy of MN-
14 labeled with either 131I, 186Re, 90Y or 177Lu was assessed and correlated with the results 
of the biodistribution studies.
Material and methods
Animal model of small peritoneal metastases
Male nude BALB/c mice (Charles River Laboratories, Germany), 8-9 weeks old, weigh-
ing 20-25 grams were used in the experiments. Mice were accustomed to laboratory 
conditions for at least one week before experimental use and were housed under 
nonsterile standard conditions (temperature 20–24°C; relative humidity 50–60%; 
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 12 h light/12 h dark) in filter-topped cages (five mice per cage), with free access to 
animal chow (Snif Voer, Soest, The Netherlands) and water. Peritoneal metastases 
were induced as described previously.2 In brief, mice were inoculated intraperitoneal-
ly with 1.0 x 106 LS174T cells (CCL 188, American Type Culture Collection, Rockville, 
MD), suspended in 500 µl of RPMI-1640 medium in a 2.5 mL syringe using a 23-gauge 
needle. In this model, the first macroscopic tumor nodules are seen seven to ten days 
thereafter, whereas bulky peritoneal carcinomatosis develops three to five weeks af-
ter tumor cell inoculation. All experiments were approved by the institutional Ani-
mal Welfare Committee of the University Medical Center Nijmegen and conducted 
in accordance with the principles laid out by the revised Dutch Act on Animal Experi-
mentation (1997).
Monoclonal antibody
The murine MN-14 MAb is a high-affinity (Ka = 10
9 M-1) class-III anti-CEA IgG1 anti-
body, produced by a hybridoma cell line culture, kindly provided by Immunomedics, 
Inc. (Morris Plains, New Jersey, USA).3 The antibodies were purified by protein A chro-
matography, as described previously.4 Purity was checked by fast protein liquid chro-
matography (FPLC) on a Phenomenex Biosep 3000 column, eluted with phosphate 
buffered saline (PBS, pH 7.2, 1 mL/min).
Table 1. Physical characteristics of most used beta-emitters in  
radioimmunotherapy
Radionuclide
Half-life
(days)
Max. ß-energy
(MeV)
Max. penetration 
depth (mm)
γ-Emission*
(keV)
131I 8.0 0.606 3.0 364 (82), 637 (6.5)
90Y 2.7 2.28 12.0 none
186Re 3.8 1.08 5.4 137 (9.5)
177Lu 6.7 0.497 2.5 208 (11), 113 (7)
*Numbers in parentheses are percentages
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Radioiodination
Antibodies were radioiodinated with 125I or 131I (Amersham, Den Bosch, The Nether-
lands and MDS Nordion, Fleurus, Belgium, respectively) using the iodogen-method 
(1,3,4,6-tetrachloro-3α,6α-diphenyl-glycoluril; Pierce, Rockford, IL).5 Briefly, antibod-
ies (1.0 – 1.5 mg) and 125I or 131I were incubated at room temperature in 85 µl of PBS 
(0.10 M, pH 7.4) in a glass vial, coated with 50-100 µg iodogen. After ten minutes, the 
reaction was stopped by adding 100 µl of a saturated tyrosine solution. The reaction 
mixture was subsequently eluted on a PD-10 column (Amersham Biosciences, Upp-
sala, Sweden), eluted with PBS, 0.5% bovine serum albumin (BSA). Labeling efficiency 
of all radioiodination reactions exceeded 90%. In the biodistribution study specific 
activity of 125I- and 131I-MN-14 was 18.5 and 37 kBq/µg. Specific activity of 131I-MN-14 in 
the therapy study was 0.46 MBq/µg.
186Re-labeling
186ReO4ˉ (specific activity 65 GBq/mg) was obtained from Tyco Mallinckrodt Medical 
BV (Petten, The Netherlands). The antibodies were labeled with 186Re using S-benzoyl-
mercaptoacetyltriglyceride (S-benzoyl-MAG3) as chelator, as described by Visser et 
al.6 Briefly, 180 µg MAG3 (1.0 mg/ml) was incubated with 150 µL 1.0 M Na2CO3, 150 µL 
Na2SO3 (100 mg/ml) and 696 MBq 
186ReO4ˉ (100 µL) in a boiling water bath (10 min). 
The solvent was then evaporated after which the solid phase was incubated for another 
15 minutes. Following derivatization of 186Re-MAG3 with 2,3,5,6-tetrafluorophenol (TFP, 
100 mg/ml in MeCN/H2O 9:1), the derivatized 
186Re-MAG3-ester was purified on a Sep-
Pak C18 cartridge (Waters, Milford, MA) and subsequently reacted with 400 µg of a con-
centrated MN-14 solution at pH 9.5, resulting in a mean number of 4.1 MAG3 groups per 
IgG molecule. The conjugated 186Re-MAG3-MN-14 (further referred to as 186Re-MN-14) 
was purified on a PD-10 column. The overall labeling efficiency of the 186Re-labeling pro-
cedures performed in the biodistribution and therapy studies was 36% and 18%, resulting 
in specific activities of 0.12 MBq/µg and 0.33 MBq/µg, respectively.
88/90Y- and 177Lu-labeling
All conjugation and labeling procedures were performed under strict metal-free condi-
tions. To allow labeling of the antibodies with 88Y, 90Y and 177Lu, MN-14 was conjugated 
with isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (ITC-DTPA, Macrocy-
clics, Dallas, TX). Briefly, ITC-DTPA was conjugated to MN-14 in a 0.1 M NaHCO3 
buffer, pH 8.2 using a 100-fold (ITC-DTPA) molar excess as described by Ruegg et al.7 
with minor modifications (conjugation period of one hour at room temperature). The 
DTPA-MAb MN-14 conjugate was purified by extensive dialysis against 0.1 M am-
monium acetate buffer (pH 5.0). The number of DTPA ligands per antibody molecule 
was determined according to the method described by Hnatowich et al.8 The purified 
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DTPA-MN-14 conjugate (DTPA/MN-14 ratio 2.5/1, 0.8 mg/mL) was incubated with 88Y 
(Isotope Products Europe Blaseg, Waldburg, Germany), 90Y (Perkin Elmer, Brussels, 
Belgium) or 177Lu (University of Missouri, Research Reactor, Columbia, MO, USA) in 
0.1 M ammonium acetate buffer, pH 5.4 at room temperature (20 minutes). Specific 
activities of the 88Y-DTPA-MN-14, 90Y-DTPA-MN-14 and 177Lu-DTPA-MN-14 prepara-
tions (further referred to as 88Y-MN-14, 90Y-MN-14 and 177Lu-MN-14) were 48.1, 159 
and 418 kBq/µg respectively. 
Quality control of the radiolabeled preparations
All radiolabeled MN-14 preparations were purified by gel filtration on a PD-10 column 
and eluted with PBS supplemented with 0.5 % BSA. For all preparations the amount 
of free radiolabel was determined by instant thin layer chromatography (ITLC) using 
ITLC silica gel strips (Gelman Sciences, Inc., Ann Arbor, MI, USA) using 0.1 M citrate 
buffer (pH 6.0) as the mobile phase. Radiochemical purity of all radiolabeled antibody 
preparations used in the studies exceeded 96%.
The immunoreactive fraction (IRF) at infinitive antigen excess of the radiolabeled 
MN-14 preparations except 90Y-MN-14 was determined on freshly trypsinized LS174T 
cells essentially as described by Lindmo et al.9 with minor modifications. Briefly, a 
fixed amount of labeled antibody (10,000 cpm) was incubated with increasing con-
centrations of LS174T tumor cells (1.2 x 106 – 20 x 106 cells/mL) in 0.5 mL binding 
buffer (RPMI medium containing 0.5% BSA and 0.05% NaN3). A duplicate of the low-
est cell concentration was incubated in the presence of an excess unlabeled antibody 
to correct for non-specific binding. After six hours of incubation at 37°C, the cells were 
washed and activity in the pellet was determined in a well-type gamma-counter. The 
inverse of the tumor cell bound fraction was plotted against the inverse of the cell 
concentration and the immunoreactive fraction (IRF) was calculated from the Y-axis 
intercept. The mean IRFs of the radiolabeled preparations used in the biodistribu-
tion and therapy studies were 89.3±6.5% and 77±6.1%, respectively. Labeled antibody 
preparations were administered within two hours after radiolabeling.
Biodistribution studies after i.p. and i.v. administration
To assess the effect of both the route of administration and the radiolabel on the 
biodistribution of radiolabeled MN-14, mice were inoculated intraperitoneally with 
1.0 x 106 LS174T tumor cells suspended in RPMI-1640 (500 µl). Ten days later, mice 
received 1.22 MBq 186Re-MN-14 intraperitoneally and 0.481 MBq 88Y-MN-14 intrave-
nously or vice versa (five mice per group). Mice were killed by O2/CO2-asphyxiation 
and dissected at 24, 48, 72, 96 or 192 hours after the administration of the radiolabeled 
antibody preparations (five mice per group). At dissection tumor, blood, liver, spleen, 
kidney, intestine, lung, muscle as well as the right femur were sampled, blotted dry, 
and weighed. Activity was measured in a shielded well-type gamma-counter (Wizard, 
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Pharmacia-LKB, Sweden). To correct for physical decay and to calculate uptake of the 
radiolabeled antibody in each sample as a fraction of the injected dose, aliquots of the 
injected dose were counted simultaneously. The results were expressed as percentage 
of the injected dose per gram tissue (%ID/g). Since we showed in a previous study that 
at protein doses exceeding 25 µg, the uptake of the radiolabeled MN-14 antibody in 
tumor tended to be lower,2 the total protein dose of each preparation was adjusted to 
10 µg per mouse (total: 20 µg per mouse). The results were compared with the previ-
ously reported data on the biodistribution of radioiodinated MN-14 after i.v. versus 
i.p. administration in the same model.2 
Estimation of radiation dose to the tumor
The biodistribution data were used to calculate the areas-under-the-curve (AUC), cor-
rected for physical decay. Subsequently, the data were processed using the MIRDOSE3 
software program10 (Oak Ridge associated Universities), in order to estimate the ab-
sorbed radiation dose to the tumor for 131I-MN-14, 186Re-MN-14, 90Y-MN-14 and 177Lu-
MN-14 at 50% of their maximal tolerated activity doses (MTD). For this purpose, it 
was assumed that the biodistribution of both 90Y-MN-14 and 177Lu-MN-14 would have 
been similar to that of 88Y-MN-14.
Radioimmunotherapy studies
Ten days after i.p. tumor cell inoculation, groups of ten mice received i.p. injections of 
131I-MN-14 (9.25 MBq), 186Re-MN-14, (9.25 MBq), 90Y-MN-14 (3.15 MBq), 177Lu-MN-14 
(8.33 MBq/mouse) or unlabeled MN-14 (control). The activity doses represented eq-
uitoxic dose levels of the respective radionuclides, i.e., equal to 50% of the respective 
MTDs. The MTD of each antibody-bound radionuclide after i.p. administration was 
defined as the activity dose below the lowest dose level that resulted in either death of 
any animal in groups of five animals, or body weight loss of more than 20%, and was 
empirically determined as described previously.11 The MTDs for 131I-MN-14, 186Re-MN-
14, 90Y-MN-14 and 177Lu-MN-14 after i.p. administration were 18.5 MBq, 18.5 MBq, 
6.29 MBq and 16.65 MBq, respectively. Preparations were administered in 400 µl PBS, 
0.5% BSA. Protein dose was adjusted to 20 µg by adding unlabeled MN-14 to a fraction 
of the primary radioimmunoconjugate preparations. Due to a lower labeling efficiency 
than anticipated, protein dose of the 186Re-MN-14 preparation was 28 µg. Mice were 
monitored daily and body weight and abdominal circumference was measured twice 
per week (MJK), as described previously.2 Besides death, humane endpoints were de-
fined as a decrease of body weight of 20% or more or an abdominal circumference 
increase of 10% or more due to i.p. tumor growth as compared to the abdominal cir-
cumference measured on the day of tumor inoculation. When either one of these 
criteria was met, mice were killed by O2/CO2 asphyxiation and cervical dislocation. 
All i.p. tumor deposits were meticulously dissected and weighed. The experiment was 
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terminated at 142 days after tumor cell inoculation when the remaining mice were 
euthanized and dissected. The abdominal cavity was conscientiously inspected. Liv-
er, spleen, lungs, pancreas, greater omentum and the diaphragm were removed for 
routine histopathological H&E-staining and immunohistochemical staining using a 
rabbit-anti-human anti-CEA polyclonal antibody (A 0115, DakoCytomation, Glostrup, 
Denmark).12
Statistical analysis
Statistical analysis was performed by means of the GraphPad InStat 3.00 software 
(GraphPad Software, San Diego, CA). Single comparisons were analyzed using the 
two-tailed, Welch corrected, unpaired t-test or the non-parametric, two-tailed Mann 
WhitneyU test. In the biodistribution studies, uptake in tissues and blood levels were 
compared using the one-way ANOVA test. Bonferroni correction for multiple testing 
was applied. In the therapy studies, survival curves were compared using the Log-rank 
test. For all tests, the level of significance was set at a P value of <0.05.
Results
Biodistribution of radioiodinated MN-14
The biodistribution of radioiodinated MN-14 in this model following i.p. or i.v. admin-
istration has been described previously.2 In brief, from 24 hours onwards, the blood 
levels of the intraperitoneally injected 131I-MN-14 and the intravenously injected 125I-
MN-14 were similar. In the first 24 hours after administration, the i.p. route resulted 
in higher uptake in the tumor than the i.v. route. From 48 hours p.i. onwards, tumor 
uptake was similar for both routes of administration (approximately 50 %ID/g). When 
corrected for physical decay of 131I, the AUCs for blood levels were similar for both 
routes of administration (0.56 versus 0.58 h x MBq/g), whereas the AUC for tumor 
after i.p. administration was somewhat higher (2.46 versus 1.96 h x MBq/g).
Comparison of biodistribution of radioiodinated MN-14, 186Re- and 88Y-labeled 
MN-14 after i.p. or i.v. administration
Mean tumor weight of the mice that received radioiodinated MN-14 was compara-
ble to that of the mice that received 186Re-MN-14 or 88Y-MN-14 (19.5 ± 24.2 mg versus 
16.1 ± 16.6 mg; p=0.50). The blood levels of radioiodinated, 186Re-, or 88Y-labeled MN-
14 after i.p. and i.v. administration are depicted in Figure 1a-b. From 24 hours p.i. on-
wards, blood levels for all radioimmunoconjugates were similar for both routes of ad-
ministration. The tissue distribution of 186Re-MN-14 and 88Y-MN-14 after both routes 
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of administration is summarized in Tables 2 and 3. At all time points, uptake in liver 
and spleen of 88Y-MN-14 was higher than that of radioiodinated MN-14 and 186Re-MN-
14 after both routes of administration. Uptake in liver of 88Y-MN-14 remained higher 
after i.v. administration than after i.p. administration throughout the experiment, 
whereas uptake in spleen was similar at all time points. From 48 hours p.i. onwards, 
uptake of 88Y-MN-14 in bone represented by the femur was significantly higher than 
that of 186Re-MN-14. However, maximum uptake of 88Y-MN-14 in bone was very low 
(2.6 ± 0.3% ID/g, 72 hours after i.v. administration). Uptake in other normal tissues 
was similar for all radioimmunoconjugates after both routes of administration.
In Figure 2a-b the uptake in tumor of 131I-MN-14, 186Re-MN-14 and 88Y-MN-14 after i.p. 
and i.v. administration is depicted. Uptake in tumor of 88Y-MN14 was higher than that 
of 186Re-MN-14 or radioiodinated MN-14 at all time points, except for 24 hours after 
i.v. administration. Maximum uptake after i.p. administration of 131I-MN-14, 186Re-
Figure 1a
Blood levels after intra-
peritoneal administration 
of 131I-, 186Re- and 88Y-la-
beled MN-14. Values are 
given as means ± stand-
ard deviation (five mice 
per group).
Figure 1b
Blood levels after intra-
venous administration of 
125I-, 186Re- and 88Y-labeled 
MN-14. Values are given 
as means ± standard devi-
ation (five mice per group).
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Table 2. Tissue distribution of intraperitoneally and intravenously 
administered 186Re-MN-14 in nude mice bearing intraperitoneal 
LS174T colon cancer xenografts
Organ Time post-injection radioconjugate (hours)
24 48 72 96 192
Intraperitoneally administered
Tumor 29.9 ± 7.3 77.8 ± 31.4 83.4 ± 18.5 66.0 ± 5.4 50.3 ± 29.2
Blood 14.8 ± 1.0 12.7 ± 0.7 11.4 ± 0.8 8.9 ± 1.1 4.4 ± 2.7
Muscle 1.24 ± 0.4 1.2 ± 0.1 1.2 ± 0.1 1.6 ± 1.4 0.5 ± 0.2
Lung 8.3 ± 1.2 7.0 ± 0.8 8.4 ± 1.5 6.6 ± 1.1 3.8 ± 2.2
Spleen 3.8 ± 0.7 3.5 ± 0.4 3.2 ± 0.4 2.3 ± 0.5 1.6 ± 0.6
Kidney 4.3 ± 0.2 3.7 ± 0.2 3.4± 0.1 3.2 ± 0.4 1.7 ± 0.7
Liver 5.2 ± 0.7 4.8 ± 0.3 4.6 ± 0.5 3.9 ± 0.5 2.0 ± 0.7
Intestine 3.5 ± 0.8 1.8 ± 0.3 2.1 ± 0.4 1.5 ± 0.5 0.7 ± 0.3
Femur 0.8 ± 0.1 1.1 ± 0.2 1.2 ± 0.2 0.7 ± 0.2 0.6 ± 0.2
Intravenously administered
Tumor 58.1 ± 18.4 50.3 ± 21.1 68.2 ± 10.7 65.1 ± 14.2 67.8 ± 42.3
Blood 12.8 ± 3.0 11.9 ± 1.36 11.2 ± 1.1 10.6 ± 2.2 6.14 ± 1.9
Muscle 0.9 ± 0.2 1.2 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 0.7 ± 0.4
Lung 7.8 ± 2.4 10.5 ± 1.1 8.5 ± 0.8 9.6 ± 1.3 5.8 ± 1.8
Spleen 3.8 ± 1.1 3.2 ± 0.3 2.8 ± 0.3 2.5 ± 0.2 1.9 ± 0.4
Kidney 3.8 ± 0.8 3.8 ± 0.3 3.3 ± 0.4 2.9 ± 0.3 1.5 ± 1.0
Liver 5.4 ± 1.2 4.7 ± 0.3 4.5 ± 0.8 3.5 ± 0.5 1.6 ± 1.1
Intestine 2.8 ± 0.9 2.2 ± 0.3 1.7 ± 0.1 1.4 ± 0.1 1.2 ± 0.2
Femur 0.9 ± 0.4 0.8 ± 0.4 1.0 ± 0.2 0.5 ± 0.1 0.5 ± 0.1
Values are given as means ± standard deviation (five mice per group)
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Table 3. Tissue distribution of intraperitoneally and intravenously 
administered 88Y-MN-14 in nude mice bearing intraperitoneal 
LS174T colon cancer xenografts
Organ Time post-injection radioconjugate (hours)
24 48 72 96 192
Intraperitoneally administered
Tumor 90.8 ± 13.4 83.5 ± 29.0 139.5 ± 22.9 128.5 ± 26.5 148.1 ± 89.4
Blood 13.2 ± 1.3 12.4 ± 1.7 12.5 ± 1.2 11.3 ± 3.0 6.9 ± 2.2
Muscle 0.9 ± 0.1 1.4 ± 0.2 1.2 ± 0.2 0.9 ± 0.1 1.0 ± 0.5
Lung 7.9 ± 1.2 11.3 ± 1.5 10.0 ± 1.0 10.5 ± 2.0 7.2 ± 2.3
Spleen 4.9 ± 0.8 5.2 ± 0.5 5.8 ± 0.8 5.9 ± 0.9 7.9 ± 1.3
Kidney 4.0 ± 0.3 4.2 ± 0.4 3.9 ± 0.4 3.3 ± 0.6 1.6 ± 1.5
Liver 6.6 ± 0.6 6.7 ± 1.1 7.4 ± 1.3 6.8 ± 1.3 4.8 ± 3.1
Intestine 2.9 ± 0.7 2.5 ± 0.5 2.0 ± 0.1 1.7 ± 0.3 1.7 ± 0.3
Femur 0.9 ± 0.2 1.3 ± 0.5 2.0 ± 0.4 1.3 ± 0.2 2.4 ± 0.7
Intravenously administered
Tumor 27.4 ± 9.4 105.3 ± 50.5 130.5 ± 49.9 115.1 ± 5.4 104.3 ± 55.9
Blood 15.6 ± 0.8 13.6 ± 0.8 12.2 ± 1.0 9.8 ± 1.5 4.9 ± 3.0
Muscle 1.0 ± 0.2 1.2 ± 0.1 1.3 ± 0.2 2.3 ± 2.6 0.6 ± 0.3
Lung 8.8 ± 1.2 8.0 ± 0.9 9.4 ± 1.9 8.0 ± 1.4 4.7 ± 2.4
Spleen 5.1 ± 0.9 6.8 ± 0.4 6.4 ± 0.9 5.8 ± 0.6 7.1 ± 0.8
Kidney 4.4 ± 0.2 4.1 ± 0.2 3.9 ± 0.3 3.8 ± 0.5 2.3 ± 0.9
Liver 9.5 ± 0.8 9.8 ± 0.6 9.4 ± 0.9 10.1 ± 1.9 8.9 ± 2.2
Intestine 3.6 ± 0.8 2.0 ± 0.4 2.5 ± 0.4 1.9 ± 0.7 0.9 ± 0.3
Femur 0.6 ± 0.3 2.0 ± 0.5 2.6 ± 0.3 1.5 ± 0.2 2.1 ± 0.8
Values are given as means ± standard deviation (five mice per group)
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MN-14 and 88Y-MN14 in tumor was 58.5 ± 6.8% ID/g (24 hours p.i.), 83.4 ± 18.5% ID/g 
(72 hours p.i.) and 148.1 ± 89.4% ID/g (192 hours p.i.), respectively. 
The tumor-to-blood ratios of the various radioimmunoconjugates after i.p. and i.v. 
administration are shown in Figure 3a-b. From 24 hours p.i. onwards, the tumor-to-
blood ratio of radioiodinated MN-14 remained relatively stable (between 4.0 and 6.0), 
whereas tumor-to-blood ratio of 186Re-MN-14 steadily increased to 12.0 at 192 hours 
p.i. Tumor-to-blood ratios of 88Y-MN-14 were higher than those of both radioiodi-
nated MN-14 and 186Re-MN-14 at every time point. Maximum tumor-to-blood ratio of 
88Y-MN-14 was reached at 192 hours p.i. (24.7 ± 11.0 after i.v. administration).
Figure 2a
Uptake of 131I-, 186Re- and 88Y-
labeled MN-14 in peritoneal 
LS174T tumor xenografts after 
intraperitoneal administration. 
Values are given as means ± 
standard deviation (five mice 
per group). ** Significant differ-
ence between 88Y and 186Re; * Sig-
nificant difference between 186Re 
and 131I; * Significant difference 
between 88Y and 131I (one-way 
ANOVA test with Bonferroni 
post-correction).
Figure 2b 
Uptake of 125I-, 186Re- and 88Y-
labeled MN-14 in peritoneal 
LS174T tumor xenografts after 
intravenous administration. 
Values are given as means ± 
standard deviation (five mice 
per group). ** Significant differ-
ence between 88Y and 186Re; * Sig-
nificant difference between 186Re 
and 125I; * Significant difference 
between 88Y and 125I (one-way 
ANOVA test with Bonferroni 
post-correction).
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Tumor absorbed radiation dose
Dosimetric analysis of the biodistribution data (summarized in Figure 2a and Table 2 
and 3) using the MIRD methodology indicated that i.p. administration of equitoxic ac-
tivity doses (50% of MTD) of 131I-MN-14 (9.25 MBq), 186Re-MN-14, (9.25 MBq), 90Y-MN-
14 (3.15 MBq), or 177Lu-MN-14 (8.33 MBq/mouse) would result in absorbed radiation 
doses to tumors of 150 Gy, 100 Gy, 45 Gy and 200 Gy, respectively. In these calcula-
tions it was assumed that the weight of the tumor nodules was 10 mg, corresponding 
to a diameter of 2.6 mm.
Figure 3a
Tumor-to-blood ratios after in-
traperitoneal administration of 
131I-, 186Re- and 88Y-labeled MN-
14 in mice bearing peritoneal 
LS174T tumor xenografts. Values 
are given as means ± standard 
deviation (five mice per group). ** 
Significant difference between 88Y 
and 186Re; * Significant difference 
between 186Re and 131I; * Signifi-
cant difference between 88Y and 
131I (one-way ANOVA test with 
Bonferroni post-correction).
Figure 3b
Tumor-to-blood ratios after in-
travenous administration of 125I-, 
186Re- and 88Y-labeled MN-14 in 
mice bearing peritoneal LS174T 
tumor xenografts. Values are 
given as means ± standard de-
viation (five mice per group). ** 
Significant difference between 88Y 
and 186Re; * Significant difference 
between 186Re and 125I; ± Signifi-
cant difference between 88Y and 
125I (one-way ANOVA test with 
Bonferroni post-correction).
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Radioimmunotherapy
Three mice developed subcutaneous tumors at the site of tumor cell inoculation and 
were therefore excluded from the analysis. Thirty-three mice were killed when their 
abdominal circumference had increased by 10% due to i.p. tumor growth. Mean tumor 
weight in these mice was 2.23 ± 1.10 gram. Furthermore, five mice were killed due to 
20% loss of body weight and three additional mice because of poor clinical condition 
without weight loss being 20% or abdominal circumference increase reaching 10%. 
Mean tumor weight of the latter eight mice was 1.62 ± 0.92 gram, which was not statis-
tically different from the tumor load found in the 33 mice mentioned above (p=0.25). 
The survival curves of the different treatment groups are shown in Figure 4. Median 
survival of the control mice that received unlabeled MN-14 was 42 days (range 32-49). 
Median survival of the mice treated with equitoxic activity doses of 186Re-MN-14 (9.25 
MBq), 90Y-MN-14 (3.15 MBq), 131I-MN-14 (9.25 MBq) or 177Lu-MN-14 (8.33 MBq/mouse) 
was 72 days (range 46-77; p=0.0002), 82 days (46-142, p=0.0001), 100 days (58-142, 
p<0.0001) and 136 days (range 56-142; p<0.0001), respectively (p vs. unlabeled MN-
14 control group, Log-rank test). The p-values of the differences between the survival 
curves of the various treatment groups are shown in Table 4. 
At the end of the experiment (142 days after tumor cell inoculation), there were nine 
mice (177Lu-MN-14, n=5; 131I-MN-14, n=3; 90Y-MN-14, n=1) without any signs of i.p. 
tumor growth. At dissection one mouse treated with 177Lu-MN-14 had some tumor 
growth (total i.p. tumor load, 0.65 g), whereas in the remaining eight mice there was 
no evidence of disease. On histopathological examination of the diaphragm, greater 
omentum, pancreas, liver, spleen and lungs, no residual disease was found in any of 
these mice.
Figure 4
Survival curves of mice 
bearing peritoneal LS174T 
tumor xenografts after i.p. 
administration of 131I-MN-
14 (9.25 MBq), 186Re-MN-
14 (9.25 MBq), 90Y-MN-14 
(3.15 MBq), 177Lu-MN-14 
(8.33 MBq per mouse) or 
unlabeled MN-14 (eight to 
ten mice per group). P-val-
ues following comparison 
of the survival curves of the 
various treatment groups 
are given in Table 4.
The most suitable radionuclide
125
Discussion
The primary aim of this study was to select the most suitable radionuclide for radio-
immunotherapy for the treatment of small peritoneal metastases of colorectal origin. 
Radioimmunotherapy using 177Lu-MN-14 resulted in the best median survival of 136 
days, which was significantly better as compared to that after treatment with 186Re-
MN-14 (72 days) or 90Y-MN-14 (82 days) but which did not differ significantly from 
survival following treatment with 131I-MN-14 (100 days). No residual tumor was found 
by histopathological examination 142 days after tumor cell inoculation in four out of 
ten mice treated with 177Lu-MN-14, three out of ten mice treated with 131I-MN-14 and 
one out of ten mice treated with 90Y-MN-14, which were considered cured at the end 
of the study.
In the biodistribution studies, 88Y-labeled MN-14 resulted in a much higher uptake in tu-
mor than either radioiodinated MN-14 or 186Re-MN-14. The higher uptake of 88Y-MN-14 
in the tumor nodules probably reflects a longer tumor residence time of 88Y as compared 
to that of 131I or 186Re, which ensues from differences between the various radiolabels in 
intratumoral catabolization.13 Although anti-CEA monoclonal antibodies, such as MN-
14, that bind to CEA-epitopes on the tumor cell surface are internalized only slowly 
and to a limited extent14, 15 intratumoral catabolism of antibodies has been shown to be 
significant not only for rapidly internalizing antibodies, but also for antibodies binding 
Table 4. P-values following comparison of survival curves of mice  
treated with unlabeled MN-14 or MN-14 labeled with equitoxic 
activity doses of 186Re, 131I, 90Y or 177Lu
Radionuclide 
(median survival)
Unlabeled 
MN-14
186Re-
MN-14
90Y-
MN-14
131I-
MN-14
177Lu-
MN-14
Unlabeled MN-14 (42) _ 0.0002 <0.0001 <0.0001 <0.0001
186Re-MN-14 (72) 0.0002 _ 0.11 0.0014 0.0012
90Y-MN-14 (82) <0.0001 0.11 _ 0.10 0.02
131I-MN-14 (100) <0.0001 0.0014 0.10 _ 0.36
177Lu-MN-14 (136) <0.0001 0.0012 0.02 0.36 _
P-values were determined by use of the Log-rank test
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to the cell surface.16 After internalization by the cancer cell, radiolabeled antibodies are 
enzymatically degraded and metabolized in the lysosomes.17, 18 After intralysosomal me-
tabolization of monoclonal antibodies that are radioiodinated by conventional meth-
ods, the radioiodinated tyrosine residues are excreted, thereby reducing the residence 
times of the radioiodine label in the tumor.13 After catabolization of MAbs labeled 
with 88/90Y- or 177Lu-DTPA, the catabolic products are the radiolabeled chelators bound 
to amino acids, such as lysine (e.g. 88Y-DTPA-lysine).19, 20 Whereas radioiodinated ty-
rosine is excreted by the cell, the 88/90Y- or 177Lu-DTPA-lysine metabolites are trapped 
within the lysosomes. Furthermore, since antibodies are metabolized by the liver and 
spleen, residualization of the 88Y radiolabel may also explain the higher uptake in these 
organs as compared to that of 125/131I or 186Re. To date, the fate and processing of 186Re-
MAG3-labeled antibodies bound to the surface of tumor cells has not been elucidated. 
Various studies, however, have shown that 186Re is not retained in the cell after intra-
cellular catabolization.17, 21 The higher uptake of 186Re-MN-14 in tumor and the higher 
tumor-to-blood ratios as compared to that of radioiodinated MN-14 in our studies, 
however, suggest that the catabolic product of 186Re-MAG3-MN-14 (presumably 186Re-
MAG3-lysine) may be released from the cell at a slower rate than radioiodine.
In the therapy studies, the administered activity doses of the different radioimmuno-
conjugates represented 50% of the MTDs for the various radionuclides. The therapeu-
tic efficacy of 90Y-MN-14 was much lower than that of 177Lu-MN-14, but did not differ 
significantly from that of 131I-MN-14 nor from that of 186Re-MN-14. Because of its high 
mean beta-emission of 935 keV and consequently a relatively high tissue penetration 
depth (maximal range 12 mm), irradiation of the small peritoneal metastases of only 
a few millimeters in this model is inefficient, since approximately 70% of the radiation 
energy is deposited outside the tumor xenografts. Indeed, dosimetric analysis of the 
biodistribution data indicated that the tumor-absorbed radiation dose for 90Y-MN-14 
was much lower as compared with the other radiolabels. Esteban et al.22, 23 studied 
the effects of 90Y-based radioimmunotherapy using the anti-CEA MAb ZCE025 in a 
similar model of small volume peritoneal LS174T carcinomatosis. In this study a clear 
dose-response effect was observed, although residual viable tumor growth was still 
found on histological examination of mice five weeks after receiving 4.44 MBq. Fur-
thermore, Sharkey et al.24 showed that in a mouse model of micrometastatic colon 
carcinoma in the lungs, radioimmunotherapy with 131I was more effective than 90Y. 
Therefore, 90Y seems to be more appropriate for radioimmunotherapeutic application 
in larger tumors, which is in line with the findings of other investigators.15, 25
Although the dosimetric analysis correctly predicted 177Lu to be more efficacious than 
186Re and 90Y, the apparently higher tumor absorbed dose for 186Re as compared to 90Y 
did not result in an improved survival. This discrepancy may be due to inaccuracies of 
the dosimetric analysis, since blood, bone marrow, liver and spleen were not included 
as source organs in this analysis. It may very well be feasible that the relatively high 
uptake of 90Y-MN-14 in the liver and spleen (approximately 7 %ID/g after i.p. adminis-
tration) in combination with its high-energy beta-emission (max. range 12 mm) may 
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have contributed to the sterilization of the small peritoneal metastases in the upper 
abdomen. Another explanation for the observed discrepancy between the survival 
and the tumor absorbed radiation dose may be failure of the animal model to reveal 
small differences in therapeutic efficacy.
Treatment of mice with 177Lu-MN-14 resulted in the highest median survival of 136 
days, which, however, did not differ significantly from that after treatment with 131I-
MN-14 (100 days; p=0.36). Given the longer intratumoral residence times of 177Lu as 
compared to that of 131I or 186Re, this radionuclide, with its medium-energy beta (maxi-
mum penetration depth, 2.5 mm) and a half-life of almost a week, seems to be very 
well suited for the treatment of microscopic or small volume disease. From a clinical 
point of view, the radiophysical characteristics of 177Lu may furthermore be more fa-
vorable as compared to those of 131I or 90Y. Firstly, due to its longer half-life of 6.7 days 
as compared to that of 90Y (2.3 days), bone marrow toxicity may be less since less of 
the decay occurs in the early time period after administration when blood levels are 
relatively high and uptake in tumor is still low. Simultaneously, after intratumoral 
accumulation of the radiolabeled antibody, the tumor is irradiated over a prolonged 
period of time. Finally, the emission of low abundance, moderate-energy gamma rays 
of 177Lu poses less radiation safety issues than those of 131I for the patient’s family and 
the health care personnel. In fact, promising results have been reported by Alvarez et 
al.26, who treated 27 patients with chemotherapy-refractory ovarian cancer with i.p. 
radioimmunotherapy using 177Lu-labeled CC-49 IgG antibody. Antitumor effects were 
noted even at lower dose levels, whereas patients with microscopic disease showed a 
prolonged disease-free survival compared to historical controls. 
Conclusion
Uptake of 88Y-MN-14 in small peritoneal LS174T xenografts was higher than that of 
186Re-MN-14 or 131I-MN-14. At equitoxic activity doses, therapeutic efficacy of 177Lu-
MN-14 was better that of 186Re-MN-14 and 90Y-MN-14, but did not differ significantly 
from that of 131I-MN-14, which is in line with the dosimetric analysis. The results of 
these studies indicate that 177Lu and 131I are the most suitable radionuclides for ra-
dioimmunotherapy of small peritoneal metastases and may be the best candidates 
for adjuvant treatment of patients at high risk for the development of i.p. relapse of 
colorectal cancer.
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Despite the promising results in hematological malignancies, the only modest therapeutic efficacy of radioimmunotherapy (RIT) using radiolabeled mono-clonal antibodies (MAbs) in patients with solid cancers has tempered the ini-
tial enthusiasm with which this treatment modality was once greeted.1 The targeting 
of intravenously administered radiolabeled antibodies to solid tumors is a relatively 
inefficient process due to various tumor-related factors, including a limited vascular 
supply, heterogeneous uptake of the antibody in the tumor, and elevated interstitial 
pressure in combination with a relatively long transport distance in the interstitium.2 
As a result, tumor uptake of radiolabeled MAbs and, consequently, the radiation doses 
delivered to solid lesions are in most cases too low to induce objective tumor respons-
es. Several innovative approaches have been pursued with the aim of improving the 
efficacy of RIT. These include strategies to improve the localization and retention of 
radiolabeled MAbs in the tumor (e.g. using high-affinity MAbs3,4), strategies to accel-
erate the blood clearance of MAbs (e.g. using antibody fragments5,6 or the pretargeting 
method7), and, strategies to increase the sensitivity of the tumor cells to radiation (e.g. 
by means of radiosensitizers8-10). 
In the early nineteen-nineties, the inducible second isoform of cyclooxygenase (COX-2) 
was recognized to play a significant role in colorectal carcinogenesis. This observation 
was derived from epidemiological studies indicating that chronic users of non-steroid 
anti-inflammatory drugs (NSAIDs) had a 40-50% reduced risk of developing colorec-
tal cancer (CRC).11 The COX-2 enzyme catalyzes the conversion of arachidonic acid to 
prostaglandin derivatives and its expression is upregulated at sites of inflammation12 
and in various epithelial cancers, including 80-90% of human colon carcinomas.13 To 
date, COX-2 has been acknowledged to be involved in various biological processes 
in epithelial and nonepithelial cancers, including the regulation of apoptosis,14,15 tu-
mor cell invasiveness and metastatic potential16, tumor angiogenesis,17 and protection 
against radiation damage.18 
Because of the gastrointestinal and hematological toxicity of nonselective NSAIDs,19 
the potential of selective inhibitors of the COX-2 enzyme (so-called coxibs) to act as 
radiosensitizing agents has been subject of investigation in various preclinical and 
ongoing clinical studies. Coxibs were indeed shown to increase the sensitivity of tu-
mor cells to external beam radiation in various experimental models of colon cancer,20 
breast cancer,21 head and neck cancer,20,22 lung cancer,21,23 sarcoma,24,25 and glioma26 
without increasing radiation-induced toxicity to normal tissue. To date, however, 
there have been no publications on the use of COX-2 inhibitors in combination with 
RIT.
We have characterized a nude mouse model for RIT of small volume peritoneal carci-
nomatosis of colorectal origin using the human colon carcinoma cell line LS174T.27,28 
RIT using the radiolabeled anti-CEA MAb MN-14 proved very effective in delaying the 
growth of intraperitoneal tumor xenografts, even at relatively low activity doses. The 
COX-2 enzyme is upregulated and actively mediates the production of prostaglandin 
E2 (PGE2) in the LS174T tumor cells.
29 PGE2 has been shown to promote the growth 
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and metastatic potential of colon carcinoma cells in vitro and implicated as a protector 
against radiation damage.18 
The novel, selective COX-2 inhibitor parecoxib is a prodrug, specifically designed 
for parenteral administration.30 After systemic administration, parecoxib is rapidly 
converted to the COX-2 inhibitor valdecoxib by enzymatic hydrolysis in the liver.31,32 
Valdecoxib is one of the most potent and selective COX-2 inhibitors that have been 
developed to date.33,34 Since parecoxib monotherapy has been reported to have antitu-
mor effects in mouse models of breast cancer and colon cancer,35,36 we hypothesized 
that co-administration of the COX-2 inhibitor parecoxib might sensitize the LS174T 
xenografts to radiation and improve the therapeutic efficacy of RIT in our model of 
small volume peritoneal carcinomatosis of colorectal origin.
To test this hypothesis, we designed a series of experiments that aimed to determine 
the efficacy of parecoxib monotherapy, and to assess the effect of parecoxib co-admin-
istration on the biodistribution and therapeutic efficacy of radiolabeled MN-14. 
Materials and methods
Animal model of small peritoneal metastases
Male nude BALB/c mice (Charles River Laboratories, Germany), 7-9 weeks old, weigh-
ing 20-25 grams were used in the experiments. Mice were accustomed to laboratory 
conditions for at least one week before experimental use and were housed under 
nonsterile standard conditions (temperature 20–24°C; relative humidity 50–60%; 12 
h light/12 h dark) in filter-topped cages (up to five mice per cage), on sawdust with 
free access to animal chow (Snif Voer, Soest, The Netherlands) and water. Peritoneal 
metastases were induced as described previously.27 Briefly, mice were inoculated intra-
peritoneally with 1.0 x 106 LS174T cells (CCL 188, American Type Culture Collection, 
Rockville, MD), suspended in 500 µl of RPMI-1640 medium using a 23-gauge needle. 
In this model, the first macroscopic tumor nodules are seen seven to ten days thereaf-
ter, whereas bulky peritoneal carcinomatosis develops three to six weeks after tumor 
cell inoculation. 
Before initiating the experimental studies, the COX-2 expression of LS174T was im-
munohistochemically confirmed using a murine anti-COX-2 polyclonal antibody 
(Brunschwig Chemie, Amsterdam, The Netherlands), as shown in Figure 1. The ex-
periments were approved by the institutional Animal Welfare Committee of the Uni-
versity Medical Center Nijmegen and conducted in accordance with the principles set 
forth by the revised Dutch Act on Animal Experimentation (1997).
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Monoclonal antibody
The murine MN-14 MAb is a high-affinity (Ka = 10
9 M-1) class-III anti-CEA IgG1 anti-
body, produced by a hybridoma cell line culture, kindly provided by Immunomedics, 
Inc. (Morris Plains, New Jersey, USA).37 The antibodies were purified by protein A 
chromatography, as described previously.38 Purity was checked by SDS-PAGE under 
nonreduced conditions and by means of fast protein liquid chromatography (FPLC) 
on a Phenomenex Biosep 3000 column, eluted with phosphate buffered saline (PBS, 
pH 7.2, 1 mL/min).
 
Radioiodination and quality control
Antibodies were radioiodinated with 125I (Amersham, Den Bosch, The Netherlands) or 
131I (MDS Nordion, Fleurus, Belgium) using the iodogen-method (1,3,4,6-tetrachloro-
3α,6α-diphenyl-glycoluril; Pierce, Rockford, IL). Briefly, antibodies and 125I or 131I were 
incubated at room temperature in 85 µl of PBS (0.10 M, pH 7.4) in a glass vial, coated 
with 50-100 µg iodogen. After twelve minutes, the reaction mixture was separated on 
a PD-10 column (Amersham Biosciences, Uppsala, Sweden), eluted with PBS, 0.5% 
bovine serum albumin (BSA). Labeling efficiency of the radioiodination reactions ex-
ceeded 70%. In the biodistribution study the specific activity of the primary 125I-MN-
14 preparation was 2.9 µCi/µg. Specific activity of the primary 131I-MN-14 preparation 
in the therapy study was 23.4 µCi/µg. In a previous study we demonstrated that the 
uptake of the radiolabeled MN-14 antibody in tumor was optimal at MN-14 protein 
doses up to 25 µg.27 Therefore, in the present study the radiolabeled antibody prepara-
tions were augmented with unlabeled MN-14 to a total antibody protein dose of 20 
µg per mouse. 
The amount of free iodine was determined by instant thin layer chromatography 
(ITLC) with ITLC silica gel strips (Gelman Sciences, Inc., Ann Arbor, MI, USA) using 
Figure 1
Anti-COX-2-immunohistochemical staining of 
a small, intraperitoneally growing LS174T xe-
nograft, showing pronounced expression of the 
COX-2 enzyme (magnification = 200x). 
Chapter 5
136
0.1 M citrate buffer (pH 6.0) as the mobile phase. Radiochemical purity of the radioio-
dinated antibody preparations used in the studies exceeded 98%. The immunoreactive 
fraction (IRF) at infinitive antigen excess of the radiolabeled MN-14 preparation was 
determined on freshly trypsinized LS174T cells essentially as described by Lindmo et 
al.39 with minor modifications. Briefly, a fixed amount of labeled antibody (10,000 cpm) 
was incubated with increasing concentrations of LS174T tumor cells (1.2 x 106 – 20 x 
106 cells/mL) in 0.5 mL binding buffer (RPMI medium containing 0.5% BSA and 0.05% 
NaN3). A duplicate of the lowest cell concentration was incubated in the presence of 
an excess unlabeled antibody to correct for non-specific binding. After six hours of 
incubation at 37°C, the cells were washed and activity in the pellet was determined in 
a well-type gamma-counter. The inverse of the tumor cell bound fraction was plotted 
against the inverse of the cell concentration and the immunoreactive fraction (IRF) 
was calculated from the Y-axis intercept. The IRFs of the 125I-MN-14 and 131I-MN-14 
preparations were 80% and 76%, respectively. The radiolabeled antibody preparations 
were administered within two hours after radiolabeling.
Parecoxib
Parecoxib sodium (Dynastat®), a selective COX-2 inhibitor specifically developed for 
parenteral administration, was purchased from Pharmacia Europe EEIG (Bucking-
hamshire, UK) as a powder in glass vials (40 mg/vial). Parecoxib was dissolved in 0.9% 
sodium chloride (saline) to the appropriate concentrations immediately before use 
and administered intraperitoneally (0.2 ml/mouse).
Therapeutic efficacy of parecoxib monotherapy
To evaluate the therapeutic efficacy of parecoxib when given as monotherapy, mice 
bearing small peritoneal metastases were treated with daily intraperitoneal admin-
istrations of increasing doses of parecoxib (0.2, 1.0, 5.0, or 25.0 mg/kg) for fourteen 
consecutive days, starting on the tenth day after tumor cell inoculation. Control mice 
received saline only (eight mice per group). Prior to each administration, body weight, 
as a surrogate measure of toxicity, was measured. Thirty days after tumor cell inocula-
tion, all mice were euthanized by O2/CO2-asphyxiation and dissected. At dissection 
the intraperitoneal tumor load was score semiquantitavely, according to the perito-
neal cancer index (PCI) as described by Eggermont et al.40 In brief, the intraperitoneal 
tumor load could be given a PCI of 0, 1, 2, or 3, where 0 indicated no macroscopic 
tumor growth, 1 meant ≤ 3 pin-point tumor foci that have a diameter of ≤ 1 mm, 2 
indicated moderate tumor growth, and 3 indicating abundant intraperitoneal tumor 
growth, replacing most of the peritoneal cavity. Subsequently, after designating a PCI 
rate, all macroscopic tumor deposits were meticulously excised and weighed. 
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Effect of parecoxib on the biodistribution of radioiodinated MN-14
To assess the effect of daily parecoxib therapy on the biodistribution of radioiodinated 
MN-14, ten days after tumor cell inoculation 45 mice received an i.p. injection of 125I-
MN-14 (5 µCi/20 µg/mouse). Parecoxib therapy, which consisted of daily intraperito-
neal administrations of 1.0 mg/kg or 5.0 mg/kg per mouse, was started concurrently 
with the administration of the radiolabeled antibodies. Control mice received saline 
only. Mice were euthanized by O2/CO2-asphyxia and dissected at 24 hours (i.e. after 
one administration of parecoxib), 72 hours (i.e. after two administration of parecoxib) 
and 168 hours (i.e. after six administrations of parecoxib) after the administration of 
125I-MN-14 (five mice per group). Tumor, blood, liver, spleen, kidney, small intestine, 
cecum, lung and muscle tissues were sampled, gently blotted dry, and immediately 
weighed. Radioactivity was measured in a shielded well-type gamma-counter (Wizard, 
Pharmacia-LKB, Sweden). To correct for physical decay and to calculate the uptake of 
the radioiodinated antibody in each sample as a fraction of the injected dose, aliquots 
of the injected dose were counted simultaneously. The results were expressed as per-
centage of the injected dose per gram tissue (% ID/g). 
Combination therapy of RIT and parecoxib
To assess the radiosensitizing effect of parecoxib when combined with RIT, ten days 
after tumor cell inoculation groups of twelve mice each were treated with either 131I-
MN-14 (125 µCi/mouse, which is approximately 25% of the maximal tolerated dose), 
parecoxib (either 1.0 mg/kg or 5.0 mg/kg/day for fourteen consecutive days) or 131I-
MN-14 combined with parecoxib. 131I-MN-14 was given intraperitoneally on day 10 
in 200 µl of PBS, 0.5% BSA. Parecoxib was given daily by intraperitoneal injections 
in from day 10 till 23. Control mice received daily intraperitoneal injections of 200 µl 
of saline. Mice treated with RIT only, were given daily injections of 200 µl of saline. 
Prior to each administration, the mice were weighted to ensure that body weight loss 
did not exceed 20%. Mice were monitored daily and body weight was measured daily 
in the first two weeks after the first administration. Mice were monitored until the 
body weight had dropped more than 20% or until the humane endpoint had been 
reached, as determined by an experienced and independent animal technician, who 
was blinded to the therapeutic regimen. At the time of the humane endpoint, mice 
were usually cachectic and drowsy, showing signs of advanced peritoneal carcinoma-
tosis, such as the presence of bloody ascites or bulky intraperitoneal tumor growth, 
and were expected to die with one or two days. When body weight had dropped more 
than 20% or the humane endpoint had been reached, mice were euthanized by O2/
CO2-asphyxiation and immediately dissected. At dissection, tumor load was scored 
by the peritoneal cancer index (PCI), as described above, and all tumor deposits 
were excised and weighed. The experiment was terminated at 118 days after tumor 
cell inoculation when the remaining mice were euthanized and dissected. The ab-
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dominal cavity was carefully inspected. Liver, spleen, lungs, pancreas, greater omen-
tum and the diaphragm were removed for routine histopathological H&E-staining 
and immunohistochemical staining using a rabbit-anti-human anti-CEA polyclonal 
antibody (A 0115, DakoCytomation, Glostrup, Denmark).
Statistical analysis
Statistical analysis was performed by means of the GraphPad Prism 4.00 software 
(GraphPad Software, San Diego, CA). Comparisons were analyzed using the one-way 
ANOVA test. Bonferroni correction for multiple testing was applied. Survival curves 
were compared using the Log-rank test. All tests were two-sided; the level of statistical 
significance was set a P-value of <0.05.
Results
Parecoxib monotherapy
Fourteen daily administrations of parecoxib, when given as sole treatment, had no 
influence on body weight at any of the dose levels tested. Thirty days after tumor cell 
inoculation, one mouse of the control group, had abundant intraperitoneal tumor 
growth. At that time it was decided to terminate the experiment and dissect all ani-
mals. At dissection, all mice of the control group that had been treated with saline had 
macroscopic tumor growth. Of the mice treated with 0.2 mg/kg or 1.0 mg/kg per ad-
Figure 2 
The peritoneal cancer index (PCI) 
designated to mice with small intra-
peritoneal LS174T xenografts after 
treatment with either daily intra-
peritoneal administrations of saline 
or increasing dosages of parecoxib 
(0.2 – 25.0 mg/kg) during fourteen 
consecutive days. Lines indicate the 
median and range. There was a bor-
derline significant trend towards a 
lower PCI at higher parecoxib dos-
ages (P=0.097).
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ministration, one mouse of each group no macroscopic tumor growth. Of those mice 
that had been treated at dose levels of 5.0 mg/kg or 25.0 mg/kg per administration, 
two out of eight and four out of eight had no macroscopic tumor growth, respectively. 
The PCI designated to the mice is depicted in Figure 2. The median PCI (range) varied 
between 2 (1-3) in the control group and 1 (0-3) in the mice treated with parecoxib at 
25.0 mg/kg. There was a borderline significant trend towards a lower PCI at higher 
parecoxib dosages (P=0.097). In Figure 3, the tumor weight found in each mouse is 
given. The mean (± SD) tumor weight varied between 1.3 (± 1.5) g in the control group 
and 0.5 (± 0.4) g in the mice treated with parecoxib at 0.2 mg/kg (P=0.15 for trend). 
There was a highly significant correlation between the PCI and the weight of the dis-
sected tumor deposits (Spearman r=0.9349, P<0.0001).
Figure 3
The tumor weight found 
in the mice with small in-
traperitoneal LS174T xe-
nografts after treatment 
with either daily intraperi-
toneal administrations of 
saline or increasing dosag-
es of parecoxib (0.2 – 25.0 
mg/kg) during fourteen 
consecutive days. Lines 
indicate mean ± SD. 
Figure 4
The uptake of 125I-MN-
14 in tumor expressed as 
percentage of the injected 
dose per gram (% ID/g), 
with of without daily in-
traperitoneal injections 
of parecoxib (1.0 mg/kg 
or 5.0 mg/kg). Control 
mice received daily admin-
istrations of saline. Par, 
parecoxib.
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Influence of parecoxib on the biodistribution of radioiodinated MN-14
The results of the experiment in which the effect of parecoxib on tumor uptake 
and biodistribution of 125I-labeled MN-14 was studied, are summarized in Table 1. 
Parecoxib co-administration had no effect on the uptake of 125I-MN-14 in tumor or 
on the blood levels or tumor-to-blood ratios. Mean uptake of 125I-MN-14 in tumor 
nodules obtained from the control mice at 24, 72 and 168 hours post-injection (p.i.) 
amounted 51.4 (± 13.8)% ID/g, 38.6 (± 5.8)% ID/g and 35.6 (± 21.6)% ID/g, respectively. 
Tumor uptake of 125I-MN-14 in the mice that received daily administration of either 
1.0 mg/kg or 5.0 mg/kg parecoxib was very similar to that in control mice, as shown 
in Figure 4. Furthermore, parecoxib co-administration had no influence on the nor-
mal tissue distribution of 125I-MN-14 at the various time points tested.
Combination therapy of parecoxib and 131I-labeled MN-14
To test the hypothesis that the COX-2 inhibitor parecoxib might improve the efficacy 
of RIT in small peritoneal metastases, parecoxib was administered daily for fourteen 
consecutive days, starting concurrently with the administration of 131I-MN-14. 
Control mice that were treated with daily injections of saline showed a maximum 
weight loss of 1.9 ± 3.9% at four days after the start of treatment. RIT alone using 125 
µCi 131I-MN-14 per mouse resulted in a maximum weight loss of 3.9 ± 1.5% four days 
after administration of the radiolabeled antibodies. The toxicity of RIT was not af-
fected by co-administration of parecoxib. Maximum weight loss after RIT combined 
Figure 5
Kaplan-Meier survival 
plot of mice with small 
intraperitoneal LS174T 
xenografts after intraperi-
toneal administration of 
131I-MN-14 (125 µg/mou-
se), parecoxib monother-
apy (fourteen daily admin-
istrations at 1.0 mg/kg or 
5.0 mg/kg), or RIT com-
bined with parecoxib. Par, 
parecoxib.
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with daily administrations of parecoxib at 1.0 mg/kg or 5.0 mg/kg was 3.5 ± 2.6% and 
4.8 ± 0.9, respectively (P=0.42). There were no treatment-related deaths.
Five mice (7%) developed large subcutaneous tumors at the inoculation site and were 
excluded from the survival analysis. The survival curves for the various treatment 
groups are shown in Figure 5. Median survival of the control mice was 48.5 days (range 
38-73). Parecoxib monotherapy at 1.0 mg/kg or 5.0 mg/kg resulted in a median sur-
vival of 52 days (range 38-118) and 52 days (range 44-118), respectively (P=0.47). RIT 
alone resulted in a significantly improved median survival of 87 days (range 55-118, 
P<0.0001). Daily intraperitoneal injections of parecoxib at 1.0 mg/kg or 5.0 mg/kg 
during fourteen consecutive days after the administration of 131I-MN-14 resulted in a 
median survival of 73.5 (range 55-118) and 76 (range 55-90) days, respectively (P=0.15, 
comparing RIT alone with RIT + parecoxib 1.0 mg/kg or 5.0 mg/kg). Although the dif-
ference between the survival of the mice treated with RIT alone and the mice treated 
with RIT + parecoxib 1.0 mg/kg was not significant (P=0.19), median survival of the 
mice treated with RIT alone was significantly better than that of the mice treated with 
RIT + parecoxib 5.0 mg/kg (P=0.029).
At dissection, the PCI was 3 for all control mice. Median PCI for the mice treated with 
parecoxib 1.0 mg/kg, parecoxib 5.0 mg/kg, RIT alone, RIT + parecoxib 1.0 mg/kg and 
RIT + parecoxib 5.0 mg/kg was 2.6 (range 2-3), 3 (range 2-3), 3 (range 2-3), 3 (range 
2-3) and 3 (range 2-3), respectively (P=0.56). Figure 6 depicts the tumor weight that 
was found at dissection at the time mice reached their humane endpoints. It varied 
between 4.3 ± 1.4 for the mice treated with parecoxib 5.0 mg/kg and 4.9 ± 1.6 for the 
mice treated with RIT + parecoxib 5.0 mg/kg (P=0.94). 
Figure 6
Scatter dot plot, speci-
fying the tumor weight 
found at dissection. Lines 
indicate means ± stand-
ard deviation. The varia-
tion between the groups is 
not statistically different 
(P=0.94). Par, parecoxib. 
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The highly similar tumor mass found in the mice demonstrates that there was no bias 
in determining the humane endpoint. The method of determining and comparing the 
survival was therefore reliable. 
At the end of the experiment (118 days after tumor cell inoculation), there were five 
long-term survivors (two treated with RIT alone; one treated with RIT + parecoxib 1.0 
mg/kg; and two treated with parecoxib monotherapy at 1.0 mg/kg and 5.0 mg/kg, re-
spectively), without signs of intraperitoneal tumor growth. At dissection, the mouse 
that had been treated with parecoxib monotherapy at 5.0 mg/kg had macroscopic tu-
mor growth (0.36 g; PCI 2), whereas in the remaining four mice there was no evidence 
of disease. Histopathological examination of relevant organs, including the greater 
omentum, mesentery, diaphragm and pancreas did not reveal residual disease in any 
of these mice.
Discussion
The primary aim of the current study was to investigate the potential of the COX-2 
inhibitor parecoxib to act as a radiosensitizer when combined with RIT in a well-char-
acterized animal model of small volume peritoneal carcinomatosis of colonic origin. 
Daily administration of parecoxib, however, failed to improve the efficacy of RIT using 
131I-MN-14 in this model.
The COX-2 inhibitor parecoxib was selected, since it has several favorable properties 
that made it attractive as a potential radiosensitizer. In contrast to other commercially 
available selective COX-2 inhibitors that are poorly soluble in water and can only be 
given orally, parecoxib is water-soluble and was specifically developed for parenteral 
(intramuscular or intravenous) administration. As such, parecoxib allows more precise 
dosing. After hydrolysis in the liver, the active metabolite valdecoxib binds non-cova-
lently to COX-2, forming a firm and stable enzyme-inhibitor complex.41 Valdecoxib 
has been shown to have a higher in vitro affinity to COX-2, and bind more rapidly to 
and dissociate from COX-2 more slowly than celecoxib,42,43 which has been one of the 
most used and studied COX-2 inhibitors. Although there are no published data on the 
pharmacokinetics of parecoxib in mice, experimental studies in rats have shown that 
after intravenous administration parecoxib is rapidly converted to valdecoxib (conver-
sion time, 8 minutes), which then has a plasma half-life of four to five hours.34 Zhang 
et al. studied the pharmacokinetics of [14C]Valdecoxib after oral ingestion at 5 mg/kg 
in mice, and found a peak plasma concentration at 30 minutes after ingestion and the 
half-life in blood of approximately four hours, with most of the [14C]Valdecoxib associ-
ated with the red blood cells.44
COX-2 inhibition with parecoxib has been shown to have antitumor effects in ex-
perimental breast cancer and colon cancer.35,36 O’Donoghue et al.35 investigated the 
therapeutic efficacy of fifteen daily intraperitoneal administrations of parecoxib (0.5 
mg/kg) in mice bearing subcutaneous breast cancer xenografts and observed growth 
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inhibition of the primary tumor and pulmonary metastases. Smakman et al. studied 
the efficacy of twice-daily intraperitoneal injections of parecoxib (5 mg/kg) during 
six days in mice immediately after inducing liver metastases of colon carcinoma and 
reported greatly reduced intrahepatic tumor cell proliferation and the rate of liver 
metastases outgrowth.36 Therefore, before combining parecoxib with RIT in the cur-
rent model of peritoneal carcinomatosis, we first investigated the toxicity and effi-
cacy of parecoxib monotherapy. Parecoxib proved to be a safe agent; body weight loss 
among the treatment groups was similar to that of the control group, and none of the 
mice had gastric ulcers at dissection. Daily intraperitoneal injections of parecoxib dur-
ing fourteen consecutive days had no statistically significant antitumor effect in this 
study, although there was a borderline trend towards a dose-dependent antitumor ef-
fect. At the highest dose level (25.0 mg/kg) four out of eight mice had no macroscopic 
tumor growth, which suggests that high doses of parecoxib might have an antitumor 
effect in this model. 
COX-2 derived prostaglandins play an important role in tumor angiogenesis.45 Selec-
tive inhibition of COX-2 has been shown to be associated with a decrease in new vessel 
formation.46,47 Therefore, it could not be excluded that COX-2 inhibition with parecox-
ib might affect the tumor uptake of radiolabeled antibodies in RIT, which prompted us 
to conduct the biodistribution study. Daily administration of parecoxib at 1.0 mg/kg 
or 5.0 mg/kg had no effect on the overall biodistribution and tumor uptake in particu-
lar, of radioiodinated MN-14 in this model.
To date, several papers have been published reporting synergistic or radiosensitizing 
activity of COX-2 inhibition when given prior to and concurrently with external beam 
gamma-irradiation in various epithelial cancers.18 Celecoxib (Celebrex®) or its bioac-
tive compound SC-236, has been the COX-2 inhibitor used in most studies. In view 
of the pronounced expression of COX-2 in LS174T, and because the efficacy of RIT at 
relatively low activity doses is limited, we hypothesized that inhibition of the COX-2 
enzyme might have a synergistic or radiosensitizing effect when combined with RIT 
in this model. RIT was given at 25% of the MTD, since we previously demonstrated 
that this activity dose significantly delays the development of peritoneal carcinoma-
tosis but is not curative in this model. Thus, we assumed that a clinically relevant 
radiosensitizing effect of parecoxib could be demonstrated at this dose level. Since the 
radiosensitizing effect of celecoxib has been demonstrated to be dose-dependent in 
external beam radiation,20 parecoxib was combined with RIT at two dose levels in the 
current study. In concert with the results of the first experiment, in which parecox-
ib had no significant antitumor effect, the median survival of the mice treated with 
parecoxib monotherapy was similar to that of the control mice. RIT alone significantly 
improved the median survival as compared to that obtained in the control mice. Daily 
intraperitoneal administrations of parecoxib, however, did not enhance the efficacy 
of RIT, and, of unknown significance, appeared even to be detrimental to the effect 
of RIT at the higher dose level of parecoxib (5.0 mg/kg). All mice were euthanized at 
the time their clinical condition had deteriorated beyond the humane endpoint due 
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to abundant intraperitoneal tumor growth. Mean tumor weight of all the treatment 
groups was very similar. Therefore, long-term adverse systemic effects of the COX-2 
inhibition seem to be an unlikely explanation for the observed survival difference 
between the mice treated with RIT alone and those treated with RIT + parecoxib 5 
mg/kg. 
Special features of the published experimental models, in which COX-2 inhibitors were 
successfully applied as radiosensitizers, that might explain the failure of parecoxib to 
act as a radiosensitizer in the current model, include the type of radiotherapy (exter-
nal beam radiation versus RIT), the animal model with respect to the localization of 
the xenografts (subcutaneous versus intraperitoneal), and the choice of the COX-2 
inhibitor. RIT differs from external beam radiation in that in RIT the radiation energy 
is deposited over a long time interval (low dose rate), whereas in external beam radia-
tion, the radiation energy is delivered in one or more fractions at a high dose rate.48 
Inhibition of the COX-2 enzyme might only sensitize tumor cells to radiation when 
given at a high dose rate. Furthermore, because of the long time-interval during which 
the radiation energy is delivered to the tumor nodules in RIT, it seems unlikely that 
a radiosensitizing effect of parecoxib would have become apparent had the drug been 
administered prior to the injection of the radiolabeled antibodies. 
Another explanation of the absence of any radiosensitizing activity by parecoxib may 
be the intraperitoneal localization of the tumor xenografts, as opposed to the sub-
cutaneous xenografts, used in other studies reporting a radiosensitizing effect when 
COX-2 inhibition was combined with radiotherapy. Whereas in subcutaneous tumor 
models therapeutic efficacy is determined by measuring the growth of the subcutane-
ous tumors, in the current model of peritoneal carcinomatosis survival has been the 
primary endpoint. Failure of the animal model to reveal small differences in thera-
peutic efficacy might have obscured any additional therapeutic effect of parecoxib co-
administration. Furthermore, although RIT alone was noncurative in eight out of ten 
mice, its efficacy could have outshined a potential radiosensitizing effect of parecoxib 
in this model.
Finally, since parecoxib is a prodrug that needs to be hydrolyzed by the liver, its active 
metabolite Valdecoxib can only reach the intraperitoneal tumors via the blood. It can-
not be excluded that the vascularization of the small intraperitoneal LS174T xenografts 
is too limited to allow sufficient supply of the COX-2 inhibitor Valdecoxib. Whether 
intraperitoneal administration of other COX-2 inhibitors that do not need conversion 
could reach the intraperitoneal xenografts more effectively and thus enhance RIT of 
peritoneal carcinomatosis of colonic origin remains yet to be ascertained.
In conclusion, monotherapy using the COX-2 inhibitor parecoxib had no antitumor 
effect in nude mice with small intraperitoneal LS174T colon cancer xenografts. When 
given concurrently with RIT, parecoxib had no effect on the biodistribution of the 
radiolabeled antibodies, did not enhance the therapeutic efficacy of RIT and appeared 
even to have a detrimental effect on the efficacy of RIT at the highest dose tested.
Chapter 5
146
References
1.  Koppe MJ, Bleichrodt RP, Oyen WJG, Boerman OC. Radioimmunotherapy and colo-
rectal cancer. Br J Surg 2005; 92:264-76.
2.  Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macro-
molecules in tumors. Cancer Res 1990; 50:814s-819s.
3.  Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley 
D, Dunn R, Siegel J, Goldenberg DM. Radioimmunotherapy of medullary thyroid can-
cer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996; 37:905-911.
4.  Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Si-
ler K. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. 
Cancer Res 1992; 52:1067-1072.
5.  Behr TM, Blumenthal RD, Memtsoudis S, Sharkey RM, Gratz S, Becker W, Goldenberg 
DM. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal 
antibody fragments. Clin Cancer Res 2000; 6:4900-4907.
6.  Buchegger F, Mach J-P, Folli S, Delaloye B, Bischof-Delaloye A, Pelegrin A. Higher ef-
ficacy of 131I-labeled anti-carcinoembryonic antigen-monoclonal antibody F(ab’)2 as 
compared to intact antibodies in radioimmunotherapy of established human colon 
carcinoma grafted in nuce mice. In Sauter-Bihl M, Bihl H, Wannenmacher W (eds). 
Systemic Radiotherapy with Monoclonal Antibodies - Recent results in Cancer Re-
search. Berlin: Springer; 1996.
7.  Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunothera-
py of cancer: progress step by step. J Nucl Med 2003; 44:400-411.
8.  Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmu-
notherapy for the treatment of pancreatic cancer. Int J Cancer 2002; 97:386-392.
9.  Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-
PAM4) combined with gemcitabine for the treatment of experimental pancreatic can-
cer. Clin Cancer Res 2003; 9:3929S-3937S.
10.  Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled 
PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the 
treatment of a human pancreatic cancer xenograft. Int J Cancer 2004; 109:618-626.
11.  Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evi-
dence. Semin Surg Oncol 1994; 10:158-164.
12.  Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Induc-
ible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698-701.
13.  Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regu-
lation of cyclooxygenase 2 gene expression in human colorectal adenomas and adeno-
carcinomas. Gastroenterology 1994; 107:1183-1188.
14.  Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation 
of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 1998; 13:591-597.
15.  Li M, Wu X, Xu XC. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 
inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 2001; 
7:1010-1016.
Combination therapy with parecoxib
147
16.  Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer 
cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94:3336-3340.
17.  Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiang-
iogenic therapy. Semin Oncol 2004; 31:2-11.
18.  Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a 
rational advance? J Natl Cancer Inst 2003; 95:1440-1452.
19.  Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of chron-
ic NSAID induced upper gastrointestinal toxicity. Cochrane Database Syst Rev 
2000;CD002296.
20.  Davis TW, O’Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL. 
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygen-
ase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. 
Cancer Res 2004; 64:279-285.
21.  Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okuni-
eff P, Ding I. Combination of radiation and celebrex (celecoxib) reduce mammary and 
lung tumor growth. Am J Clin Oncol 2003; 26:S103-S109.
22.  Amirghahari N, Harrison L, Smith M, Rong X, Naumann I, Ampil F, Shi R, Glass J, 
Nathan CA. NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radia-
tion-induced expression of COX-2. Int J Radiat Oncol Biol Phys 2003; 57:1405-1412.
23.  Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN. A selective 
cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in 
vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 
7:2998-3005.
24.  Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas 
L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. 
Cancer Res 2000; 60:1326-1331.
25.  Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement of tu-
mor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl 
Cancer Inst 1999; 91:1501-1504.
26.  Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor 
cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 
2000; 6:2513-2520.
27.  Koppe MJ, Soede AC, Pels W, Oyen WJ, Goldenberg DM, Bleichrodt RP, Boerman OC. 
Experimental radioimmunotherapy of small peritoneal metastases of colorectal ori-
gin. Int J Cancer 2003; 106:965-972.
28.  Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boer-
man OC. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, 
or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice 
with small peritoneal metastases of colorectal origin. J Nucl Med 2004; 45:1224-1232.
29.  Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cycloox-
ygenase-2 expression in colon carcinoma cells. J Biol Chem 2000; 275:33951-33956.
30.  Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for 
acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 2003; 3:1.
Chapter 5
148
31.  Stichtenoth DO. The second generation of COX-2 inhibitors: clinical pharmacological 
point of view. Mini Rev Med Chem 2004; 4:617-624.
32.  Padi SS, Jain NK, Singh S, Kulkarni SK. Pharmacological profile of parecoxib: a novel, 
potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol 2004; 491:69-
76.
33.  Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61:1133-1141.
34.  Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, 
Yuan J, Zhang YY, Seibert K. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]pr
opanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 
for parenteral administration. J Med Chem 2000; 43:1661-1663.
35.  O’Donghue GT, Roche-Nagel G, Harmey JH, Bouchier-Hayes DJ. Cyclooxygenase-2 
inhibition attenuates surgically induced residual tumour growth and metastases fol-
lowing cytoreductive surgery in a murine model of breast cancer. Journal of Surgical 
Research 2003; 114:227.
36.  Smakman N, Kranenburg O, Vogten JM, Bloemendaal AL, van Diest P, Borel R, I. Cy-
clooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 
colorectal liver metastases. Clin Cancer Res 2005; 11:41-48.
37.  Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization 
of second-generation monoclonal antibodies against carcinoembryonic antigen. Can-
cer 1993; 71:3478-3485.
38.  Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobu-
lins from mouse serum using protein A-sepharose. Immunochemistry 1978; 15:429-436.
39.  Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immu-
noreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to 
binding at infinite antigen excess. J Immunol Methods 1984; 72:77-89.
40.  Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tu-
mor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-ac-
tivated killer cells. Surgery 1987; 102:71-78.
41.  Alsalameh S, Burian M, Mahr G, Woodcock BG, Geisslinger G. Review article: The 
pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-
selective inhibitor. Aliment Pharmacol Ther 2003; 17:489-501.
42.  Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muham-
mad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K. Valdecoxib: Assessment of 
COX-2 potency and selectivity. J Pharmacol Exp Ther 2004.
43.  Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB. 
Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharma-
col 2003; 63:870-877.
44.  Zhang JY, Yuan JJ, Wang YF, Bible RH, Jr., Breau AP. Pharmacokinetics and metabo-
lism of a COX-2 inhibitor, valdecoxib, in mice. Drug Metab Dispos 2003; 31:491-501.
45.  Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates 
angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
46.  Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary 
tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. 
Int J Cancer 2001; 93:497-506.
Combination therapy with parecoxib
149
47.  Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygen-
ase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 
79:1469-1477.
48.  Buchsbaum DJ, Roberson PL. Experimental radioimmunotherapy: biological effective-
ness and comparison with external beam radiation. Recent Results Cancer Res 1996; 
141:9-18.

Manuel J. Koppe1
Wim J.G. Oyen2
Robert P. Bleichrodt1
Albert A. Verhofstad3
David M. Goldenberg4
Otto C. Boerman2
6
Combination therapy using gemcitabine and 
radioimmunotherapy in nude mice with small 
peritoneal metastases of colonic origin
From the Departments of Surgery1, Nuclear Medicine2 and Pathology3,
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
The Garden State Cancer Center4, Center for Molecular Medicine 
and Immunology, Belleville, New Jersey, USA
Cancer Biotherapy & Radiopharmaceuticals 2006; in press

153
Despite the promising results of radioimmunotherapy (RIT) using radiola-beled monoclonal antibodies (MAbs) for the treatment of non-Hodgkin lymphoma (NHL), the therapeutic efficacy of RIT in solid tumors has been 
modest at best. Solid cancers are targeted less efficiently with radiolabeled antibod-
ies than hematological malignancies, which has been attributed to the presence of 
various physiological barriers between the circulation and the tumor cell surface. It 
has been pointed out that the vascular endothelium, the relatively large transport 
distances in the tissue and the enhanced interstitial pressure in the tumor tissue, 
hamper the penetration of antibodies into the tumor tissue to bind to their target 
antigen.1 As a result, tumor uptake of radiolabeled MAbs and, consequently, the ra-
diation doses delivered to solid lesions are in most cases too low to induce objective 
tumor responses. Several innovative approaches have been pursued with the aim to 
improve the efficacy of RIT. These include strategies to improve the localization and 
retention of radiolabeled MAbs in the tumor (e.g. using high-affinity MAbs2), strate-
gies to accelerate the blood clearance of the radiolabel (e.g. using antibody fragments3 
or the pretargeting method4), and strategies to increase the sensitivity of the tumor 
cells to radiation (e.g. using radiosensitizers5-7).
Gemcitabine (2’-deoxy-2’2’-difluorocytidinemonohydrochloride) is a pyrimidine ana-
logue and has been shown to exert antitumor effects in a wide range of solid tumors, 
as well as some hematological malignancies.8 Gemcitabine acts by depleting the de-
oxynucleoside triphosphate pool and is incorporated in the DNA, in the same way as 
5-fluorouracil (5-FU), thereby inhibiting DNA synthesis and, probably, DNA repair.9 
Gemcitabine has been shown to sensitize a wide range of mainly epithelial cancers 
to radiation, including adenocarcinoma of the pancreas and colon, and squamous 
cell carcinoma.10 Although in most chemoradiotherapy studies gemcitabine was com-
bined with external beam radiation, in recent years a few studies have been published 
reporting radiosensitizing effects of gemcitabine when combined with RIT in animal 
models of pancreatic cancer and colon cancer.5-7,11
We have previously characterized a nude mouse model for RIT of small volume peri-
toneal carcinomatosis of colorectal origin using the human colon carcinoma cell line 
LS174T.12 RIT using the radiolabeled anti-CEA MAb MN-14 proved very effective in 
inhibiting the growth of intraperitoneally growing tumor nodules, even at relatively 
low activity doses. 131I and 177Lu proved to be the most effective radionuclides in this 
model.13 Since gemcitabine has previously been shown to exert some antitumor activ-
ity against LS174T14 and improve the efficacy of RIT in a subcutaneous tumor model 
using LS174T,11 we hypothesized that gemcitabine co-administration might sensitize 
the intraperitoneally growing LS174T xenografts to radiation and improve the ther-
apeutic efficacy of RIT in our model of small volume peritoneal carcinomatosis of 
colorectal origin. To test this hypothesis, first the maximum tolerated dose (MTD) of 
gemcitabine was determined in two different administration regimens. Subsequent-
ly, the effect of both administration regimens of gemcitabine on the efficacy of RIT 
using 131I-labeled MN-14 was assessed. 
Chapter 6
154
Materials and methods
Animal model of small peritoneal metastases
Male nude BALB/c mice (Charles River Laboratories, Germany), 8-10 weeks old, 
weighing 20-25 grams were used in the experiments. Mice were accustomed to labo-
ratory conditions for at least one week before experimental use and were housed un-
der nonsterile standard conditions (temperature 20–24°C; relative humidity 50–60%; 
12 h light/12 h dark) in filter-topped cages (up to five mice per cage), on sawdust with 
free access to animal chow (Snif Voer, Soest, The Netherlands) and water. At the start 
of therapy, all mice were housed on iron grate floors. Peritoneal metastases were in-
duced as described previously.12 In brief, mice were inoculated intraperitoneally with 
1.0 x 106 LS174T cells (CCL 188, American Type Culture Collection, Rockville, MD), 
suspended in 500 µl of RPMI-1640 medium in a 2.5 mL syringe using a 23-gauge nee-
dle. In this model, the first macroscopic tumor nodules are seen seven to ten days lat-
er, whereas bulky peritoneal carcinomatosis develops three to five weeks after tumor 
cell inoculation. All experiments were conducted in accordance with the principles 
laid out by the revised Dutch Act on Animal Experimentation (1997) and approved by 
the institutional Animal Welfare Committee of the Radboud University Nijmegen.
Monoclonal antibody
The murine MN-14 MAb is a high-affinity (Ka = 10
9 M-1) class-III anti-CEA IgG1 an-
tibody, produced by a hybridoma cell line culture, kindly provided by Immunomed-
ics, Inc. (Morris Plains, New Jersey, USA). The antibodies were purified by protein-A 
chromatography, as described previously.15 Purity was checked by fast protein liquid 
chromatography (FPLC) on a Phenomenex Biosep 3000 column (size 300x7.8mm), 
eluted with phosphate buffered saline (PBS, pH 7.2, 1 mL/min).
Radioiodination
Antibodies were radioiodinated with 131I (MDS Nordion, Fleurus, Belgium, respec-
tively) using the iodogen-method (1,3,4,6-tetrachloro-3α,6α-diphenyl-glycoluril; 
Pierce, Rockford, IL). Briefly, antibodies and 131I were incubated at room temperature 
in 85 µl of phosphate buffered saline (PBS 0.10 M, pH 7.4) in a glass vial, coated with 
100 µg iodogen. The reaction mixture was subsequently separated on a PD-10 column 
(Amersham Biosciences, Uppsala, Sweden), eluted with PBS, 0.5% bovine serum al-
bumin (BSA). Labeling efficiency of the radioiodination reactions was approximately 
70%. Specific activities of the 131I-MN-14 preparations were 1.6 MBq/µg (43 µCi/µg) 
and 0.64 MBq/µg (17 µCi/µg), respectively. In a previous study we demonstrated that 
the uptake of the radiolabeled MN-14 antibody in tumor was optimal at MN-14 pro-
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tein doses up to 25 µg.12 Therefore, in the present study unlabeled MN-14 was added 
to the radiolabeled antibody preparations to adjust the total antibody protein dose to 
20 µg per mouse.
Quality control of the radiolabeled antibody preparations 
The amount of free 131I was determined by instant thin layer chromatography (ITLC) 
using ITLC silica gel strips (Gelman Sciences, Inc., Ann Arbor, MI, USA) using 0.1 
M citrate buffer, pH 6.0, as the mobile phase. Radiochemical purity of all radiola-
beled antibody preparations used in the studies exceeded 97%. The immunoreactive 
fraction (IRF) of the radiolabeled MN-14 preparations was determined on freshly 
trypsinized LS174T cells essentially as described by Lindmo et al.16 with minor mod-
ifications. Briefly, a fixed amount of labeled antibody (10,000 cpm) was incubated 
with increasing concentrations of LS174T tumor cells (1.2 x 106 – 20 x 106 cells/mL) 
in 0.5 mL binding buffer (RPMI medium containing 0.5% BSA and 0.05% NaN3). A 
duplicate of the lowest cell concentration was incubated in the presence of an excess 
unlabeled antibody to correct for non-specific binding. After six hours of incubation 
at 37 °C, the cells were washed and activity in the pellet was determined in a well-type 
gamma-counter. The inverse of the tumor cell bound fraction was plotted against the 
inverse of the cell concentration and the immunoreactive fraction (IRF) was calcu-
lated from the Y-axis intercept. The IRF of the 131I-MN-14 preparations was 82% and 
77%, respectively. The radiolabeled antibody preparations were administered within 
two hours after radiolabeling.
Gemcitabine
Gemcitabine (Gemzar®) was purchased from Ely Lilly Company (Houten, The Neth-
erlands) as a powder in a glass vial (200 mg/vial). Immediately before administra-
tion, gemcitabine was dissolved in 0.9% sodium chloride (saline) to the appropriate 
concentrations. 
Studies to determine the maximum tolerated gemcitabine dose
To determine the MTD of gemcitabine, groups of 6-8 mice were injected intraperito-
neally with escalating doses of gemcitabine. Two dosing regimens were investigated 
in two separate experiments. In the first regimen, mice were treated on day 0, 3, 6, 
and 9 with gemcitabine at 0.11 mg, 0.33 mg, 1.0 mg, or 3.0 mg/mouse/administra-
tion. The second dosing regimen consisted of daily intraperitoneal administrations of 
0.022, 0.066, 0.20, or 0.60 mg/mouse/administration, which was given daily on five 
consecutive days. Control mice received saline only. Mice were monitored daily, and 
body weight was measured daily to ensure that body weight loss did not exceed 20%. 
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Combination therapy with radioimmunotherapy and gemcitabine
To assess the radiosensitizing effect of gemcitabine, two separate therapy experi-
ments were carried out in which each of the two gemcitabine dosing regimens de-
scribed above was combined with RIT. In both experiments, RIT consisted of 125 
µCi 131I-MN-14/mouse, which was given intraperitoneally ten days after tumor cell 
inoculation (20 µg/mouse). This activity dose represents approximately 25% of the 
maximum tolerated activity dose of 131I-labeled IgG antibodies, which has previously 
been shown to significantly delay the growth of intraperitoneally growing LS174T 
xenografts in the present model.13 The majority of mice still develop peritoneal carci-
nomatosis only after 9-10 weeks. Thus, we assumed that a relevant radiosensitizing 
effect of gemcitabine could be demonstrated at this dose level.
In the first therapy study, mice were treated with either RIT alone (125 µCi 131I-MN-
14/mouse, 10 days after tumor cell inoculation), gemcitabine alone (either 0.11 mg or 
0.33 mg/mouse/administration on day 10, 13, 16, and 19 after tumor cell inoculation) 
or 131I-MN-14 combined with gemcitabine. In the second therapy study, mice were 
treated with either RIT alone (125 µCi 131I-MN-14/mouse, 10 days after tumor cell in-
oculation), gemcitabine alone (0.022 mg/per/mouse on day 10, 11, 12, 13, and 14 after 
tumor cell inoculation), or RIT combined with gemcitabine. In both studies, control 
mice received unlabeled MN-14 in PBS, 0.5% BSA. Furthermore, control mice and the 
mice that were treated with RIT alone received intraperitoneal injections of saline 
instead of gemcitabine (ten to twelve mice per group). 
Mice were monitored until the humane endpoint had been reached, as determined 
by an experienced and independent animal technician, who was blinded to which 
treatment mice had received.17 At the time of the humane endpoint, mice were usu-
ally cachectic and lethargic, showing signs of advanced peritoneal carcinomatosis, 
such as the presence of bloody ascites or bulky intraperitoneal tumor growth, and 
were expected to die within one or two days. When the humane endpoint had been 
reached, mice were euthanized by O2/CO2-asphyxiation and immediately dissected. 
At dissection, all macroscopic tumor deposits were meticulously excised and weighed. 
The experiments were terminated at 134 and 96 days after tumor cell inoculation 
when the remaining mice were euthanized and dissected. The abdominal cavity was 
conscientiously inspected. Liver, spleen, lungs, pancreas, greater omentum and the 
diaphragm were removed for routine histopathological H&E-staining and immuno-
histochemical staining using a rabbit-anti-human anti-CEA polyclonal antibody (A 
0115, DakoCytomation, Glostrup, Denmark).13
Statistical analysis
Data are expressed as means ± standard deviation (SD) unless stated otherwise. 
Statistical analysis was performed by means of the GraphPad Prism 4.00 software 
(GraphPad Software, San Diego, CA). Single comparisons were analyzed the non-
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parametric Mann Whitney U test. Multiple comparisons were analyzed using the 
one-way ANOVA test. Bonferroni correction for multiple testing was applied. In the 
therapy studies, comparisons between the groups for differences in survival were 
analyzed using the Log-rank test. All tests were two-sided; the level of statistical 
significance was set at a P value of <0.05.
Results
Toxicity of gemcitabine
To determine the dose of gemcitabine that could be administered safely, mice re-
ceived intraperitoneal injections of gemcitabine in two dosing regimens. In the first 
experiment, in which four injections of gemcitabine were given every third day, four 
out of six and one out of six mice that were treated at 3.0 and 1.0 mg/mouse/ad-
ministration, respectively, died due to severe gemcitabine-related toxicity during the 
treatment period. Body weight loss exceeded 20% and mice suffered from gastroin-
testinal toxicity, which consisted of diarrhea, and, in some mice, hematologic toxic-
ity, manifesting by the presence of skin petechiae. When administered at 0.33 or 0.11 
mg/administration, none of the mice developed diarrhea or skin petechiae. Figure 
1a depicts the relative body weight during the study. Whereas control mice showed a 
gradual increase in body weight, maximum average body weight loss was 2.4 ± 1.4% in 
the mice treated at 0.33 mg/administration (two days after the first administration) 
and 1.7 ± 2.2% in the mice treated at 0.11 mg/administration (one day after second 
administration; P=0.24).
In the second experiment, in which five daily injections of gemcitabine were given, 
all mice treated at 0.60 mg/administration or 0.20 mg/administration and six out of 
eight mice treated at 0.066 mg/administration died due to severe gemcitabine-related 
toxicity either during or shortly after the treatment period. Daily administration at 
0.022 mg/administration did not result in clinically evident toxicity. As shown in Fig-
ure 1b, the maximum average body weight loss amounted 6.4 ± 3.6% seven days after 
the first administration, which did not differ significantly from the maximum weight 
loss of 4.8% ± 3.6% in the control mice given daily injections of saline (P=0.19). 
Based on these observations, gemcitabine was considered safe when administered at 
0.33 mg/mouse/administration every third day for a total of four administrations, 
or at 0.022 mg/mouse/administration, when administered daily for five consecutive 
days.
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Figure 1a
Relative body weight of nude mice after once-daily intraperitoneal administration 
of gemcitabine at 0, 0.11, 0.33, 1.0 or 3.0 mg/administration every third day for a 
total of four administrations. Data respresent means ± standard error of the mean 
(SEM).
Figure 1b
Relative body weight of nude mice after once-daily intraperitoneal administra-
tion of gemcitabine at 0, 0.022, 0.066, 0.20 or 0.60 mg/administration for a 
total of five administrations. Data represent means ± SEM.
Combination therapy with gemcitabine
159
RIT combined with gemcitabine administered every third day for four 
consecutive days
The survival curves for the various treatment groups are shown in Figure 2A. Median 
survival of the control mice was 39 days (range 34-52). Gemcitabine monotherapy at 
0.11 mg or 0.33 mg/mouse/administration every third day for a total of four adminis-
trations resulted in a median survival of 52 days (range 48-62) and 57 days (range 52-
69), respectively (P=0.0003 for trend when compared to controls). RIT alone resulted 
in a significantly improved median survival of 66 days (range 55-143, P<0.0001 com-
pared to controls). RIT combined with four administrations of gemcitabine at 0.11 
mg or 0.33 mg/mouse/administration every third day resulted in a median survival 
of 73 days (range 66-101) and 94 days (range 66-143), respectively (P=0.12 for trend 
compared to RIT alone). 
The tumor weight found at dissection at the time mice reached their humane end-
points varied between 4.0 ± 1.4 g for the mice treated with gemcitabine monotherapy 
0.11 mg/administration and 5.4 ± 1.1 g for the mice treated with RIT + gemcitab-
ine 0.33 mg/administration (P=0.24). The similar tumor mass found in the mice in 
the various treatment groups demonstrates that there was no bias in determining 
the humane endpoint. The method of determining and comparing the survival was 
therefore reliable. 
At the end of the experiment (143 days after tumor cell inoculation), there were 
four long-term survivors (two treated with RIT alone; and two treated with RIT + 
gemcitabine 0.33 mg/mouse/administration), without signs of intraperitoneal tu-
mor growth. At dissection, two mice (one from each group) had macroscopic tumor 
growth (0.13 g and 0.06 g, respectively), whereas in the remaining two mice there was 
no evidence of disease. Histopathological examination of relevant organs, including 
the greater omentum, mesentery, diaphragm and pancreas did not reveal residual 
disease in any of these mice.
RIT combined with gemcitabine administered daily for five consecutive days
The survival curves for the various treatment groups are shown in Figure 2B. Median 
survival of the control mice was 48 days (range 31-58). Daily gemcitabine monothera-
py at 0.022 mg/mouse/administration for five consecutive days resulted in a median 
survival of 49 days (range 34-73, P=0.17 compared with controls). RIT alone resulted 
in a significantly improved median survival of 66 days (range 45-96, P=0.0010 com-
pared with controls). Five daily gemcitabine administrations at 0.022 mg/mouse/ad-
ministration starting concurrently with RIT resulted in a median survival of 65 days 
(range 49-91), which did not differ significantly from the survival of the mice treated 
with RIT alone (P=0.43). 
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Figure 2a
Survival curves of mice with peri-
toneal LS174T tumor xenografts 
after intraperitoneal treatment 
with either gemcitabine alone (ei-
ther 0.11 mg or 0.33 mg/mouse/
administration on day 10, 13, 16, 
and 19 after tumor cell inocula-
tion), RIT alone, (131I-MN-14, 125 
µCi/mouse on day 10 after tumor 
cell inoculation), or RIT combined 
with gemcitabine. Control mice 
received unlabeled MN-14 (10-12 
mice per group).
Figure 2b
Survival curves of mice with peri-
toneal LS174T tumor xenografts 
after intraperitoneal treatment 
with either gemcitabine alone 
(0.022 mg/mouse/administra-
tion on day 10, 11, 12, 13, and 
14 after tumor cell inoculation), 
RIT alone, (131I-MN-14, 125 µCi/
mouse on day 10 after tumor cell 
inoculation), or RIT combined 
with gemcitabine. Control mice 
received unlabeled MN-14 (10-
12 mice per group).
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The tumor weight that was found at dissection at the time mice reached their hu-
mane endpoints varied from 4.4 ± 1.9 g for the mice treated with RIT + gemcitabine 
and 6.0 ± 2.0 g for the mice treated with gemcitabine monotherapy (P=0.15). 
At the end of the experiment (96 days after tumor cell inoculation), one mouse treat-
ed with RIT only was still alive, without signs of intraperitoneal tumor growth. At 
dissection, this mouse had no macroscopic tumor growth. Histopathological exami-
nation of relevant organs, including the greater omentum, mesentery, diaphragm 
and pancreas did not reveal residual disease.
Discussion
Radiosensitization can be defined as the use of agents with the aim to increase the 
sensitivity of tissue to radiation therapy. The primary aim of the present study was 
to investigate the radiosensitizing potential of two gemcitabine treatment schedules 
when combined with single-dose radioimmunotherapy in a well-characterized ani-
mal model of peritoneal carcinomatosis of colorectal origin. Gemcitabine, however, 
failed to significantly improve the efficacy of radioimmunotherapy in both adminis-
tration regimens tested.
Originally intended for development as an antiviral agent, gemcitabine was intro-
duced in the late nineteen eighties as a novel and very potent pyrimidine antime-
tabolite, with antitumor activity against a wide range of epithelial cancers, including 
non-small cell and small cell lung cancer, breast cancer, pancreatic cancer, head-and-
neck squamous cell cancer, and cervical cancer.18 Furthermore, probably because of 
its interference with DNA repair, gemcitabine has shown to be a potent radiosen-
sitizer. Although only marginally effective when administered as a single agent in 
patients with advanced colorectal carcinoma,19 gemcitabine has been demonstrated 
to sensitize colorectal carcinoma to radiation therapy in both preclinical and clinical 
studies.20,21 Interestingly, gemcitabine can induce radiosensitization at tissue concen-
trations 1,000 times lower than typical plasma levels obtained with the drug.21 Fur-
thermore, the radiosensitizing effects of gemcitabine have been shown to be dose-
dependent.18 This prompted us to conduct the experimental studies described in the 
present paper. 
To date, four reports have been published on the combination of experimental RIT 
and gemcitabine, three of which are in animal models of pancreatic cancer,5-7 and 
one in an animal model of colon cancer.11 The group of Goldenberg published three 
reports on the efficacy of combination therapy using 131I-labeled or 90Y-DOTA-labeled 
chimeric PAM4 MAb and gemcitabine in nude mice bearing subcutaneous CaPan1 
human pancreas carcinoma xenografts. In their first study, mice bearing subcutane-
ous tumors of about 1 cm3 were treated with 131I-cPAM4 (100 or 200 µCi) alone, gem-
citabine alone on day 0, 3, 6, 9, and 12 at 333 mg/m2 (2 mg/mouse), or the combination 
of both treatments.5 Whereas both monotherapies did not have antitumor effects, the 
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combination of both treatment modalities showed a statistically significant synergis-
tic effect, which led the authors to conclude that gemcitabine lowered the threshold 
for antitumor response sufficiently, so that the radiation dose provided by the low-
dose RIT could still carry antitumor activity. Furthermore, combination therapy was 
well tolerated, even at the higher RIT activity dose of 200 µCi. In their second study, 
mice with somewhat smaller subcutaneous tumors (0.5 cm3) were treated with either 
three cycles of 25 µCi 90Y-DOTA-labeled cPAM4 only at week 0, 4 and 7, or once weekly 
intraperitoneal injections of gemcitabine (6 mg/mouse, which equals 1000 mg/m2/
week), or combination therapy.7 Both RIT and gemcitabine monotherapy when given 
as monotherapy had some antitumor effects. When combined, however, there was a 
supra-additive antitumor effect, at the cost of only minimal toxicity to normal tis-
sues, as evidenced by an average loss in body weight of less than 2% for all treatment 
groups. In their last report, RIT using 90Y-DOTA-labeled cPAM4 was combined with 
gemcitabine according to the same dose regimen as utilized in their first study with 
131I-cPAM4 in mice bearing 1 cm3 tumors.6 Gemcitabine was not effective when given 
as single treatment, but still improved the efficacy of RIT when given in combination 
with 90Y-DOTA-cPAM4. Finally, Graves et al. reported on the radiosensitizing effect 
of gemcitabine when combined with pretargeted RIT in nude mice with human colon 
cancer xenografts.11 In that study, mice bearing 100-200 mm3 subcutaneous LS174T 
tumors were treated with either pretargeted RIT, two intraperitoneal injections of 
gemcitabine at 50-200 mg/kg one day before and one day after administration of 
131I-labeled peptide, or combined modality treatment. Whereas both pretargeted RIT 
and gemcitabine given as monotherapies did not result in significant growth delay 
of the subcutaneous tumors, the combination of both treatment modalities resulted 
in a highly significant delay of tumor growth, which was dependent on the dose of 
gemcitabine used. 
In the present study gemcitabine was very toxic in both dosing regimens tested. The 
dose levels chosen in both MTD studies were based on the doses utilized in the above-
mentioned studies in which gemcitabine was combined with RIT. Cardillo et al.5 and 
Gold et al.7 administered gemcitabine intraperitoneally every third day for a total of 
five administrations at 2 mg/mouse and reported a maximum mean weight loss of 
only 4.5 ± 5.5% on day 7. In the present study, however, one out of six mice treated at 
1 mg/mouse died of gemcitabine-related toxicity two days after the first administra-
tion, whereas of the six mice treated at 3 mg/mouse four died of acute treatment-re-
lated toxicity. Therefore, the MTD of gemcitabine administered every third day for a 
total of four administrations was set at <1.0 mg/mouse. Since once-weekly adminis-
trations of up to 6 mg/mouse have been reported feasible,6 the MTD of gemcitabine 
when administered daily for five consecutive days was sought between 0.022 mg and 
0.6 mg per mouse per administration. Gemcitabine, however, was lethal in the ma-
jority of mice treated at 0.066 mg/administration and in all mice treated at higher 
doses. Hence, the MTD of daily administrations of gemcitabine on five consecutive 
days was set at only 22 µg/mouse/administration. The differences between the MTDs 
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found in the present studies and those reported by other authors might be attributed 
to differences in mouse strains.
The most efficacious dosing regimen of gemcitabine to fully exploit its radiosensi-
tizing effect is still a matter of investigation in both preclinical and clinical stud-
ies. From preclinical studies on the combination of gemcitabine and external beam 
radiotherapy (RT), it became clear that the effects of combination therapy become 
synergistic when gemcitabine treatment precedes RT.21 In vitro studies indicated that 
a brief exposure (2 hours) of HT-29 colon cancer cells to gemcitabine resulted in ra-
diosensitization for up to 48 hours.22 In RIT the radiation energy is delivered to the 
tumors over a prolonged period of time. Furthermore, since in a previous study we 
showed that the uptake of radioiodinated MN-14 in the small intraperitoneal tumor 
deposits is more than 50% ID/g for up to 72 hours p.i.12, we assumed that, similar to 
the administration regimen reported by the group of Cardillo and Gold, repeated 
administrations of gemcitabine starting concurrently with RIT, might effectively 
sensitize the intraperitoneal tumors to RIT. In contrast to the synergistic effects of 
gemcitabine when combined with RIT as reported by other authors, gemcitabine did 
not enhance the efficacy of RIT in the present studies. When administered every 
third day for a total of four administrations, gemcitabine monotherapy still had a 
modest, albeit significant antitumor effect, which was dose-dependent. When com-
bined with RIT at this dosing schedule, median survival of the combination therapy 
groups improved relative to the RIT monotherapy group, although the differences did 
not reach statistical significance. In the second therapy study, daily administrations 
of gemcitabine at 0.022 mg/mouse/administration for five consecutive days, which 
was considered the MTD of this administration regimen, did not affect survival, nor 
did it enhance the efficacy of RIT. 
In conclusion, when given concurrently with RIT either every third day for a total of 
four administrations or daily for a total of five consecutive days, gemcitabine did not 
enhance the therapeutic efficacy of RIT at the dose regimens employed. 
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Next to the lymphatic and hematogenous routes of dissemination, colorectal cancer can give rise to peritoneal spread of cancer cells. This so-called seeding of cancer cells may lead to peritoneal carcinomatosis, a disease characterized 
by the presence of multiple tumorous implants on the peritoneum. Although hema-
togenous dissemination forms the greatest threat to patients with colorectal cancer, 
it has been estimated that peritoneal carcinomatosis dominates the clinical picture 
in one out of four patients with recurrent colorectal cancer.1-3 In the past two decades 
peritoneal carcinomatosis of colorectal origin is increasingly being recognized as a 
distinct clinical entity, which should not necessarily be regarded as generalized disease 
but, similar to liver metastases, may rather be one of the first steps of dissemination.4 
For this reason the efficacy of cytoreductive surgery and intraperitoneal chemothera-
py, aimed at locoregional, i.e. intraperitoneal control, has been subject of investigation 
in a dozen medical centers worldwide.5 The results published to date indicate that this 
aggressive approach is effective and may indeed result in improved survival compared 
to strictly palliative chemotherapy and surgery when needed in selected groups of 
patients.6,7 The completeness of resection as well as the tumor load were consistently 
shown to be the most important factors predictive of long-term survival. Still, after 
complete resection of all macrosopic disease and adjuvant intraperitoneal chemother-
apy the reported five-year survival rate varies from 20% till 54% with the majority of 
recurrences occurring intraperitoneally.6,8,9 More effective adjuvant treatment modali-
ties are therefore necessary to improve the results of cytoreductive surgery. 
Radioimmunotherapy using radiolabeled monoclonal antibodies directed against tu-
mor-associated antigens offers the opportunity to selectively irradiate tumor cells, 
while sparing normal tissues. Several preclinical studies, including animal models 
of liver metastases or peritoneal carcinomatosis of colorectal origin, have indicated 
that radioimmunotherapy can be very effective and possibly even superior to chemo-
therapy.10-12 Since tumor targeting with radiolabeled monoclonal antibodies is more 
efficient in small volume disease, radioimmunotherapy is considered most suitable 
for minimal or microscopic residual disease.13 In this regard, the results of a recently 
published phase II trial investigating the efficacy of adjuvant radioimmunotherapy 
using the 131I-labeled anti-CEA MAb hMN-14 after salvage resection of liver metas-
tases of colorectal origin, suggested that radioimmunotherapy may indeed improve 
both overall median survival and five-year survival rate, compared to historical and 
contemporaneous controls.14 
The MG1 MAb, raised against the syngeneic rat colon carcinoma cell line CC-531, has 
been shown to localize to in vivo growing CC-531 tumors in Wag/rij rats.15,16 We hy-
pothesized that radioimmunotherapy using radiolabeled MG1 might be an effective 
adjuvant treatment modality after cytoreductive surgery of peritoneal carcinomato-
sis. To test this hypothesis, first the biodistribution of MG1 labeled with 125I or 111In 
was determined in Wag/Rij rats with small volume peritoneal CC-531 carcinomatosis. 
Subsequently, the efficacy of radioimmunotherapy using 177Lu-labeled MG1 was as-
certained. Finally, the efficacy of cytoreductive surgery followed by adjuvant radioim-
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munotherapy using 177Lu-labeled MG1 was assessed and compared with that of ex-
ploratory laparotomy followed by radioimmunotherapy, cytoreductive surgery only, 
or exploratory laparotomy only. 
Materials and methods
Animals
Male Wag/Rij-rats, ten to twelve weeks old with a mean weight of 245 ± 8 g were ob-
tained from Charles River Laboratories (Sulzfeld, Germany). Rats were accustomed 
to laboratory conditions for one week prior to experimental use and housed under 
nonsterile, standard laboratory conditions (temperature, 20–24°C; relative humidity,    
50-60%; 12 h light/12 h dark) on sawdust in filter-topped cages (two rats per cage) with           
free access to animal chow (Snif Voer, Soest, The Netherlands) and water. All experi-
ments were conducted in accordance with the principles laid out by the revised Dutch 
Act on Animal Experimentation (1997) and approved by the institutional Animal Wel-
fare Committee of the Radboud University Nijmegen.
Cell line
The syngeneic rat colon carcinoma cell line CC-531, derived from colon tumors of Wag/
Rij rats exposed to 1,2-dimethyl-hydrazine, was used.17 CC-531 was cultured and main-
tained as monolayers on plastic in Dulbecco’s Modified Eagle Medium (DMEM, GIB-
CO, BRL Life Sciences Technologies, The Netherlands) supplemented with 10% fetal 
calf serum (GIBCO), 2 mM L-glutamine, penicillin (100 units/mL) and streptomycin 
(100 µg/mL) at 37°C in a humidified atmosphere with 5% CO2. Prior to inoculation, 
tumor cells were washed with phosphate-buffered saline (PBS), harvested with 0.25% 
trypsin (3 min at 37 °C), resuspended in PBS, spun down (5 min at 700 x g), counted 
and resuspended once again in PBS to the appropriate concentration.
Monoclonal antibody
The MG1 MAb was purchased from Antibodies for Research Applications BV (Gouda, 
The Netherlands, www.abforresearch.nl). The MG1 MAb is a murine IgG2a antibody, 
raised by immunization of mice with CC-531 colon carcinoma cells.15,16,18 It recognizes 
a cell surface structure of about 80 kDa and localizes to tumor cells when injected in 
rats bearing CC-531 tumors with minimal cross reactivity to other cell types. Purity 
was checked by SDS-PAGE under nonreduced conditions and by means of fast protein 
liquid chromatography (FPLC) on a Phenomenex Biosep 3000 column, eluted with 
phosphate buffered saline (PBS, pH 7.2, 1 mL/min).
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Radioiodination
Antibodies were radioiodinated with 125I (Amersham, Den Bosch, The Netherlands) us-
ing the iodogen-method, as described previously.19 Briefly, antibodies (20 µg) and 125I 
(4.07 MBq) were incubated at room temperature in 80 µl of PBS (0.10 M, pH 7.4) in a 
glass vial, coated with 50 µg iodogen. After twelve minutes, the reaction mixture was 
separated on a PD-10 column (Amersham Biosciences, Uppsala, Sweden), eluted with 
PBS, 0.5% bovine serum albumin (BSA). Labeling efficiency of the radioiodination 
reaction was 42%. The specific activity of 125I-MG1 was 85 kBq/µg. 
111In- and 177Lu-labeling
111In and 177Lu (specific activity 862 GBq/mg in the radioimmunotherapy monotherapy 
study, and 982 GBq/mg in the cytoreductive surgery + radioimmunotherapy study, 
respectively) was purchased from Tyco Mallinckrodt Medical BV (Petten, The Nether-
lands) and IDB Holland BV (Baarle Nassau, The Netherlands), respectively. 111In- and 
177Lu-labeling was performed under strict metal-free conditions. To allow labeling of 
the antibodies with 111In or 177Lu, the MG1 MAb was conjugated with isothiocyana-
tobenzyl-diethylenetriaminepentaacetic acid (ITC-DTPA, Macrocyclics, Dallas, TX). 
Briefly, ITC-DTPA was conjugated to MG1 in a 0.1 M carbonate buffer, pH 9.0 using a 
100-fold molar excess of ITC-DTPA as described by Ruegg et al.20 with minor modifica-
tions (conjugation period of one hour at room temperature). The DTPA-MG1 immu-
noconjugate was then purified by extensive dialysis against 0.1 M ammonium acetate 
buffer, pH 5.4. The number of DTPA ligands per antibody molecule was determined 
according to the method described by Hnatowich et al.21 The purified DTPA-MG1 con-
jugate (DTPA/MG1 ratio 1.6 : 1, 1.0 mg/mL) was incubated with 111In or 177Lu in 0.1 M 
ammonium acetate buffer, pH 5.4 at room temperature (60 minutes). Labeling effi-
ciency of both labeling procedures exceeded 98%. Specific activity of the 111In-DTPA-MG1 
preparation (hereafter referrend to as 111In-MG1) used in the biodistribution study was 
1.1 MBq/µg. Specific activities of the 177Lu-DTPA-MG1 preparations (hereafter refer-
rend to as 177Lu-MG1) used in the radioimmunotherapy monotherapy study and the 
cytoreductive surgery + radioimmunotherapy study was 0.81 MBq/µg and 0.89 MBq/
µg, respectively. Since 177Lu is a bone-seeking radionuclide, after completion of the 
labeling procedure 1 mM EDTA was added to the solutions to scavenge the remaining 
free 177Lu ions.22 
Quality control of the radiolabeled preparations
All reaction mixtures were purified on a PD-10 column, eluted with PBS, 0.5% BSA. 
Radiochemical purity (RCP) was determined using instant thin-layer chromatography 
(ITLC) on silicagel strips (Gelman Sciences, Ann Arbor, MI) using 0.10 M citrate buffer 
Chapter 7
172
(pH 6.0) as the mobile phase. The RCP of the 125I-, 111In- and 177Lu-MG1 preparation was 
98%, 99% and 99%, respectively. 
The immunoreactivity of the radiolabeled MG1 preparations was essentially deter-
mined as described by Lindmo et al.23 Briefly, a fixed amount of labeled antibody 
(10,000 cpm) was incubated (6 hours, 37 °C) with increasing concentrations of CC-531 
tumor cells (1.2 x 106 – 20 x 106 cells/mL) in 0.5 mL binding buffer (RPMI medium 
containing 0.5% BSA and 0.05% NaN3). A duplicate of the lowest cell concentration 
was incubated in the presence of an excess unlabeled antibody to correct for non-spe-
cific binding. After six hours of incubation at 37°C, the cells were spun down (500 g, 
5 min) and activity in the pellet was determined in a well-type gamma-counter. The 
inverse of the tumor cell bound fraction was plotted against the inverse of the cell 
concentration and the immunoreactive fraction (IRF) was calculated from the y-axis 
intercept. Immunoreactivity of each of the radiolabeled MG1 preparations exceeded 
65%. Radiolabeled antibody preparations were administered within two hours after 
the labeling procedures.
Animal model of peritoneal carcinomatosis
The animal model of peritoneal carcinomatosis using CC-531 has been described previ-
ously.16 Briefly, peritoneal carcinomatosis was induced by intraperitoneal inoculation 
of 2.0 – 5.0 x 106 CC-531 tumor cells, suspended in 2.5 mL PBS in a 5.0 mL syringe using 
a 18 gauge needle. In this model, the first macroscopic tumor deposits are seen 4 to 
7 days after tumor cell inoculation. Three to five weeks after tumor induction, bulky 
peritoneal carcinomatosis with hemorrhagic ascites is present.
Biodistribution of 125I-/111In-labeled MG1
We previously demonstrated in a nude mouse model of peritoneal carcinomatosis of 
colonic origin that 131I and 177Lu are the most suitable radionuclides for radioimmuno-
therapy of small peritoneal metastases.24 To determine the most suitable radionuclide 
for radioimmunotherapy in the current model, the biodistribution of MG1 labeled 
with either 125I or 111In, as surrogate radionuclides for 131I and 177Lu, respectively, was 
determined. Eight days after intraperitoneal inoculation of 5.0 x 106 CC-531 tumor 
cells, five rats received an intraperitoneal injection of 370 kBq 125I-MG1 and 370 kBq  
111In-MG1 (total MG1 protein dose 5 µg per rat), solubilized in 1 mL PBS, BSA 0.5%. 
Three days after injection of the radiolabeled antibodies, the rats were euthanized 
using O2/CO2-asphyxiation and dissected. At dissection tumor, blood, bone marrow, 
liver, spleen, kidney, intestine, lung, muscle, skin and thymus were sampled, blotted 
dry, and immediately weighed. Activity was measured in a shielded well-type gamma-
counter (Wizard, Pharmacia-LKB, Sweden). To correct for physical decay and to cal-
culate uptake of the radiolabeled antibody in each sample as a fraction of the injected 
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dose, aliquots of the injected dose were counted simultaneously. The results were ex-
pressed as percentage of the injected dose per gram tissue (% ID/g).
The efficacy of radioimmunotherapy using 177Lu-MG1
Before investigating the efficacy of adjuvant radioimmunotherapy after cytoreductive 
surgery, first the efficacy of radioimmunotherapy given as monotherapy was assessed. 
Four days after intraperitoneal inoculation of 2.0 x 106 CC-531 tumor cells, rats were 
randomly assigned to be treated with radioimmunotherapy (74 MBq 177Lu-MG1, 91 µg 
per rat, solubilized in PBS, 0.5% BSA, 1 mM EDTA), unlabeled MG1 (91 µg, solubilized             
in PBS, 0.5% BSA, 1 mM EDTA) or the carrier (PBS, 0.5% BSA, 1 mM EDTA) (8-10 rats 
per group). In addition, an extra group of five rats received tracer doses of 177Lu-MG1 
(3.7 MBq per rat) to determine the biodistribution at 72 hours post-injection (p.i.). 
Since 177Lu is a bone-seeking radionuclide, uptake in femur was determined as well. 
The radiolabeled preparation used to determine the biodistribution was augmented 
with unlabeled DTPA-MG1 to the same total protein dose of 91 µg per rat, as used in 
the rats that were given radioimmunotherapy. Thirty days after tumor cell inocula-
tion, rats were euthanized and dissected. At dissection, all tumor nodules were ex-
cised and weighed. 
The effect of cytoreductive surgery with or without adjuvant radioimmuno-
therapy
Fourteen days after intraperitoneal inoculation of 2.0 x 106 CC-531 tumor cells, 35 
rats were randomly assigned to undergo cytoreductive surgery (n=18) or exploratory 
laparotomy (n=17). Subsequently, all rats underwent a midline laparotomy during 
which the intraperitoneal tumor load was semiquantitatively scored (see below). Af-
ter completion of the surgical procedures, those rats that had undergone cytoreduc-
tive surgery were distributed into two groups by an independent nuclear medicine 
physician (WJGO), after stratification for tumor load, completeness of resection and 
whether or not a splenectomy had been performed. Similarly, those rats that had un-
dergone exploratory laparotomy only were divided into two groups after stratification 
for tumor load. Three days after surgery, one group of rats that had been treated with 
cytoreductive surgery and one group of rats that undergone exploratory laparotomy 
only received an intraperitoneal injection of 56 MBq 177Lu-MG1 (total MG1 protein 
dose 63 µg). The remaining rats received intraperitoneal injections of the carrier (PBS, 
0.5% BSA, 1 mM EDTA). Thus, four treatment groups were created: 1. exploratory 
laparotomy only (n=9); 2. exploratory laparotomy + radioimmunotherapy (n=8); 3. 
cytoreductive surgery only (n=9); 4. cytoreductive surgery + radioimmunotherapy 
(n=9). 
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Operative procedures
The surgical procedures were carried out under clean conditions. One hour prior to 
operation, rats received buprenorphine subcutaneously (5 µg, 0.1 mL) for analgesia. 
Immediately after the onset of general anesthesia (isoflurane/O2/N2O), the abdomen 
was shaved and disinfected with chlorohexidine/ethanol. During the operation, rats 
were placed on a warmed mattress to limit heat loss. Rats subsequently underwent a 
7.5 cm midline laparotomy from the xyphoidal process till just above the penis. After 
opening the abdomen, the abdominal cavity was carefully inspected, starting with 
the upper abdomen, including the greater omentum, the liver hylum, the perisplenic 
region and the diaphragm. Subsequently, the gonadal fat pads and the kidneys were 
inspected. Finally, the intestines were gently lifted out of the abdomen, enabling in-
spection of the complete mesentery and Douglas’ pouch. Tumor growth at each of 
these sites was scored 0, 1, 2, or 3, where 0 indicated no macroscopic tumor growth, 
1 meant little tumor growth, 2 indicated moderate tumor growth, and 3 indicating 
abundant tumor growth. The sum of the tumor scores of all sites represented the 
peritoneal cancer index (PCI). 
In those rats assigned to undergo cytoreductive surgery, it was then attempted to re-
sect all macroscopic tumor deposits (MJK). In case of irresectable disease, tumor nod-
ules were fulgurated using an electrocoagulation device. The resected tumor nodules, 
including the omentectomy specimens, were collected and weighed. When the surgi-
cal cytoreduction was considered maximal, the muscular layer of the abdomen was 
closed by continuous Vicryl 3/0 sutures. The skin was closed by iron wound autoclips. 
10 mL of warmed saline was injected subcutaneously for rehydration. Twelve hours 
postoperatively, and once-daily on the second and third day postoperatively, rats once 
again received subcutaneous injections of buprenorphine (5 µg, 0.1 mL). 
Follow-up
The primary endpoint was survival. Body weight was measured daily in the first 14 
days after treatment and three times weekly thereafter as measure of toxicity. Rats 
were monitored daily until the humane endpoint had been reached, as determined by 
one single experienced and independent animal technician, who was blinded to the 
therapeutic regimen. At the time of the humane endpoint, rats were usually lethargic, 
showing signs of advanced peritoneal carcinomatosis, such as the presence of ascites 
or bulky intraperitoneal tumor growth, and were expected to die within one or two 
days. When the humane endpoint had been reached, rats were euthanized by O2/CO2-
asphyxiation and immediately dissected. At dissection, intraperitoneal tumor growth 
was semi-quantitatively scored as described above. After calculating a PCI, all macro-
scopic tumor deposits were excised and weighed. The experiment was terminated at 
118 days after tumor cell inoculation when the remaining rats were euthanized and 
dissected. In case of absence of macroscopic tumor growth, relevant organs, including 
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the greater omentum, the mesentery and the diaphragm were removed for routine 
histopathological hemotoxilin & eosin (H&E) and/or immunohistochemical staining 
using the murine MG1 antibody and a horse-anti-mouse IgG antibody (Vector Labo-
ratories Inc., Burlingame, CA, USA).
Statistical analysis
Data are expressed as means ± standard deviation (SD) unless stated otherwise. 
Statistical analysis was performed by means of the GraphPad Prism 4.00 software 
(GraphPad Software, San Diego, CA, USA). Single comparisons were analyzed using 
the paired t-test or the non-parametric Mann Whitney U test. Multiple comparisons 
were analyzed using the one-way ANOVA test. Bonferroni correction for multiple 
testing was applied. Survival curves were compared using the Log-rank test. All tests 
were two-sided; the level of statistical significance was set at a P value of <0.05.
Results
Biodistribution of 125I-/111In-labeled MG1
To assess the most suitable radionuclide for radioimmunotherapy, the biodistribution 
of 125I-MG1 and 111In- MG1 was determined 72 hours post-injection. The results are 
summarized in Figure 1. There was a preferential uptake of both radiolabeled antibody 
preparations in the tumor, although uptake of 125I-MG1 in tumor tissue was not sig-
nificantly higher than the corresponding blood levels (P=0.093). Uptake of 111In-MG1 
in tumor tissue was higher than that of 125I-MG1, although the difference was not 
statistically significant (4.1 ± 2.3% ID/g vs 1.1 ± 0.5% ID/g, P=0.053). Tumor-to-blood 
and tumor-to-bone marrow ratios were significantly higher than those obtained for 
125I-MG1 (9.2 ± 5.3 vs. 2.4 ± 1.4 (P=0.040) and 19.5 ± 8.4 vs. 7.6 ± 4.1 (P=0.036), respec-
tively. Likewise, uptake of 111In-MG1 in spleen and liver was higher than that of 125I-
MG1, although the difference for the latter organ did not reach statistical significance. 
Based on the favorable biodistribution of 111In-MG1, it was decided to use 177Lu in the 
radioimmunotherapy studies.
Efficacy of radioimmunotherapy using 177Lu-MG1
To investigate the therapeutic potential of radioimmunotherapy using 177Lu-labeled 
MG1, rats with small peritoneal metastases were treated with either 177Lu-MG1 (74 
MBq/rat), unlabeled DTPA-MG1, or the carrier. In addition, the biodistribution of 
177Lu-MG1 was determined. Mean body weight of the control rats as well as that of 
the rats treated with DTPA-MG1 gradually increased during the course of the study. 
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Tumor weight at dissec-
tion of Wag/Rij rats with 
small peritoneal CC-531 
metastases 26 days after 
treatment with either 
PBS, 0.5% BSA (controls), 
unlabeled MG1 or 177Lu-
MG1. 
Figure 1
Biodistribution of 
125I-, 111In, or 177Lu-
labeled MG1 in 
Wag/Rij rats with 
small peritoneal 
CC-531 metastases.
Note that the 
biodistribution of 
177Lu-MG1 was de-
termined in a sepa-
rate experiment.
Mean body weight of the rats treated with 74 MBq 177Lu-MG1, however, decreased to 
a maximum mean body weight loss of 2.6 ± 3.2% on day 5 and 6 after intraperitoneal 
administration, after which all rats regained body weight again (data not shown). 
The biodistribution of 177Lu-MG1 at 72 hours p.i. was similar to that of 111In-MG1 (Fig-
ure 1). Mean uptake in tumor tissue was 3.9 ± 1.0% ID/g, whereas the tumor-to-blood 
and tumor-to-bone marrow ratios were 3.5 ± 0.2 and 7.0 ± 1.2, respectively. Uptake in 
femur was only 0.25 ± 0.02% ID/g.
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Thirty days after intraperitoneal tumor cell inoculation the rats were euthanized. At 
dissection the majority of the rats that had received PBS, 0.5% BSA, 1mM EDTA (con-
trols) or unlabeled DTPA-MG1 had abundant intraperitoneal tumor growth with he-
morrhagic ascites. In contrast, the rats that had been treated with 74 MBq 177Lu-MG1 
had very little tumor growth. Mean tumor weight of the control rats and the rats 
treated with unlabeled ITC-DTPA-MG1 was practically identical, 5.8 ± 3.0 g and 5.9 ± 
4.3 g, respectively. In contrast, mean tumor weight of the rats that had been treated 
with radioimmunotherapy was 0.00 ± 0.00 g (P<0.01 comparing radioimmunothera-
py with either PBS, 0.5% BSA or unlabeled MG1; Figure 2). 
The effect of cytoreductive surgery with or without adjuvant radioimmuno-
therapy
To assess the efficacy of radioimmunotherapy when given as adjuvant treatment after 
cytoreductive surgery, rats with small peritoneal metastases were treated with cytore-
ductive surgery only, exploratory laparotomy + radioimmunotherapy, or cytoreduc-
tive surgery + radioimmunotherapy. Control rats underwent exploratory laparotomy 
only. 
Tumor load at laparotomy
The greater omentum was the most common site of tumor growth (all rats), followed 
by the liver hylum (34 out of 35 rats), the mesentery (30 out of 35 rats) and the peris-
plenic region (25 out of 35 rats). Fifteen rats had tumor growth on the parietal perito-
neum at the site of tumor cell inoculation. Macroscopic tumor growth in the gonadal 
fatpads was observed in eight rats, at the diaphragm in one rat, near the kidneys in 
one rat, whereas none of the rats had developed macroscopic tumor growth in Doug-
las’ pouch. The diameter of the tumor nodules was always lower than 5 mm and ranged 
from 1 to 4 mm. None of the rats had malignant ascites. Median PCI of all the rats was 
7 (range 3-10). In Figure 3 three representative examples of macroscopic tumor growth 
at the greater omentum, the liver hylum and the mesentery are depicted.
Resections
In the eighteen rats assigned to undergo cytoreductive surgery an omentectomy was 
routinely carried out. Omentectomy involved removing as much of the omental tis-
sue as posssible, from the hilum of the spleen (conserving the splenic artery arcade), 
from the greater curvature of the stomach (removing the epiploic arcade) and from 
the retrogastric extension of the omental leaf. Perisplenic tumor growth necessitated 
splenectomy in nine out of eighteen rats that underwent cytoreductive surgery. In fif-
teen out of eighteen rats undergoing cytoreductive surgery, the resection of all tumor 
nodules seemed macroscopically complete, whereas in three rats macroscopic disease 
was left behind. In those three rats that had undergone an incomplete cytoreduction, 
•
•
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Figure 3
Macroscopic appearance of intraperitoneally 
growing CC-531 tumors in Wag/Rij rats. A, multi-
ple tumor deposits in the greater omentum; B, two 
tumor deposits in the liver hylum; C, one tumor 
deposit on the mesentery.
A B
C
the size of the residual disease was always less than 1 mm. The mean weight of the 
resection specimens was 0.21 ± 0.07 gram. 
Assignment to (adjuvant) radioimmunotherapy.
After stratification for PCI, completeness of resection and whether a splenectomy had 
been or would have been carried out, seventeen rats (nine rats that had undergone 
cytoreductive surgery and eight rats that had undergone exploratory laparotomy), re-
ceived an intraperitoneal injection of 56 MBq 177Lu-MG1, whereas the remaining rats 
received the carrier (PBS, BSA 0.5%, EDTA 1mM). The four treatment groups were 
well-balanced with regard to the above-mentioned stratification factors, as well as 
body weight, the number of tumor nodules per site (data not shown) and, when ap-
plicable, the weight of the resection specimens (Table 1).
Toxicity
The relative body weight, expressed as the percentage of the body weight on the day 
of surgery, is depicted in Figure 4. On the third postoperative day, prior to the admin-
istration of radioimmunotherapy, those rats that were treated with cytoreductive sur-
•
•
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Table 1. Rat-, surgical and pathological characteristics
EL only EL + RIT CS only CS + RIT 
Body weight (g) 275 ± 8 271 ± 7 273 ± 8 274 ± 11
Tumor score per site†
Subcutaneously 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
Greater omentum 2 (1-3) 2 (1-3) 2 (2-3) 2 (2-3)
Liver hylum 2 (1-2) 2 (1-2) 2 (1-2) 2 (0-2)
Perisplenic 1 (0-2) 1 (0-1) 1 (0-2) 1 (0-2)
Mesentery 1 (0-2) 1 (0-2) 1 (1-2) 1 (0-2)
Gonadal fatpads 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1)
Diaphragm 0 (0-1) 0 (0-0) 0 (0-0) 0 (0-0)
Subrenal 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1)
Parietal peritoneum 0 (0-1) 0 (0-1) 0 (0-1) 1 (0-1)
Douglas’ pouch 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
Total 6 (4-8) 7 (3-8) 6 (5-10) 7 (5-10)
Weight resection specimen (g) NA NA 0.21 ± 0.09 0.22 ± 0.06
Splenectomy
Yes NA NA 4 5
No NA NA 5 4
Resection macroscopically complete
Yes NA NA 8 7
No NA NA 1 2
EL, Exploratory laparotomy; CS, cytoreductive surgery; RIT, Radioimmunotherapy; NA, Not ap-
plicable. † Tumor score is expressed as median (range)
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gery had lost more body weight than those that underwent exploratory laparotomy 
(6.7 ± 1.9% vs 4.5 ± 1.1%, P=0.0002). Maximum mean body weight loss of the rats of 
the exploratory laparotomy only group was 6.4 ± 0.6% four days after the surgery. 
Maximum body weight loss of the rats of the exploratory laparotomy + radioimmu-
notherapy group amounted 8.5 ± 1.7% five days after surgery or two days after start 
of the radioimmunotherapy (P=0.001 compared to the maximum weight loss of the 
rats of the exploratory laparotomy only group). Maximum body weight loss of the 
rats of the cytoreductive surgery only group amounted 8.1 ± 1.9% four days after sur-
gery (P=0.015 compared to the exploratory laparotomy only group; P=0.888 compared 
to the exploratory laparotomy + radioimmunotherapy group). Maximum mean body 
weight loss of the rats of the cytoreductive surgery + radioimmunotherapy group was 
Figure 4
The relative body weight of Wag/
Rij rats with small peritoneal CC-
531 metastases in the first month 
after exploratory laparotomy 
(EL) only, EL + radioimmuno-
therapy (RIT), cytoreductive sur-
gery (CS) only, or CS + RIT. Data 
represent means ± standard error 
of the mean (SEM).
Figure 5
Survival curves for Wag/Rij rats 
with small peritoneal CC-531 me-
tastases after exploratory laparot-
omy (EL) only, EL + radioimmu-
notherapy (RIT), cytoreductive 
surgery (CS) only, or CS + RIT. 
There was a highly significant 
trend towards improved survival 
for the rats treated with CS + RIT 
as compared to both CS only and 
EL + RIT (P=0.0004 for both 
trend analyses).
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Figure 6a
Ascites weight found in Wag/
Rij rats with small peritoneal 
CC-531 metastases at the time 
of death after exploratory 
laparotomy (EL) only, EL + ra-
dioimmunotherapy (RIT), cy-
toreductive surgery (CS) only, 
or CS + RIT. Differences were 
not statistically significant 
(P=0.2219). 
Figure 6b
Tumor weight found in Wag/
Rij rats with small peritoneal 
CC-531 metastases at the time 
of death after exploratory 
laparotomy (EL) only, EL + ra-
dioimmunotherapy (RIT), cy-
toreductive surgery (CS) only, 
or CS + RIT. Tumor weight 
of the rats treated with EL + 
RIT was significantly lower as 
compared to that obtained in 
rats treated with EL only or CS 
only (P<0.05). 
Figure 6c
PCI found in Wag/Rij rats with 
small peritoneal CC-531 metas-
tases at the time of death after 
exploratory laparotomy (EL) 
only, EL + radioimmunotherapy 
(RIT), cytoreductive surgery (CS) 
only, or CS + RIT. The PCI of the 
rats treated with RIT, preceded 
by either EL or CS, was signifi-
cantly lower as compared to that 
obtained in rats treated with EL 
only or CS only (P<0.05). Lines 
indicate medians.
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10.7 ± 3.3% six day after surgery or three days after start of the radioimmunotherapy 
(P=0.0003 compared to the exploratory laparotomy only group; P=0.200 compared 
to the exploratory laparotomy + radioimmunotherapy group; P=0.136 compared to 
the cytoreductive surgery only group. After reaching their nadirs, rats regained body 
weight again at approximately the same rate.
Survival
Thirty-two rats died due to intraperitoneal tumor growth. The survival curves of the 
various treatment groups are shown in Figure 5. Median survival of the control rats 
that underwent exploratory laparotomy only was 41 days (range 37-82). Median sur-
vival of the rats that had undergone cytoreductive surgery only amounted 51 days 
(45-118) (P=0.0544 when compared to the control rats). Median survival of the rats 
that were treated with exploratory laparotomy followed by intraperitoneal radioim-
munotherapy was 61.5 days (47-118) (P=0.0304 when compared to the control rats; 
P=0.47 when compared to the cytoreductive surgery only group). Cytoreductive 
surgery + radioimmunotherapy resulted in the highest median survival of 88 days 
(68-118) (P=0.0001 when compared to the control rats; P=0.0503 when compared to 
the cytoreductive surgery only group; P=0.0822 when compared to the exploratory 
laparotomy + radioimmunotherapy group). There was a highly significant trend to-
ward improved survival in the cytoreductive surgery + radioimmunotherapy group, 
both when compared to the cytoreductive surgery only group as well as the explora-
tory laparotomy + radioimmunotherapy group (P=0.0004 for both trend analyses). 
Observations at dissection
Formation of hemorrhagic ascites was the most common cause of death. Of the 32 
rats that died due to intraperitoneal tumor growth, 31 had hemorrhagic ascites. In 
Figure 6a-c the ascites weight, tumor weight and PCI found at dissection are depicted. 
Mean ascites weight varied from 32.2 ± 21.0 g in the rats that had undergone cytore-
ductive surgery only to 50.2 ± 15.0 g in the control group (P=0.22). Mean tumor weight 
found at dissection at the time rats reached their humane endpoints varied from 3.8 
± 3.4 g in the exploratory laparotomy + radioimmunotherapy group to 13.6 ± 6.2 g in 
the cytoreductive surgery only group (P=0.011). Median PCI varied from 11 (range 
10-18) in the exploratory laparotomy + radioimmunotherapy group to 20 (18-26) in 
the cytoreductive surgery only group (P=0.0002). Multiple comparison analyses indi-
cated that the median PCI of the exploratory laparotomy + radioimmunotherapy and 
cytoreductive surgery + radioimmunotherapy was significantly lower when compared 
to both the exploratory laparotomy only as well as the cytoreductive surgery only 
groups. There was a highly significant correlation between the PCI and the weight of 
the dissected tumor deposits (Spearman r=0.8283, P<0.0001). However, there was no 
correlation between ascites weight and PCI (Spearman r=0.1948, P=0.2670) or tumor 
weight (Spearman r=-0.0629, P=0.7239).
•
•
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Long-term survivors
At the end of the experiment (118 days after tumor cell inoculation), there were three 
rats (one treated with exploratory laparotomy + radioimmunotherapy; one treated 
with cytoreductive surgery only; and one treated with cytoreductive surgery + radi-
oimmunotherapy, respectively), without signs of intraperitoneal tumor growth. At 
dissection, there was no evidence of disease in any of these rats. Histopathological 
examination of relevant organs, including the diaphragm, the mesentery, and, when 
available, the greater omentum did not reveal microscopic residual disease in any of 
these rats.
Discussion
The primary aim of the present experimental studies was to investigate the therapeu-
tic efficacy of radioimmunotherapy when administered postoperatively as adjuvant 
treatment after surgical cytoreduction of peritoneal carcinomatosis of colonic origin. 
Whereas the median survival following cytoreductive surgery only and exploratory 
laparotomy + radioimmunotherapy was only 10 days (P=0.05) and 21.5 days (P=0.03) 
longer than that of the control rats that had undergone exploratory laparotomy only, 
the combination of cytoreductive surgery and radioimmunotherapy resulted in an 
improvement of 43 days (P=0.0001), which suggests an additive effect of the two 
treatment modalities.
The syngenic rat colon carcinoma cell line CC-531 was used because of its reproducible 
in vivo growth pattern in Wag/Rij rats. Hagenaars et al. studied the tumor targeting 
capabilities of the MG1 MAb after intraperitoneal administration in Wag/Rij rats 
with CC-531 liver metastases and found that the antibody selectively localized to the 
CC-531 tumors, with some cross-reactivity to thymus, lymph node, salivary glands, 
and skin.15,16 However, no data were provided on the absolute or percentual uptake in 
tumor tissue of MG1. Therefore, before initiating radioimmunotherapy studies, the 
biodistribution of the MG1 MAb labeled with 125I or 111In, as surrogate radionuclides 
for 131I and 177Lu, respectively, was studied. Both 125I- and 111In-labeled MG1 preferen-
tially accumulated in the intraperitoneal CC-531 tumors. The uptake of 111In-MG1 in 
tumor tissue, however, was higher, which is probably due to differences in cellular 
routing of the radiolabeled metabolites after intracellular catabolization of the an-
tibodies.25 After internalization by the cancer cell, radiolabeled antibodies are enzy-
matically degraded and metabolized in the lysosomes. After intralysosomal metabo-
lization of monoclonal antibodies that are radioiodinated by conventional methods, 
the radioiodinated tyrosine residues are excreted, whereas the catabolic products of 
monoclonal antibodies labeled with 111In- or 177Lu-DTPA, presumably 111In- or 177Lu-
DTPA-lysine metabolites, are trapped within the lysosomes, resulting in a prolonged 
tumor residence time.26,27 The higher uptake of 111In-ITC-DTPA-MG1 therefore favored 
the use of 177Lu instead of 131I in radioimmunotherapy studies. Furthermore, the me-
•
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dium-energy beta-emission of 177Lu and its concomitant maximum penetration range 
in tissue of 2.5 mm in combination with its physical half-life of six days, make 177Lu an 
attractive radionuclide for radioimmunotherapy of small volume disease, as indeed 
reported in preclinical and clinical studies.24,28 
Being an IgG2a antibody, MG1, theoretically, could have an antitumor effect itself 
through complement-mediated tumor cell lysis or complement- or antibody-depend-
ent cellular cytotoxicity (ADCC). In this regard, Gelderman et al. studied the comple-
ment activation potential of the MG1-4 MAb family, and found that MG1 was not 
able to activate the complement system in vitro.29 These findings corroborate with the 
results of the first therapy study reported in the present paper, in which unlabeled 
MG1 had no measurable antitumor effect in rats with CC-531 peritoneal metastases. 
radioimmunotherapy using 177Lu-MG1 was given at an activity dose of 74 MBq per rat. 
Since we previously demonstrated that the maximal tolerated activity dose (MTD) of 
177Lu-labeled IgG in 25 g nude mice is 16.7 MBq,24 the MTD of 177Lu-labeled IgG in 250 g 
rats could theoretically be as high as 167 MBq. Indeed, radioimmunotherapy using 74 
MBq 177Lu-MG1 resulted in minor toxicity, as evidenced by a maximum mean body 
weight loss of only 2.6 ± 3.2%, which suggests that higher activity dose could safely be 
given. Still, radioimmunotherapy using 74 MBq 177Lu-labeled MG1 almost completely 
ablated tumor growth, when given as sole treatment in unoperated rats.
In the therapy studies, cytoreductive surgery consisted of complete/median laparot-
omy and resection of all macroscopic disease, including formal omentectomy, as is 
practiced in patients undergoing cytoreductive surgery followed by intraperitoneal 
chemotherapy.7 The modest survival benefit (P=0.0504) of the rats treated with cy-
toreductive surgery only, may partially be explained by the omentectomy, which was 
routinely carried out in all rats assigned to undergo cytoreductive surgery. In various 
experimental models it has been demonstrated that tumor cells preferentially accu-
mulate in the so-called milky spots of the omentum in the early stages of intraperi-
toneal dissemination.16,30 In a rat model Lawrance et al. showed that omentectomy 
three to four weeks prior to intraperitoneal or intraluminal tumor cell inoculation 
significantly reduced intra-abdominal tumor growth.31 Weese et al. studied the influ-
ence of the omentum on intraperitoneal tumor growth in a rat model of peritoneal 
carcinomatosis of colonic origin and found that omentectomy reduced the incidence 
of small bowel obstruction by more than 50%.32 Thus the omentum has been impli-
cated as an initial site of tumor growth after which secondary seeding occurs at sites 
of peritoneal trauma.
Although cytoreductive surgery and adjuvant intraperitoneal chemotherapy is in-
creasingly being accepted as one of the treatment options for patients with peritoneal 
carcinomatosis of colorectal origin, there is little experimental data on the efficacy of 
this treatment. Benoit et al. studied the efficacy of surgical cytoreduction, intraperi-
toneal chemotherapy using Cisplatin/epinephrine or both treatment modalities in 
BDIX rats with peritoneal carcinomatosis of colonic origin.33 Whereas cytoreductive 
surgery alone did not improve survival, intraperitoneal chemotherapy alone signifi-
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cantly improved survival without curing any of the animals. Cytoreductive surgery 
followed by intraperitoneal chemotherapy, however, cured four out of five animals.
Since the uptake of radiolabeled monoclonal antibodies is inversely correlated with 
tumor size,13 the efficacy of radioimmunotherapy, theoretically, should be higher in 
smaller tumor deposits. Therefore, we hypothesized that the combination of cytore-
ductive surgery followed by radioimmunotherapy would act additively. Indeed, the 
combination of both treatment modalities resulted in the highest median survival 
and a highly significant trend towards improved survival, both when compared to 
cytoreductive surgery only and exploratory laparotomy + radioimmunotherapy. The 
majority of rats were euthanized because of the development of massive hemor-
rhagic ascites. Interestingly, whereas the amount of ascites at the time of dissection 
was similar between the groups, rats treated with radioimmunotherapy, preceded by 
either exploratory laparotomy or cytoreductive surgery, showed (significantly) less 
solid tumor growth as compared to those treated with exploratory laparotomy or 
cytoreductive surgery only. Apparently, radioimmunotherapy effectively inhibited 
tumor growth but was not able to prevent the formation of ascites. 
Conclusion
This is the first experimental study on the efficacy of combined modality treatment 
including surgery and radioimmunotherapy in an animal model of cancer. Radioim-
munotherapy using the 177Lu-labeled MG1 MAb effectively inhibited tumor growth, 
even at relatively low activity doses. When given postoperatively after cytoreductive 
surgery in rats with peritoneal carcinomatosis of colonic origin, radioimmunothera-
py was associated with improved survival as compared to both cytoreductive surgery 
and radioimmunotherapy alone. This study provides proof of principle that radioim-
munotherapy can be an effective treatment modality when applied as adjuvant treat-
ment modality after resection of tumors with a high risk of recurrence. 
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Peritoneal carcinomatosis (PC) of colorectal origin represents an advanced stage of disease, which for long has been regarded as incurable. Until the be-ginning of the 21st century, patients were usually treated with palliative chemo-
therapy and surgery when needed. The reported median survival associated with this 
approach ranges from 5 to 12 months.1-4 In the nineteeneighties surgical oncologists 
gained renewed interest in patients with PC, particularly those without hematoge-
nous metastases. Sugarbaker has pioneered a new aggressive approach, consisting of 
cytoreductive surgery (CS) followed by (hyperthermic) intraperitoneal chemotherapy 
(HIPEC), aiming at locoregional control of disease.5 After two decades of phase II trials 
investigating the feasibility and efficacy of CS followed by HIPEC, Verwaal et al. con-
ducted a phase III trial comparing this aggressive approach to systemic 5-fluorouracil 
(5-FU) based chemotherapy and surgery when needed and confirmed its superiority.6 
An analysis of the results of 16 clinical trials on the efficacy of CS + HIPEC in patients 
with PC of colorectal origin, indicated that the extent of carcinomatosis and complete-
ness of resection were the factors most prominently related to survival.7 Still, five-year 
survival rates of the patients with the most favorable clinicopathological characteristics 
varies from only 20% to 53%, with most recurrences occurring intraperitoneally.8 There-
fore, more effective adjuvant treatments are necessary to improve the results of CS.
Although radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies 
(MAbs) directed against tumor-associated antigens has been accepted as one of the 
clinically accepted treatment options in patients with non-Hodgkin lymphoma (NHL), 
preclinical and clinical studies have indicated that in solid cancers only small volume 
or minimal residual disease might be a suitable target for this treatment modality.9 
In an animal model of PC using Wag/Rij rats with intraperitoneal CC-531 tumors we 
have shown that the therapeutic effects of CS combined with adjuvant RIT using the 
177Lu-labeled MG1 MAb was significantly better than that of CS or RIT alone.10 In that 
study RIT was given three days after surgery. We hypothesized that the efficacy of RIT 
after CS might be dependent on the timing of postoperative administration of the 
radiolabeled MAbs. To test this hypothesis, we investigated the efficacy of adjuvant 
RIT when given at various timepoints after CS.
Materials and methods
Animals
Male Wag/Rij-rats, ten to twelve weeks, weighing 240-260 g were obtained from Har-
lan (Horst, The Netherlands). Rats were accustomed to laboratory conditions for one 
week prior to experimental use and housed under nonsterile, standard laboratory 
conditions (temperature, 20–24°C; relative humidity, 50-60%; 12 h light/12 h dark) on           
sawdust in filter-topped cages (two rats per cage) with free access to animal chow (Snif 
Chapter 8
192
Voer, Soest, The Netherlands) and water. All experiments were conducted in accor-
dance with the revised Dutch Act on Animal Experimentation (1997) and approved by 
the institutional Animal Welfare Committee of the Radboud University Nijmegen.
Cell line
The syngeneic rat colon carcinoma cell line CC-531, derived from colon tumors of Wag/
Rij rats exposed to 1,2-dimethyl-hydrazine, was used.11 CC-531 was cultured and main-
tained as monolayers on plastic in Dulbecco’s Modified Eagle Medium (DMEM, GIB-
CO, BRL Life Sciences Technologies, The Netherlands) supplemented with 10% fetal 
calf serum (GIBCO), 2 mM L-glutamine, penicillin (100 units/mL) and streptomycin 
(100 µg/mL) at 37°C in a humidified atmosphere with 5% CO2. Prior to inoculation, 
tumor cells were washed with phosphate-buffered saline (PBS), harvested with 0.25% 
trypsin (3 min at 37 °C), resuspended in PBS, spun down (5 min at 700 x g), counted 
and resuspended once again in PBS to the appropriate concentration.
Monoclonal antibody
The MG1 MAb was purchased from Antibodies for Research Applications BV (Gouda, 
The Netherlands). The MG1 MAb is a murine IgG2a antibody, raised by immunization 
of mice with CC-531 colon carcinoma cells.12,13 It recognizes a cell surface structure of 
about 80 kDa and localizes to tumor cells when injected in rats bearing CC-531 tumors 
with minimal cross reactivity to other cell types. Purity was checked by SDS-PAGE 
under nonreduced conditions and by means of fast protein liquid chromatography 
(FPLC) on a Phenomenex Biosep 3000 column, eluted with phosphate buffered saline 
(PBS, pH 7.2, 1 mL/min).
177Lu-labeling
177Lu was purchased from IDB Holland BV (Baarle Nassau, The Netherlands). 177Lu-
labeling was performed under strict metal-free conditions. To allow labeling of the 
antibodies with 177Lu, the MG1 MAb was conjugated with isothiocyanatobenzyl-di-
ethylenetriaminepentaacetic acid (ITC-DTPA, Macrocyclics, Dallas, TX). Briefly, ITC-
DTPA was conjugated to MG1 in a 0.1 M carbonate buffer, pH 9.0 using a 100-fold 
molar excess of ITC-DTPA as described by Ruegg et al.14 with minor modifications 
(conjugation period of one hour at room temperature). The DTPA-MG1 immunocon-
jugate was then purified by extensive dialysis against 0.1 M ammonium acetate buffer, 
pH 5.4. The number of DTPA ligands per antibody molecule was determined accord-
ing to the method described by Hnatowich et al.15 The purified DTPA-MG1 conjugate 
(DTPA/MG1 ratio 1.6 : 1, 1.0 mg/mL) was incubated with 177Lu in 0.1 M ammonium 
acetate buffer, pH 5.4 at room temperature (60 minutes). Labeling efficiency of the la-
beling procedure exceeded 98%. Specific activities of the 177Lu-DTPA-MG1 preparation 
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(hereafter referrend to as 177Lu-MG1) was 0.74 MBq/µg. Since 177Lu is a bone-seeking 
radionuclide, after completion of the labeling procedure 1 mM EDTA was added to the 
solutions to scavenge the remaining free 177Lu ions.16 
Quality control of the radiolabeled preparations
The reaction mixture was purified on a PD-10 column, eluted with PBS, 0.5% BSA. 
Radiochemical purity (RCP) was determined using instant thin-layer chromatography 
(ITLC) on silicagel strips (Gelman Sciences, Ann Arbor, MI) using 0.10 M citrate buffer 
(pH 6.0) as the mobile phase. The RCP of the 177Lu-MG1 preparation was 99%. 
The immunoreactivity of the radiolabeled MG1 preparations was essentially deter-
mined as described by Lindmo et al.17 Briefly, a fixed amount of labeled antibody 
(10,000 cpm) was incubated (6 hours, 37°C) with increasing concentrations of CC-531 
tumor cells (1.2 x 106 – 20 x 106 cells/mL) in 0.5 mL binding buffer (RPMI medium con-
taining 0.5% BSA and 0.05% NaN3). A duplicate of the lowest cell concentration was 
incubated in the presence of an excess unlabeled antibody to correct for nonspecific 
binding. After six hours of incubation at 37°C, the cells were spun down (500 g, 5 min) 
and activity in the pellet was determined in a well-type gamma-counter. The inverse 
of the tumor cell bound fraction was plotted against the inverse of the cell concentra-
tion and the immunoreactive fraction (IRF) was calculated from the y-axis intercept. 
Immunoreactivity of the 177Lu-MG1 preparation was 67%. 
Experimental design
Seven days after intraperitoneal inoculation of 2.0 x 106 CC-531 tumor cells, 75 rats 
were randomly assigned to undergo exploratory laparotomy (EL) only, CS only, CS + 
RIT administered immediately postoperatively (CS + RIT 0 group), CS + RIT adminis-
tered four days postoperatively (CS + RIT 4 group), or CS + RIT administered fourteen 
days postoperatively (CS + RIT 14 group) (fifteen rats per group). Subsequently, all rats 
underwent a complete midline laparotomy during which the intraperitoneal tumor 
load was semiquantitatively scored as described previously.10 In brief, after opening 
the abdomen, the abdominal cavity was carefully inspected, starting with the upper 
abdomen, including the greater omentum, the liver hylum, the perisplenic region and 
the diaphragm. Subsequently, the gonadal fat pads and the kidneys were inspected. 
Finally, the intestines were gently lifted out of the abdomen, enabling inspection of 
the complete mesentery and Douglas’ pouch. Tumor growth at each of these sites was 
scored 0, 1, 2, or 3, where 0 indicated no macroscopic tumor growth, 1 meant little 
tumor growth, 2 indicated moderate tumor growth, and 3 indicating abundant tumor 
growth. The sum of the tumor scores of all sites represented the peritoneal cancer 
index (PCI). RIT consisted of 56 MBq 177Lu-MG1 (total MG1 protein dose 75 µg), which 
was injected intraperitoneally. 
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Follow-up
The primary endpoint was survival. Body weight was measured daily in the first week 
postoperatively and once weekly thereafter as measure of toxicity. Rats were moni-
tored daily until the humane endpoint had been reached, as determined by one single 
experienced and independent animal technician, who was blinded to the therapeutic 
regimen. At the time of the humane endpoint, rats were usually lethargic, showing 
signs of advanced PC, such as the presence of ascites or bulky intraperitoneal tumor 
growth, and were expected to die within one or two days. When the humane endpoint 
had been reached, rats were euthanized by O2/CO2-asphyxiation and immediately 
dissected. The experiment was terminated at 118 days after tumor cell inoculation 
when the remaining rats were euthanized and dissected. In case of absence of macro-
scopic tumor growth, relevant organs, including the greater omentum, the mesentery 
and the diaphragm were removed for routine histopathological hemotoxilin & eosin 
(H&E) and/or immunohistochemical staining using the murine MG1 antibody and a 
horse-anti-mouse IgG antibody (Vector Laboratories Inc., Burlingame, CA, USA).
Statistical analysis
Data are expressed as means ± standard deviation (SD) unless stated otherwise. Sta-
tistical analysis was performed using the SPSS software (Chicago, IL) software and 
Graphpad Prism 4.00 (Graphpad Software Inc. San Diego USA). Comparison of di-
chotomous values was done using Chi square or Fisher’s Exact test and post-hoc test-
ing with homogeneity of variance correction using Games-Howell. Multiple compari-
sons were analyzed using the one-way ANOVA test. Bonferroni correction for multiple 
testing was applied. Survival portions were analyzed using the Log-rank test. All tests   
were two-sided; the level of statistical significance was set at a P-value of <0.05.
Results
Surgery
All surgical procedures went uneventful, except for one rat that needed resuscitation 
twice (probably due to too deep anesthesia) and one rat in which the cecum was ac-
cidentally perforated while resecting a tumor lesion in the mesentery (without further 
adverse events). At laparotomy all rats had macroscopic tumor growth, mainly in the 
greater omentum, the liver hilum, the perisplenic region and the mesentery. In all 
rats, except those that underwent EL only, an omentectomy was routinely carried out. 
CS did not require splenectomy in any of the rats. In 53 out of the 60 rats undergoing 
CS, the resection of all tumor nodules seemed macroscopically complete, whereas in 
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seven rats macroscopic disease had to be left behind, in all cases located in the liver 
hilum. In those seven rats that had undergone an incomplete cytoreduction, the size 
of the residual disease was always less than 1 mm. As shown in Table 1, all treatment 
groups were well balanced with regard to PCI and whether or not the cytoreduction 
had been complete. 
Table 1. Surgical and pathological characteristics at laparotomy
EL 
only
CS 
only
CS + 
RIT 0
CS + 
RIT 4
CS + 
RIT 14
Tumor score per site†
Subcutaneously 0 (0-3) 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1)
Greater omentum 2 (2) 2 (2) 2 (2-3) 2 (2-3) 2 (2-3)
Liver hylum 1 (0-1) 1 (0-1) 1 (0-1) 1 (0-1) 1 (0-1)
Perisplenic 0 (0) 0 (0-1) 0 (0) 0 (0) 0 (0-1)
Mesentery 1 (0-1) 1 (0-3) 1 (0-2) 1 (0-2) 1 (0-2)
Gonadal fatpads 0 (0-1) 0 (0-2) 1 (0-2) 1 (0-1) 1 (0-2)
Diaphragm 0 (0) 0 (0) 0 (0-1) 0 (0-1) 0 (0-1)
Parietal peritoneum 1 (0-1) 1 (0-1) 1 (0-1) 1 (0-2) 1 (0-1)
Total 5 (3-6) 5 (3-7) 5 (3-8) 5 (3-7) 6 (3-7)
Resection macroscopically complete
Yes NA 14 14 13 12
No NA 1 1 2 3
† Values are given as medians (range). EL, exploratory laparotomy; CS, cytoreductive surgery; RIT 
0, radioimmunotherapy given immediately postoperatively; RIT 4, radioimmunotherapy given 4 
days postoperatively. RIT 14, radioimmunotherapy given 14 days postoperatively
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Figure 2
Survival curves for Wag/Rij rats with small peritoneal CC-531 metastases after exploratory laparoto-
my (EL) only, cytoreductive surgery (CS) only, CS + radioimmunotherapy given immediately postop-
eratively (CS + RIT 0), CS + radioimmunotherapy given four days postoperatively (CS + RIT 4), or CS 
+ radioimmunotherapy given 14 days postoperatively (CS + RIT 14).
Figure 1
The relative body weight of Wag/Rij rats with small peritoneal CC-531 metastases in the first three 
weeks after exploratory laparotomy (EL) only, cytoreductive surgery (CS) only, CS + radioimmuno-
therapy given immediately postoperatively (CS + RIT 0), CS + radioimmunotherapy given four days 
postoperatively (CS + RIT 4), or CS + radioimmunotherapy given 14 days postoperatively (CS + RIT 
14). Data represent means ± standard error of the mean (SEM).
Timing of adjuvant radioimmunotherapy
197
Toxicity
The relative body weight, expressed as the percentage of the body weight on the day 
of surgery, is depicted in Figure 1. Maximum body weight loss after EL or CS only was 
similar (5.6 ± 1.4% vs. 6.5 ± 2.0% four days postoperatively, P=0.272). Those rats that 
were given adjuvant RIT immediately postoperatively had a maximum body weight 
loss of 8.8 ± 2.1%, which was significantly higher than that after EL (P=0.0001) or CS 
only (P=0.003). Maximum body weight loss of those rats that received adjuvant RIT 
four days postoperatively was 7.7 ± 2.5% five days postoperatively. The body weight of 
those rats that were treated with adjuvant RIT fourteen days postoperatively was not 
measured in the week following RIT. However, at 21 days after surgery body weight 
loss of the rats that received RIT fourteen days postoperatively, i.e. 7 days after RIT, 
was significantly lower as compared to that of the rats that received adjuvant RIT im-
mediately or four days postoperatively (one-way ANOVA test, P=0.004). 
Survival
64 Rats died as a result of intraperitoneal tumor growth, in most cased accompanied by 
the formation of ascites. Mean ascites weight varied from 25.9 ± 18.2 g in the rats that 
received adjuvant RIT four days postoperatively to 35.1 ± 10.1 g in the rats that under-
went EL only (P=0.60). Two rats, one of the CS group and one of the CS + RIT 0 group, 
were euthanized because of massive weight loss at 25 days and 26 days after tumor cell 
inoculation, respectively. At dissection these rats had only minor tumor growth, that 
could not explain their deteriorating condition. The survival curves, including all rats, 
are shown in Figure 2. Median survival of animals in the rats that underwent EL or CS 
only was 29 days (range 25-39) and 39 days (range 25-57), respectively (P=0.039). The 
rats that received adjuvant RIT immediately postoperatively, or four or fourteen days 
postoperatively was 77 days (range 26-118), 52 days (range 32-118) and 45 days (range 
33-118), respectively. Adjuvant RIT significantly improved survival relative to CS only, 
at all time points administered (P<0.002 for all comparisons), with a highy significant 
trend towards improved survival with earlier administration (P<0.0001). The medi-
an survival after adjuvant RIT given immediately postoperatively was significantly 
better when compared to that after RIT administered fourteen days postoperatively 
(P=0.02). The difference between the survival of the rats that were given RIT immedi-
ately postoperatively and that of the rats that received RIT four days postoperatively, 
however, was not significant (P=0.17). 
Long-term survivors
118 Days after tumor cell inoculation nine rats (four of the CS + RIT 0 group, three 
of the CS + RIT 4 group and two of the CS + RIT 14 group) were still alive, without 
clinical evidence of PC. At dissection, one rat of the CS + RIT 0 group, two rats of 
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the CS + RIT 4 group and both rats of the CS + RIT 14 group had macroscopic tumor 
growth. In those rats without macroscopic evidence of residual disease, histopatho-
logical examination of relevant organs including the diaphragm, the omental rem-
nant, and the mesentery revealed minimal residual disease in one rat of the CS + 
RIT 0 group.
Discussion
The aim of the present experimental study was to compare the efficacy of adjuvant 
RIT when given at various time points after CS of PC of colonic origin. Although adju-
vant RIT improved survival relative to CS alone at every time point tested, there was a 
highly significant trend towards improved survival with earlier administration of the 
radiolabeled antibodies. 
The present animal model of PC using Wag/Rij rats and the syngeneic colon carci-
noma cell line CC-531 was used because of the reproducible tumor growth in these rats 
and its similarity to the clinical presentation of PC.18 The MG1 MAb has previously 
been shown to localize preferentially in CC-531 liver tumors in Wag/Rij rats.12,19 In a 
biodistribution study in rats with intraperitoneal CC-531 tumor lesions the uptake of 
125I-labeled MG1 was lower than that of 111In-labeled MG1 (1.1% ID/g vs 4.1% ID/g), 
which is probably due to the different handling of the radiolabeled catabolites of the 
antibody after internalization of the radiolabeled antibody by the tumor cells.10 In 
view of the higher uptake of 111In-MG1 we decided to use 177Lu in RIT studies. The beta-
emitter 177Lu has several favorable physical characteristics for RIT, including a half-life 
of 6.7 days and a medium-energy beta-emission, resulting in a maximum penetration 
range in tissue of 2.5 mm. 177Lu is therefore considered a very suitable radionuclide for 
RIT in small volume disease, as demonstrated in preclinical studies.20 
In a mouse model of PC of colonic origin, we previously demonstrated that intraperi-
toneal administration of radioiodinated anti-CEA MAbs results in higher uptake in 
small (1-3 mm) tumor lesions than intravenous administration up to 72 hours postin-
jection.20,21 Therefore, in the present study RIT was given intraperitoneally. 
The marked differences in survival between those rats that received adjuvant RIT im-
mediately postoperatively and the rats that received RIT four of fourteen days later 
might be related to several factors. Firstly, abdominal surgery inevitably results in 
peritoneal trauma, which elicits an inflammatory response and the production of fi-
brinogen-rich peritoneal exudate.22 Activation of the coagulation cascade subsequent-
ly results in the production of thrombin, which catalyzes the conversion of fibrinogen 
into fibrin. It has been hypothesized that tumor cells can be encapsulated in the fi-
brin network and as such be less accessible to local therapy, such as chemotherapy or 
antibodies (tumor cell entrapment theory).23 In the present study the formation of 
fibrin might have hampered tumor targeting of the radiolabeled MG1 antibodies and 
consequently might have impaired their therapeutic efficacy at four and fourteen days 
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postoperatively. Secondly, the production of fibrin is a common pathway for the de-
velopment of adhesions, which are inevitably formed after abdominal surgery.24 Intra-
abdominal adhesions may have hampered the distribution of the radiolabeled MAbs 
over the peritoneal surfaces in the rats that received adjuvant RIT four or fourteen 
days postoperatively. Thirdly, since CC-531 is a rapidly growing cell line, microscopic 
residual disease might have grown to macroscopic disease, especially in the rats that 
received adjuvant RIT fourteen days postoperatively. The uptake and consequently 
therapeutic efficacy of radiolabeled antibodies is inversely correlated with tumor size.9 
The growth of minimal residual disease into larger tumors might therefore have had a 
negative effect on therapeutic efficacy of the radiolabeled MAbs. 
To date two clinical trials have been published investigating the efficacy of adjuvant 
RIT for the treatment of minimal residual disease, one of which in patients with PC. 
In a phase II trial Liersch et al. investigated the safety and efficacy of adjuvant RIT 
using the 131I-labeled humanized anti-CEA MAb Labetuzumab (MN-14) in 23 patients 
who had undergone R0 liver resection for metastatic colorectal cancer.25 The major 
side effect was transient grade 3 or less neutropenia and/or thrombopenia. Median 
disease-free and overall survival was 18 months (95% CI 11-31) and 68 months (95% 
CI 41-infinity), with a five-year survival rate of 51%. The authors concluded that since 
these results seemed to be improved when compared to historical and contemporane-
ous controls, a phase III randomized controlled trial is justified.
In a phase III trial Verheijen et al. compared the efficacy of a single intraperitoneal 
administration of the 90Y-labeled murine anti-MUC1 HMFG1 MAb plus standard 
treatment to standard treatment alone in patients with stage Ic to IV ovarian can-
cer.26 Patients were randomized after they had attained a laparoscopically confirmed 
complete remission after CS and platinum-based chemotherapy. The radiolabeled an-
tibodies were administered intraperitoneally via a CAPD catheter, after scintigraphic 
confirmation of equal intra-abdominal distribution using a tracer dose of 111In-labeled 
HMFG1. RIT using 90Y-HMFG1, however, did not prolong disease-free nor overall sur-
vival. Several comments on this RCT seem justified. Firstly, the selection of the high-
energy beta-emitter 90Y with a maximum tissue penetration of 12 mm does not seem 
appropriate, since most of the energy will have been deposited outside the microscop-
ic tumor nodules. Secondly, the radiolabeled antibody preparation was augmented 
with 20 mg of unlabeled antibody to a total of 25 mg 90Y-HMFG1, with the intent to 
provoke a human-anti-mouse-antibody response. However, the high antibody dose 
might have had a negative effect on the uptake of the radiolabel in the tumor lesions.21 
Thirdly, in view of the results of the present study, the time interval between CS and 
the administration of at least two months might have had a negative impact on tumor 
targeting.
In conclusion, the results of the present experimental study confirm the potential 
therapeutic efficacy of RIT when given as adjuvant treatment after CS in PC of colonic 
origin. Timing of RIT greatly affected the efficacy of the radiolabeled antibodies. In 
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clinical trials studying the efficacy of radiolabeled antibodies after CS in patients with 
PC, the adjuvant RIT should therefore be administered as early as possible.
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The experimental studies described in the present thesis showed that radioimmu-notherapy can be an effective treatment modality in small volume experimental peritoneal carcinomatosis of colorectal origin. In nude mice with small peritoneal 
metastases of the human colon carcinoma cell line LS174T, radioimmunotherapy using the 
radiolabeled high-affinity murine anti-CEA MAb MN-14 effectively delayed tumor growth. 
The efficacy of radioimmunotherapy, however, could not be enhanced by combining radio-
immunotherapy with either gemcitabine or the selective COX-2 inhibitor parecoxib. Still, 
in a rat model using the syngeneic rat colon carcinoma cell line CC-531 and the radiolabeled 
murine anti-CC-531 MAb MG1 the combination of cytoreductive surgery and adjuvant ra-
dioimmunotherapy had an effect that was at least additive. These results provided proof of 
principle that radiolabeled MAbs can constitute an effective adjuvant treatment modality 
after resection of tumors with a high risk of recurrence.
Whereas 5-fluorouracil (5-FU) has been the only cytostatic agent available for chemother-
apy in patients with colorectal cancer for forty years, two new cytostatic agents, irinote-
can and oxaliplatin, have been introduced in the new millennium.1 In addition, targeted 
therapies using the anti-vascular endothelial growth factor MAb bevacizumab and the 
anti-epidermal growth factor receptor MAb cetuximab have been added to the thera-
peutic armamentarium.2 These changes represent important progress, both for patients 
requiring adjuvant therapies after surgery as well as for patients requiring medical ther-
apy for recurrent disease. To date, there is little data with regard to the efficacy of these 
agents in patients with peritoneal carcinomatosis of colorectal origin.3 In the nude mouse 
model used in the experimental studies described in the present thesis, the efficacy of 
radioimmunotherapy should therefore preferably be compared with that of 5-FU, irinote-
can and oxaliplatin. Furthermore, 5-FU, irinotecan and oxaliplatin are well-documented 
radiosensizers, that could potentially enhance the efficacy of radioimmunotherapy. Thus, 
the efficacy of radioimmunotherapy in the present mouse model should be compared to 
that of modern medical therapy and be further optimized using radiosensitizers.
The experimental study on the efficacy of radioimmunotherapy after cytoreductive sur-
gery in rats with peritoneal carcinomatosis described in Chapter 7 has been the first in-
vestigating the efficacy of adjuvant radioimmunotherapy after resection of tumors with 
a high risk of recurrence. This animal model could be further optimized with regard to 
the maximal tolerated activity dose that can be administered safely. More importantly, 
the efficacy of radioimmunotherapy should be compared to that of (hyperthermic) in-
traperitoneal chemotherapy, as currently given after cytoreductive surgery in patients 
with peritoneal carcinomatosis of colorectal origin. As described in Chapter 2, in patients 
undergoing cytoreductive surgery followed by intraperitoneal chemotherapy, Mitomy-
cin-C (MMC) was the cytostatic agent frequently used. In this regard, Pelz et al. recently 
published the results of an experimental study of (hyperthermic) intraperitoneal chemo-
therapy using MMC in a similar rat model of peritoneal carcinomatosis, using Wag/Rij 
rats and CC-531 tumors.4 In that study rats were subjected to either hyperthermic peri-
toneal perfusion with MMC at 15 mg/m2 or perfusion with MMC at 10 mg/m2 only (no 
hyperthermia) using an open-abdomen technique. Control rats received no treatment. 
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The maximum weight loss in the treatment groups was only 5%, whereas hyperthermic 
intraperitoneal chemotherapy resulted in a significant reduction of intraperitoneal tu-
mor growth ten days after treatment. After adding cytoreductive surgery to hyperther-
mic intraperitoneal chemotherapy in this animal model, cytoreductive surgery followed 
by hyperthermic intraperitoneal chemotherapy could elegantly be compared to cytore-
ductive surgery followed by adjuvant radioimmunotherapy. 
The experimental studies described in the present thesis were performed in mice or rats. 
Hence, although apparently promising, it is too early to draw conclusions on the poten-
tial of radioimmunotherapy for the treatment of peritoneal carcinomatosis in patients. 
Before trying to answer the question of how to introduce this rather sophisticated treat-
ment modality in the complex surgical treatment protocol currently inflicted on patients 
with peritoneal carcinomatosis, valid arguments for its necessity need to be identified. 
Although the results of the patient series published to date indicate that the outcome 
of patients undergoing cytoreductive surgery can probably only be improved by means 
of more effective adjuvant treatment strategies, there is at present no evidence for or 
against the efficacy of hyperthermic intraperitoneal chemotherapy.3 The only way to as-
certain the efficacy of hyperthermic intraperitoneal chemotherapy after cytoreductive 
surgery is to compare cytoreductive surgery followed by hyperthermic intraperitoneal 
chemotherapy to cytoreductive surgery alone. Indeed, one such trial has been conducted.5 
Unfortunately, the trial had to be stopped prematurely after inclusion of only 35 patients 
due to difficulties in patient recruitment. Still, two- and five-year survival rates of both 
treatment arms were very similar (60% vs 55% and 20% vs 25%, respectively). Several 
experts in the field argue that only surgery-related factors have been linked to treatment 
success and question the efficacy of hyperthermic intraperitoneal chemotherapy, plead-
ing for a new trial similar to that conducted by Elias et al.6,7 The doubts concerning the ef-
ficacy of hyperthermic intraperitoneal chemotherapy also give room for the clinical trials 
investigating the efficacy of other adjuvant treatments, such as radioimmunotherapy.
Clinical evidence favoring the application of radioimmunotherapy for the treatment of 
peritoneal metastases is very limited and predominantly stems from clinical series of pa-
tients with ovarian cancer (see Chapter 1). Recently, Verheijen et al. published the results 
of an open-label randomized trial investigating the efficacy of adjuvant radioimmuno-
therapy using 90Y-labeled murine anti-MUC1 HMFG-1 MAb after cytoreductive surgery 
and standard consolidation chemotherapy in patients with ovarian cancer.8 After a laparo-
scopically confirmed complete remission, patients were randomly assigned to receive to 
either 90Y-HMFG1 (666 MBq/m2, one single administration) or no treatment. Aiming at 
both an antitumor response due to selective uptake of the radionuclide as well as due 
to a human-antimurine-antibody (HAMA) response, each patient of the radioimmuno-
therapy arm received a HMFG1 MAb protein dose of 25 mg. Adjuvant radioimmunothera-
py, however, failed to improve overall or disease-free survival. Several comments on this 
randomized trial seem justified. Firstly, the choice for the high-energy beta-emitter 90Y 
for radioimmunotherapeutic purposes for the treatment of minimal residual disease is 
questionable. Given the rather high tissue penetration range in tissue (up to 12 mm), most 
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of the radiation energy has been deposited outside the tumor lesions that were targeted. 
Secondly, the very high MAb protein dose of 25 mg per patient might have had a negative 
impact on the uptake of activity in the tumor lesions. The only conclusion that can there-
fore be reliably drawn from this randomized trial is that the murine HMFG1 MAb has no 
measurable antitumor effect in patients with minimal residual ovarian cancer.
Based on the results of the experimental radioimmunotherapy as described in the present 
thesis, one might hypothesize that radioimmunotherapy could be a valuable adjuvant 
treatment modality after cytoreductive surgery in patients with peritoneal carcinoma-
tosis of colorectal origin, provided that the antibody protein dose and the radionuclide 
are selected with care. The previously mentioned randomized trial comparing cytoreduc-
tive surgery followed by hyperthermic intraperitoneal chemotherapy to cytoreductive 
surgery alone could therefore be completed by adding a third treatment arm, consisting 
of cytoreductive surgery followed by radioimmunotherapy. Given the promising results 
of adjuvant radioimmunotherapy using the radioiodinated humanized (h)MN-14 MAb 
after resection of liver metastases in patients with colorectal cancer, 131I-hMN-14 or 177Lu-
hMN-14 seem to be suitable radionuclide-MAb constructs.9 
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The working hypothesis for the experimental work described in this thesis was established in view of the clinical picture of a small group of patients with peritoneal carcinomatosis of colorectal origin, for whom there still is no effec-
tive treatment. Although aggressive cytoreductive surgery, resecting as much mac-
roscopic disease as is considered feasible, followed by hyperthermic intraperitoneal 
chemotherapy has been shown to be effective in selected patients with peritoneal 
carcinomatosis of colorectal origin, most patients eventually present with intraperi-
toneal recurrence and succumb to their disease. Since most patients with favorable 
clinicopathological characteristics, i.e. those in whom a macroscopically complete re-
section is achieved, die from their disease, one might conclude that the chemotherapy 
given is not sufficiently effective and that other therapies could be of benefit. The 
success of radioimmunotherapy using radiolabeled monoclonal antibodies (MAbs) di-
rected against tumor-associated antigens for the treatment of non-Hodgkin lympho-
ma (NHL) inspired us to hypothesize that this treatment modality could be used in 
peritoneal carcinomatosis of colorectal origin. The experimental studies described in 
het present thesis therefore aimed to investigate the therapeutic potential of radioim-
munotherapy in small volume and resectable peritoneal carcinomatosis of colorectal 
origin.
After a short historical overview of radioimmunotherapy, Chapter 1 provides a de-
tailed description of various relevant technical aspects of radioimmunotherapy, and 
finally, an extensive review of the clinical results of radioimmunotherapy in various 
malignancies, including NHL, breast cancer, renal cell cancer, ovarian cancer, and 
colorectal cancer. While radioimmunotherapy has become one of the standard treat-
ment options for patients with NHL, inefficient localization of radiolabeled MAbs 
to nonhematological cancers due to various tumor-related factors has refrained ra-
dioimmunotherapy from outgrowing the experimental stage in solid tumors. Still, 
small volume or minimal residual disease has been recognized as a potentially suit-
able target for radiolabeled antibodies. Focusing on patients with colorectal cancer, 
twenty-three phase I/II studies have been published investigating the feasibility and 
efficacy of radioimmunotherapy using five radionuclides and fifteen MAbs against 
carcinoembryonic antigen (CEA), tumor-associated glycoprotein (TAG)-72, Epithelial 
cellular adhesion molecule (Ep-CAM), A33 or Colon specific antign (CSA)-p mainly in 
patients with advanced colorectal cancer. A few responses were recorded. Given the 
few responses observed in patients with bulky disease and the fact that uptake of radi-
olabeled MAbs in tumors is inversely related to tumor size, radioimmunotherapy still 
might be an effective treatment modality for patients with minimal residual disease, 
small volume disease or as adjuvant treatment. It was concluded that future studies 
should be focused on its application in patients with small volume disease, e.g. as ad-
juvant treatment modality after tumors with a high risk of recurrence.
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Although hematogenous dissemination to the liver and lungs still poses the greatest 
threat to patients with colorectal cancer, peritoneal carcinomatosis can be a major 
source of morbity and is associated with a poor prognosis. Chapter 2 describes the 
incidence of peritoneal seeding of tumor cells during surgical resection of colorectal 
cancer, which presumably is an important pathophysiological mechanism of intraper-
itoneal dissemination. Furthermore, the incidence rates of intraperitoneal recurrence 
as well as the current treatment strategies for peritoneal carcinomatosis are discussed. 
Peritoneal seeding of cancer cells proved to be a relatively common event during sur-
gery for colorectal cancer (3%-28% during curative surgery) although its clinical signifi-
cance remains obscure. Furthermore, macroscopically evident peritoneal carcinoma-
tosis at primary diagnosis (up to 7%) and local recurrence or peritoneal carcinomatosis 
after potentially curative surgery (4%-36%) is encountered more frequently than often 
realized. The small number of four patient series dedicated to the efficacy of chemo-
therapy for the treatment of peritoneal carcinomatosis of colorectal origin, once more 
indicates that this site of tumor recurrence has for long been regarded as less im-
portant than the liver. Treatment with palliative systemic 5-FU based chemotherapy 
seems less efficacious than aggressive cytoreductive surgery followed by intraperito-
neal chemotherapy aimed at locoregional control of disease. Still, the role of modern 
cytostatic agents, such as irinotecan or oxaliplatin, remains to be elucidated. 
Although the clinical results of radiolabeled MAbs in the treatment of various solid 
cancers, including colorectal cancer, have been modest, preclinical research has indi-
cated that radioimmunotherapy can effectively inhibit the growth of small lesions, 
and in some instances even ablate them. In Chapter 3 the mouse model used in the 
preclinical studies of this thesis is described and characterized. Nude mice were used, 
in which peritoneal carcinomatosis was induced by intraperitoneal inoculation of the 
human colon carcinoma cell line LS174T. The macroscopic appearance of the intraperi-
toneal tumor xenografts resembles the clinical picture of peritoneal carcinomatosis 
seen in man, including preferential tumor growth in the greater omentum, the liver 
hylum and on the diaphragm and, eventually, the formation of hemorrhagic ascites. 
Since LS174T tumor cells, like most human colon carcinoma cells, express the carcino-
embryonic antigen (CEA), the murine high-affinity anti-CEA MAb MN-14, developed 
at the Center for Molecular Medicine and Immunology (CMMI, Belleville, New Jersey, 
USA) was used. This antibody has already been successfully applied for radioimmuno-
therapy in clinical trials. Before initiating therapy studies, first the effect of the MN-14 
protein dose on the uptake in tumor tissue and the optimal route of administration 
(intraperitoneal vs. intravenous) was investigated. In a protein dose-escalation study, 
it was demonstrated that the uptake in tumor and tumor-to-blood ratio significant-
ly decreased when the MN-14 protein dose exceeded 25 µg and 20 µg respectively, 
indicating saturation of the CEA epitopes in the tumor nodules. Intraperitoneal ad-
minstration, furthermore, resulted in a higher uptake in tumor and higher tumor-
to-blood ratios up to 48 hours post-injection (p.i.). Indeed, dosimetric analysis of the 
Summary
213
biodistribution data (taking the physical half-life, energy and tissue penetration of the 
emitted electrons into account) indicated that intraperitoneal administration would 
consequently result in a 25% higher tumor absorbed radiation dose than intravenous 
administration. These data favored intraperitoneal over intravenous administration 
of no more than 20 µg MN-14, labeled with therapeutic activity doses. Finally, in the 
therapy studies, intraperitoneal radioimmunotherapy using 131I-labeled MN-14 proved 
to be highly effective, even at relatively low activity doses.
Although 131I is well-known, cheap, easy to label, and therefore probably the most fre-
quently used radionuclide used in radioimmunotherapy, several other radionuclides, 
such as 186Re, 90Y, and 177Lu are available that also have suitable characteristics for appli-
cation in radioimmunotherapy. In Chapter 4 the results of experimental biodistribu-
tion as well as therapy studies are reported, that aimed to select of the most effective 
radionuclide in the present model. For this purpose, the biodistribution of MN-14 
labeled with either 186Re or 88Y (as surrogate marker for 90Y and 177Lu) was assessed, 
both after intraperitoneal and intravenous administration and compared with that of 
radioiodinated MN-14. Again, uptake of 186Re-labeled or 88Y-labeled MN-14 in tumor 
was higher after intraperitoneal adminitration than after intravenous administration. 
Furthermore, uptake of 88Y-labeled MN-14 in tumor was higher than that of 186Re-
labeled or radioiodinated MN-14, which probably ensues from differences in the fate 
of the radionuclides after intratumoral catabolization of the radiolabeled antibodies, 
favoring the use of MN-14 labeled with either 90Y or 177Lu. Dosimetric analysis indi-
cated that radioimmunotherapy using MN-14 labeled with 177Lu or 131I resulted in the 
highest tumor absorbed radiation doses. Indeed, the survival of mice treated with 
177Lu-labeled or 131I-labeled MN-14 displayed the highest median survival as compared 
to the mice treated with either 90Y-labeled or 186Re-labeled MN-14. Based on the results 
of the biodistribution and therapy studies, it was concluded that 177Lu and 131I were 
the most suitable radionuclides to be used for radioimmunotherapy of small volume 
peritoneal carcinomatosis.
After having characterized and optimized the experimental model, strategies were 
pursued to further improve the efficacy of radioimmunotherapy in the present model. 
Since there is increasing evidence that inhibition of the cyclo-oxygenase (COX)-2 en-
zyme can sensitize tumor cells to external beam radiation therapy, we hypothesized 
that COX-2 inhibition might also sensitize the COX-2 positive LS174T tumors to ra-
dioimmunotherapy. In Chapter 5 the results of experimental studies are described 
that aimed to test this hypothesis. For this purpose parecoxib, a analgesic drug de-
veloped for parenteral administration, was used. Parecoxib is a prodrug that after 
parenteral administration is converted to the active agent valdecoxib, which is the 
strongest COX-2 inhibitor currrently available on the market. Parecoxib monotherapy 
consisting of fourteen daily intraperitoneal administrations at 0.2 – 25 mg/kg had no 
measurable antitumor effect, nor did parecoxib co-administration affect the biodistri-
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bution of radiolabeled MN-14. When administered in combination with radioimmu-
notherapy, parecoxib failed to enhance the efficacy of radioimmunotherapy.
In Chapter 6 a similar attempt was made to sensitize the LS174T tumors to radiation 
by co-administration of gemcitabine, a cytostatic agent with strong radiosensitizing 
potential. The choice for gemcitabine was furthermore inspired by previous reports, 
demonstrating that gemcitabine could indeed enhance the efficacy of radioimmuno-
therapy in animal models of pancreatic and colon cancer. After establishing the maxi-
mum tolerated dose that can be administered safely, two administration regimens 
were tested. The first regimen consisted of four intraperitoneal administrations at 
0.11 mg or 0.33 mg every third day, starting on the day of radioimmunotherapy. In 
the second regimen gemcitabine was administered at 0.022 mg on five consecutive 
days, again starting on the day of radioimmunotherapy. The maximal tolerated dose 
of gemcitabine in both treatment regimens was far lower than that reported by other 
authors, which may be due to differences between mouse strains. Gemcitabine, how-
ever, failed to significantly improve the efficacy of radioimmunotherapy in both regi-
mens tested.
In Chapter 7, radioimmunotherapy is combined with cytoreductive surgery. Since 
cytoreductive surgery was considered not feasible in nude mice, a rat model was used. 
Peritoneal carcinomatosis was induced in Wag/Rij rats by intraperitoneal inoculation 
of the syngeneic rat colon carcinoma cell line CC-531. The murine MG1 MAb, specifi-
cally reactive with CC-531 tumor cells with limited cross-reactivity with normal tissues 
in Wag/Rrij rats was used. The results of biodistribution studies of MG1 labeled with 
either 125I or 111In (as surrogate radionuclides for 131I and 177Lu, respectively) indicated 
that the uptake of 111In-labeled MG1 in the tumor was higher than that of 125I-labeled 
MG1. Subsequently, the therapeutic efficacy of MG1 labeled with 177Lu was assessed 
and compared with that of unlabeled MG1 or the carrier. Radioimmunotherapy using 
177Lu-labeled MG1 (74 MBq= 2 mCi per rat) nearly eradicated tumor growth, whereas 
unlabeled MG1 had no antitumor effect at all. Finally, in the surgery study, rats with 
resectable intraperitoneal CC-531 tumors were subjected to exploratory laparotomy 
only, cytoreductive surgery only, exploratory laparotomy + radiommunotherapy (55 
MBq = 1.5 mCi per rat), or cytoreductive surgery + radiommunotherapy. Whereas 
cytoreductive surgery monotherapy resulted in a small survival benefit of 10 days, 
exploratory laparotomy + radioimmunotherapy produced a significant survival ben-
efit of 21 days. The combination of both treatment modalities, however, resulted in 
a survival benefit of 47 days, which suggests an additive effect of the combination of 
both treatment modalities. These results provided proof of principle that radioim-
munotherapy can be an effective treatment modality, when administered as adjuvant 
treatment modality after resection of tumors with a high risk of recurrence.
Summary
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In Chapter 8, the hypothesis that the efficacy of adjuvant RIT after cytoreductive 
surgery depends on the timing of administration, is tested. For this purpose, Wag/Rij 
rats with resectable peritoneal CC-531 carcinomatosis were subjected to exploratory 
laparotomy only, cytoreductive surgery only, cytoreductive surgery + radioimmuno-
therapy administered immediately postoperatively, cytoreductive surgery + radio-
immunotherapy administered four days postoperatively, or cytoreductive surgery + 
radioimmunotherapy administered fourteen days postoperatively. Cytoreductive sur-
gery resulted in a small survival benefit as compared to exploratory laparotomy only. 
Adjuvant RIT significantly improved survival relative to CS only, at all time points 
administered (P<0.002 for all comparisons), with a highy significant trend towards 
improved survival with earlier administration. It was concluded that adjuvant radio-
immunotherapy after cytoreductive surgery of peritoneal carcinomatosis should be 
administered as soon as possible. 
In Chapter 9, the experimental results are discussed and future perspectives are out-
lined.
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Kwaadaardige tumoren van de dikkedarm (coloncarcinoom) of endeldarm (rec-tumcarcinoom) zaaien dikwijls uit naar de lymfeklieren, de lever, de longen en het buikvlies (peritoneum). Uitzaaiingen op het buikvlies (peritoneale me-
tastasen) kunnen leiden tot darmobstructie, fistelvorming en ascites. Dit ziektebeeld 
wordt peritoneale carcinomatose of carcinosis peritonei genoemd. Sommige patiënten 
hebben alleen peritoneale carcinomatose, zonder metastasen in lever of longen of 
elders in het lichaam. Tot voor kort werden deze patiënten alleen behandeld met pal-
liatieve chemotherapie en was de gemiddelde overleving ongeveer een jaar. Sinds en-
kele jaren kunnen deze patiënten operatief worden behandeld. Daarbij worden de in de 
buikholte aanwezige tumoren zo veel mogelijk verwijderd (chirurgische cytoreductie of 
‘debulking’) waarna de buikholte onder verwarming wordt gespoeld met chemothera-
peutica (Hypertherme Intraperitoneale Chemotherapie (HIPEC)). Deze behandeling 
gaat gepaard met aanzienlijke morbiditeit (ca. 35%) en mortaliteit (ca. 5-10%). Toch lijkt 
deze agressieve benadering te leiden tot een betere overleving dan gebruikelijke be-
handeling met alleen chemotherapie. Analyse van de resultaten van deze ingrijpende 
ingreep heeft ons inmiddels geleerd dat de resultaten mogelijk door effectievere adju-
vante behandelingen kunnen worden verbeterd.
Bij radioimmunotherapie wordt gebruik gemaakt van een radionuclide dat aan een 
antistof (antilichaam) is gekoppeld. Dit antilichaam is gericht tegen eiwitstructuren 
op tumorcellen (antigenen), zodat het zich na toediening in de buikholte of de bloed-
baan kan ophopen in tumoren. Op die wijze kunnen tumorcellen preferentieel worden 
bestraald, terwijl gezonde weefsels relatief gespaard blijven. Radioimmunotherapie is 
effectief gebleken in de behandeling van patiënten met lymfeklierkanker (non-Hodgkin 
lymfoom). Bij de zogenaamde solide tumoren, zoals colon- en rectumcarcinoom, lijkt 
radioimmunotherapie alleen effectief als de tumor klein is, zoals het geval is in de vroege 
stadia van peritoneale metastasering of na cytoreductieve chirurgie van peritoneale carci-
nomatose. 
Het doel van de in dit proefschrift beschreven studies was te onderzoeken of radioim-
munotherapie werkzaam kan zijn tegen kleine peritoneale metastasen en of radioim-
munotherapie mogelijk een waardevolle aanvullende behandeling kan zijn na cytoreduc-
tieve chirurgie van peritoneale carcinomatose van colorectale origine.
Na een kort historisch overzicht van de toepassing van radioimmunotherapie, wor-
den in hoofdstuk 1 verschillende technische aspecten van radionucliden en antilicha-
men besproken. Bovendien wordt een uitgebreid overzicht gegeven van de klinische 
resultaten van radioimmunotherapie bij patiënten met lymfeklierkanker, mammacar-
cinoom (borstkanker), niercelcarcinoom, ovariumcarcinoom (eierstokkanker) en 
colon- of rectumcarcinoom. Het effect van radioimmunotherapie bij patiënten met 
lymfeklierkanker is zo goed, dat deze behandeling inmiddels is geregistreerd als een van 
de standaardbehandelingen voor deze ziekte. De effectiviteit bij de andere genoemde 
vormen van kanker (de solide tumoren) is echter beperkt. Dit wordt ondermeer veroor-
zaakt door verschillende tumor-gerelateerde factoren, die de opname van de gelabelde 
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antilichamen, en dus de hoeveelheid radioactiviteit, in deze tumoren beperken. Wel is 
gebleken dat de opname van de antilichamen in tumoren omgekeerd evenredig is met 
de grootte van de tumoren. In geval van kleine tumoren, of minimaal residuale ziekte, 
zou radioimmunotherapie dus wel degelijk effectief kunnen zijn. 
Tot op heden zijn 23 klinische onderzoeken gepubliceerd, waarin patiënten met colon- 
of rectumcarcinoom werden behandeld met radioimmunotherapie. In totaal werden 
in deze onderzoeken vijftien verschillende antilichamen gericht tegen hetzij carcino-
embryonic antigeen (CEA), tumor-geassocieerd glycoproteine (TAG)-72, epitheliaal cel-
lulair adhesie molecuul (Ep-CAM), A33 of het colon-specifiek antigeen (CSA)-p, en vijf 
verschillende radionucliden gebruikt. In alle onderzoeken, op één na, werden patiënten 
geïncludeerd met grote tumoren. Het is daarom opvallend dat toch enkele patiënten 
een respons vertoonden. Omdat verwacht mag worden dat het effect van radioimmu-
notherapie groter is in kleine tumoren, werd geconcludeerd dat in toekomstige studies 
radioimmunotherapie moet worden gegeven in patiënten met kleine tumoren of mi-
nimaal residuale ziekte.
In hoofdstuk 2 wordt nader ingegaan op het pathofysiologisch mechanisme van peri-
toneale metastasering, de incidentie en de huidige behandelingsmethoden van perito-
neale metastasen in patiënten met colon- of rectumcarcinoom. Peritoneale metastasen 
worden waarschijnlijk veroorzaakt door tumorcellen die zich hetzij reeds voor de ope-
ratieve verwijdering in de buikholte bevinden, hetzij tijdens de operatie als gevolg van 
doorsnijding van bloed- en/of lymfevaten de vrije buikholte bereiken. Het blijkt dat 
deze vorm van uitzaaien, in het Engels aangeduid met ‘peritoneal seeding’, kan worden 
aangetoond in 3-28% van patiënten die met curatieve intentie voor het eerst worden 
geopereerd in verband met een colon- of rectumcarcinoom. De klinische significantie 
van het aantreffen van deze cellen is echter nog niet duidelijk. Macroscopisch evidente 
peritoneale carcinomatose wordt verder gediagnosticeerd in ongeveer 7% van de pa-
tiënten ten tijde van de eerste operatie. Na chirurgische verwijdering van de primaire 
tumor, treedt lokaal recidief of peritoneale carcinomatose op in 4-36% van de patiënten 
tijdens follow-up. Tot op heden zijn slechts vier onderzoeken gepubliceerd waarin het 
effect van palliatieve chemotherapie voor de behandeling van patiënten met perito-
neale carcinomatose wordt beschreven. Dit onderstreept nogmaals dat uitzaaiingen 
naar het buikvlies lange tijd zijn gezien als minder belangrijk dan leveruitzaaiingen. 
Palliatieve chemotherapie op basis van 5-fluorouracil en operatief ingrijpen wanneer 
noodzakelijk is minder effectief dan agressieve chirurgische cytoreductie gevolgd door 
intraperitoneale chemotherapie, veelal met mitomycine-C. De plaats van nieuwe cyto-
statica, zoals irinotecan of oxaliplatin, moet echter nog worden onderzocht.
In hoofdstuk 3 wordt een muizenmodel beschreven en gekarakteriseerd, waarin de ef-
fectiviteit van radioimmunotherapie voor de behandeling van peritoneale carcinoma-
tose wordt onderzocht. Hiervoor werden zogenaamde naakte muizen gebruikt, waarin 
peritoneale carcinomatose werd geïnduceerd door middel van een injectie met tumor-
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cellen van de humane coloncarcinoom-cellijn LS174T in de buikholte. Dit leidt tot een 
macroscopisch beeld van tumorgroei in de buikholte hetgeen sterk lijkt op dat van 
peritoneale carcinomatose in de mens. Tumorgroei wordt hierbij met name gezien ter 
plaatse van het omentum, nabij de lever en op het diafragma (middenrif). Uiteindelijk 
wordt bloederige ascites gevormd. Omdat LS174T CEA tot expressie brengt, werd het 
MN-14 antilichaam met hoge affiniteit voor CEA gebruikt. Dit antilichaam is ontwik-
keld in het Center for Molecular Medicine and Immunology (CMMI) te Belleville, New 
Jersey (Verenigde Staten) en reeds succesvol toegepast in patiënten. Allereerst werd 
onderzocht wat het effect was het de MN-14 eiwit dosis op de opname van MN-14 in de 
tumoren en via welke route het radioactief gelabeld MN-14 moest worden toegediend 
om een zo hoog mogelijke opname in de tumoren te bewerkstelligen. Het bleek dat bij 
een MN-14 eiwit dosis van meer dan 20 µg of 25 µg de tumor/bloed-ratio respectievelijk 
opname in tumor significant afnamen. Dit wordt waarschijnlijk verklaard door verza-
diging van het tumor-geassocieerd CEA. Intraperitoneale toediening leidde voorts tot 
een hogere opname in tumorweefsel en hogere tumor/bloed ratio’s dan intraveneuze 
toediening gedurende de eerste 48 uur na toediening. Op basis van dosimetrische ana-
lyse van de biodistributie-data kon worden berekend dat intraperitoneale radioimmu-
notherapie zou leiden tot een stralingsdosis op de intraperitoneale tumoren welke 25% 
hoger lag dan die na intraveneuze radioimmunotherapie. Radioimmunotherapie met 
131I-gelabeld MN-14 was inderdaad zeer effectief en vertraagde de tumorgroei zelfs bij 
relatief lage doses. 
131I is goedkoop, gemakkelijk te labelen en het meest gebruikte radionuclide in radioim-
munotherapie. Inmiddels is er een aantal nieuwe radionucliden, zoals 186Re, 90Y en 177Lu 
beschikbaar, die geschikt zijn voor radioimmunotherapeutische toepassing. In hoofd-
stuk 4 worden de resultaten beschreven van een aantal experimentele studies, die tot 
doel hadden het meest geschikte radionuclide te identificeren voor radioimmunothe-
rapie voor kleine peritoneale metastasen. Hiertoe werd de biodistributie bepaald van 
MN-14 gelabeld met 186Re of 88Y (als surrogaat radionuclide voor 90Y en 177Lu), zowel na 
intraveneuze als na intraperitoneale toediening, en vergeleken met die na toediening 
van 131I/125I-gelabeld MN-14. Opnieuw bleek dat intraperitoneale toediening leidde tot 
een hogere opname in tumorweefsel dan intraveneuze toediening. De opname van 
88Y-gelabeld MN-14 in tumor was hoger dan die van 186Re- of 131I/125I-gelabeld MN-14, 
hetgeen waarschijnlijk wordt verklaard door verschillen in het lot van de radiolabels 
na afbraak van de gelabelde antilichamen in de tumoren. Op basis van dosimetrische 
analyse van de biodistributiegegevens werd berekend dat 131I en 177Lu de hoogste stra-
lingsdosis aan tumoren konden afgeven. Radioimmunotherapie met 131I- en 177Lu-ge-
labeld MN-14 leidde inderdaad tot de hoogste mediane overlevingscijfers, vergeleken 
met 186Re- en 90Y-gelabeld MN-14. Op basis van de rsultaten van biodistributie- en the-
rapiestudies werd geconcludeerd dat 131I en 177Lu de meeste geschikte radionucliden zijn 
voor radioimmunotherapie van kleine peritoneale metastasen.
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Nadat het bovenbeschreven muizenmodel was gekarakteriseerd en geoptimaliseerd 
wat betreft antilichaamdosis, route van toediening, en radionuclide werd gezocht naar 
strategieën om de werking van radioimmunotherapie te versterken. Omdat er toene-
mend bewijs is dat remming van het cyclo-oxygenase (COX)-2 tumorcellen gevoeliger 
kan maken voor bestraling, werd verondersteld dat remming van het in de LS174T tu-
moren aanwezige COX-2 de werking van radioimmunotherapie zou kunnen versterken. 
In hoofdstuk 5 worden de resultaten beschreven van studies waarin deze hypothese 
wordt getest. Hiertoe werd parecoxib, een pijnstiller speciaal ontwikkeld voor parente-
rale toediening. Parecoxib is een zogenaamde prodrug, welke na parenterale toediening 
wordt omgezet in het actieve metaboliet valdecoxib, de krachtigste COX-2 remmer die 
momenteel verkrijgbaar is. Parecoxib monotherapie bestaande uit dagelijkse intraperi-
toneale injecties van 0.2 – 25 mg/kg had geen meetbaar antitumor-effect. Parecoxib had 
ook geen effect op de biodistributie van 125I-gelabeld MN-14. Toediening van parecoxib 
in combinatie met radioimmunotherapie, leidde tenslotte niet tot een verbetering van 
de overleving vergeleken met radioimmunotherapie monotherapie.
In de studies beschreven in hoofdstuk 6 is een vergelijkbare poging gedaan om de 
werking van radioimmunotherapie te versterken, nu met behulp van gemcitabine, een 
frequent gebruikt cytostaticum voor chemotherapie van verschillende tumoren, en ge-
kenmerkt door een sterk radiosensiterend vermogen. De keus van gemcitabine werd 
verder geinspireerd door een aantal publicaties waarin werd aangetoond dat gemci-
tabine de werking van radioimmunotherapie kon versterken in muizenmodellen van 
pancreascarcinoom (alvleesklierkanker) en coloncarcinoom. Na bepaling van de maxi-
maal tolereerbare dosis van gemcitabine, bleek dat deze lager lag dan die geraporteerd 
in de literatuur, hetgeen mogelijk wordt verklaard door verschillen in muizenstam-
men. Uiteindelijk werden twee doseringsschema’s getest. Het eerste schema bestond 
uit vier intraperitoneale injecties (0.11 mg of 0.33 mg/muis) op dag 0, 3, 6, en 9, waarbij 
de radioimmunotherapie (eenmalig) op dag 0 werd gegeven. In het tweede doserings-
schema werd gemcitabine op vijf achtereenvolgende dagen toegedien (0.022 mg/muis), 
waarbij opnieuw de radioimmunotherapie eenmalig op dag 0 werd gegeven. In beide 
schema’s, echter, leidde combinatietherapie niet tot een verbetering van de overleving, 
vergeleken met die na radioimmunotherapie alleen.
In hoofdstuk 7 wordt de waarde van radioimmunotherapie als adjuvante behandeling 
onderzocht. Omdat cytoreductieve chirurgie niet haalbaar werd geacht in naakte mui-
zen, werd hiervoor een reeds bestaand rattenmodel gebruikt. Peritoneale carcinoma-
tose werd geinduceerd in Wag/Rij ratten door intraperitoneale injectie met tumorcel-
len van de ratten coloncarcinoom-cellijn CC-531. Gebruik werd gemaakt van het MG1 
antilichaam, opgewekt in muizen geïmmuniseerd met CC-531 tumor cellen en geken-
merkt door weinig kruisreactiviteit met gezonde weefsels in Wag/Rij ratten. In een 
biodistributiestudie werd aangetoond dat de opname in tumor van MG1 gelabeld met 
111In (als surrogaat radionuclide voor 177Lu) hoger was dan dat van MG1 gelabeld met 125I 
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(als surrogaat radionuclide voor 131I). Vervolgens werd het effect van radioimmunothe-
rapie met 177Lu-gelabeld MG1 onderzocht en vergeleken met dat van ongelabeld MG1 
of een zoutoplossing. Radioimmunotherapie met 177Lu-MG1 (74 MBq = 2 mCi per rat) 
had een uitgesproken antitumor effect, terwijl ongelabeld MG1 geen enkel antitumor-
effect toonde. In de chirurgie-studie werden ratten met peritoneale carcinomatose 
behandeld met hetzij een exploratieve laparotomie (buikoperatie), een exploratieve 
laparotomie gevolgd door radioimmunotherapie met 177Lu-MG1 (56 MBq = 1.5 mCi per 
rat), cytoreductieve chirurgie, of cytoreductieve chirurgie gevolgd door radioimmuno-
therapie. Cytoreductieve chirurgie resulteerde in een korte verlenging van de mediane 
overleving (10 dagen). Een exploratieve laparotomie gevolgd door radioimmunothera-
pie resulteerde in een verlenging van de mediane overleving van 21 dagen. Combinatie 
van beide behandelingen resulteerde uiteindelijk in een zeer significante verlenging 
van de mediane overleving van 47 dagen, hetgeen een additief effect van beide behan-
delingsmodaliteiten (cytoreductieve chirurgie en radioimmunotherapie) suggereert. 
Geconcludeerd werd dat radioimmunotherapie een effectieve adjuvante behandeling 
kan zijn na resectie van tumoren met een hoog risico op recidief, zoals na cytoreduc-
tieve chirurgie van peritoneale carcinomatose van colorectale origine.
In hoofdstuk 8 wordt de hypothese getoetst dat het effect van adjuvante radioim-
munotherapy na cytoreductieve chirurgie afhangt van het tijdstip van toediening van 
de gelabelde antilichamen. Wag/Rij ratten met kleine peritoneale metastasen werden 
hiertoe behandeld met hetzij een exploratieve laparotomie, cytoreductieve chirurgie, 
of cytoreductieve chirurgie gevolgd door radioimmunotherapie met 177Lu-MG1 (56 
MBq = 1.5 mCi per rat). De adjuvante radioimmuntherapie werd onmiddellijk, vier da-
gen, of veertien dagen na chirurgische cytoreductie gegeven. De chirurgische cytore-
ductie alleen resulteerde opnieuw in een korte verlenging van de overleving van tien 
dagen. Adjuvante radioimmunotherapie onmiddellijk na chirurgische cytoreductie, of 
vier dagen of veertien dagen later, resulteerde in een verlenging van de overleving van 
respectievelijk 48, 23 en 16 dagen. Het effect van adjuvante radioimmunotherapie na 
chirurgische cytoreductie was hiermee sterk afhankelijk van het tijdstip waarop de ge-
labelde antilichamen werden toegediend en nam snel af wanneer dit wordt uitgesteld. 
Geconcludeerd werd dat adjuvante radioimmunotherapie zo snel mogelijk na de cyto-
reductieve chirurgie moet worden gegeven.
In hoofdstuk 9 worden de bovengenoemde resultaten bediscussieerd en wordt een 
perspectief geschetst voor toekomstig onderzoek naar de waarde van radioimmunothe-
rapie voor de behandeling van peritoneale carcinomatose bij patiënten met een colon- 
of rectumcarcinoom.
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